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Background:	   Bacille	  Calmette-­‐Guerin	   (BCG)	   vaccination	  prevents	  disseminated	  
tuberculosis	   in	   children,	   and	   induces	   strong	   Th1	   responses	   in	   neonates.	   BCG	  
may	  also	  improve	  immune	  responses	  to	  other	  vaccines	  and	  antigens.	  However,	  
BCG	  vaccination	  can	  result	  in	  severe	  disease	  in	  the	  context	  of	  HIV-­‐infection,	  and	  
is	   therefore	   contraindicated.	   In	   tuberculosis	   endemic	   regions,	   BCG	   is	  
administered	   soon	   after	   birth,	   before	   in	   utero	   and	   perinatal	   HIV	   infection	   is	  
ruled	   out.	   Therefore	   determining	   the	   effect	   of	   delaying	   BCG	   vaccination	   on	  
adaptive	   immune	   functions	   in	   HIV-­‐exposed	   infants	   is	   a	   central	   aim	   of	   this	  
dissertation.	   T	   cell	   proliferation	   and	   cytokine	   responses	   to	   BCG,	   and	   other	  
vaccines	   and	   antigens	   including	   pertussis,	   tetanus,	   and	   SEB	   were	   assessed	   in	  
HIV-­‐exposed	   infants	  who	  received	  BCG	  at	  birth	  and	  compared	  to	   responses	   in	  
infants	  who	  received	  the	  vaccine	  at	  8	  weeks	  of	  age.	  
Methods:	   HIV-­‐exposed,	   uninfected	   infants	   were	   randomized	   to	   receive	   BCG	  
vaccination	  at	  birth	  (early	  BCG	  arm)	  or	  8	  weeks	  of	  age	  (delayed	  BCG	  arm),	  after	  
testing	   HIV	   deoxyribonucleic	   acid	   (DNA)	   PCR	   negative	   at	   birth	   and	   six	   weeks	  
respectively.	  Between	  1-­‐	  3mL	  whole	  blood	  was	  collected	  from	  28	  participants	  in	  
each	  arm	  at	  6,	  8	  and	  14	  weeks	  of	  age	  and	  stimulated	  with	  Mycobacterium	  bovis	  
bacillus	   Calmette-­‐Guérin	   (BCG),	   Tetanus	   toxoid	   (TT),	   Bordetella	   pertussis	   (BP)	  
antigens,	   a	   negative	   control	   (medium	   alone)	   and	   a	   positive	   control,	  
Staphylococcal	   enterotoxin	   B	   (SEB).	   Cells	   were	   fixed	   and	   upon	   thawing,	  




(ICS)	   and	   Ki67,	   CD3	   and	   CD8	   with	   fluorescence-­‐conjugated	   antibodies	   and	  
measured	  using	  multiparameter	   flow	  cytometry.	  Data	  analysis	  was	  performed	  
using	  FlowJo	  V9.4,	  GraphPad	  prism	  V5,	  STATA	  V11,	  Pestle	  V1.7	  and	  Spice	  V5.22	  
software	  packages.	  	  
Results:	   There	   was	   no	   difference	   in	   BCG-­‐specific	   T-­‐cell	   proliferation	   between	  
infants	  in	  the	  two	  arms	  when	  measured	  at	  weeks	  6,	  8	  and	  14.	  However,	  in	  those	  
infants	  who	  received	  delayed	  BCG,	   there	  were	  significantly	  higher	   frequencies	  
of	   IFN-­‐γ-­‐expressing	  CD4+	  T	  cells	  and	  multifunctional	  BCG-­‐specific	   responses	  at	  
week	   14.	   There	   were	   no	   differences	   in	   CD4+	   and	   CD8+	   T	   cell	   proliferative	  
responses	  as	  well	  as	  IFNγ-­‐expressing	  CD4+	  T	  cells	  in	  response	  to	  BCG	  six	  weeks	  
post-­‐vaccination.	  	  
When	   compared	   with	   the	   delayed	   BCG	   arm,	   there	   were	   significantly	   higher	  
CD4+	  T	  cell	  proliferative	  responses	  to	  SEB	  at	  week	  14	  in	  the	  early	  BCG	  arm,	  but	  
no	  differences	  in	  proliferative	  response	  to	  TT	  or	  pertussis.	  Higher	  frequencies	  of	  
pertussis-­‐specific	   IL-­‐13-­‐expressing	   CD4+	   and	   CD8+	   T	   cells	   at	   week	   14	   were	  
evident	  in	  the	  early	  BCG	  arm,	  but	  there	  were	  no	  differences	  in	  IL-­‐2,	  IFN-­‐y	  or	  IL-­‐
17	   expression	   to	   pertussis.	   There	   were	   no	   significant	   differences	   in	   cytokine	  
responses	  to	  TT	  or	  SEB	  at	  any	  time	  point.	  	  
Conclusion:	  HIV-­‐exposed	   infants	   in	   the	  delayed	  BCG	  arm	  (BCG	  vaccinated	  at	  8	  
weeks	  of	  age)	  had	  signifcantly	  higher	  Th1	  responses	  to	  BCG	  when	  compared	  to	  
infants	   in	   the	  early	  BCG	  arm.	   This	   implies	   that	   delaying	  BCG	  vaccination	   from	  
birth	  to	  8	  weeks	  in	  HIV-­‐exposed,	  uninfected	  infants	  does	  not	  impinge	  on	  vaccine	  




When	  assessing	  how	  delaying	  BCG	  vaccination	  affected	  T	  cell	  responses	  to	  other	  
unrelated	   vaccines	   (pertussis	   and	   TT)	   and	   antigens	   (SEB),	   BCG	   timing	   did	   not	  
have	  any	  remarkable	  effect	  on	  T	  cell	  proliferative	  responses,	  except	  for	  higher	  
CD4+	   T	   cell	   proliferative	   responses	   to	   SEB.	   This	   suggests	   that	   early	   BCG	  
vaccination	   may	   have	   minimal	   non-­‐specific	   effects	   on	   the	   infant	   immune	  
system.	  Compared	  to	   infants	   in	  the	  early	  BCG	  arm,	   infants	   in	  the	  delayed	  BCG	  
arm	  had	  higher	  frequencies	  of	  pertussis-­‐specific	  IL-­‐13-­‐expressing	  T	  cells	  at	  week	  
14.	  Thus,	  even	  though	  the	  non-­‐specific	  effects	  of	  BCG	  are	   limited,	   the	  vaccine	  
may	   have	   an	   adjuvant-­‐like	   effect	   on	   immune	   responses	   to	   other	   unrelated	  
vaccines.	   The	   results	   in	   this	   dissertation	   have	   important	   implications	   for	   the	  
design	  of	  optimal	  BCG	  vaccination	  and	  TB	  prevention	  strategies	  in	  HIV-­‐exposed,	  
uninfected	  infants.	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Chapter	  1.	  Literature	  Review	  
	  
1.1.	  The	  immune	  system	  
Throughout	  a	  lifetime,	  an	  individual	  is	  continuously	  exposed	  to	  pathogens	  that	  
can	   cause	   infections	   and	   diseases.	   The	   immune	   system	   is	   the	   organized	  
assembly	   of	   cells	   and	   molecules	   that	   have	   evolved	   to	   protect	   the	   host	   from	  
these	  invading	  pathogens	  (Janeway	  et	  al.,	  2008).	  In	  order	  to	  do	  so,	  the	  immune	  
system	   must	   accomplish	   four	   functions:	   immunological	   recognition,	   immune	  
effector	   function,	   immune	  regulation	  and	   immunological	  memory	   (Janeway	  et	  
al.,	   2008).It	   can	   be	   divided	   into	   two	   arms	   that	   are	   characterized	   by	   different	  
features	   and	   play	   diverse	   functions:	   the	   innate	   immune	   system	   and	   the	  
adaptive	   immune	   system	   (Iwasaki	   et	   al.,	   2010).	   However,	   these	   systems	   are	  
tightly	  linked.	  	  
	  
1.1.1.	  Innate	  immunity	  
Innate	  immunity	  is	  generally	  non-­‐specific	  and	  made	  up	  of	  immune	  cells	  that	  are	  
activated	  shortly	  after	  pathogen	  exposure	  (Janeway	  et	  al.,	  2008).	  The	  cells	  that	  
make	   up	   the	   innate	   immune	   system	   are	   derived	   from	   white	   blood	   cells	   or	  
leucocytes	   and	   originate	   in	   the	   bone	   marrow	   (Janeway	   et	   al.,	   2008).	   They	  
recognize	   pathogen-­‐associated	   molecular	   patterns	   (PAMPs)	   on	   pathogens	   via	  
their	   pathogen	   recognition	   receptors	   (PRR)	   (Iwasaki	   et	   al.,	   2010).	   However,	  
these	   cells	   largely	   lack	   immunological	   memory	   and	   remain	   unchanged	  
regardless	  of	  the	  number	  of	  encounters	  with	  an	  antigen	  over	  time	  (Janeway	  et	  
al.,	   2008).	   Innate	   cells	  provide	   the	   first	   line	  of	  defense	  against	  pathogens	  and	  
defects	   in	   their	  mechanisms	   can	  be	  harmful	   to	   the	   host	   (Iwasaki	   et	   al.,	   2010,	  
Akira	  et	  al.,	  2006).	  The	  innate	  immune	  system	  is	  made	  up	  of	  different	  types	  of	  





Macrophages	  are	   innate	  cells	  which	  are	   long-­‐lived,	  reside	   in	  almost	  all	   tissues,	  
and	   are	   the	   differentiated	   form	   of	   monocytes	   that	   circulate	   in	   the	   blood	  
(Gordon	   et	   al.,	   2010;	   Murray	   et	   al.,	   2011).	   Macrophages	   are	   phagocytes,	  
therefore	   one	   of	   their	   main	   functions	   is	   to	   engulf	   pathogens	   at	   the	   sites	   of	  
infection	   and	   present	   antigens	   to	   T-­‐cells	   (Gordon	   et	   al.,	   2010;	  Murray	   et	   al.,	  
2011).	   Macrophages	   are	   antigen-­‐presenting	   cells	   (APCs:	   a	   group	   of	   a	  
immunocompetent	   cells	   that	   mediate	   immune	   response	   by	   processing	   and	  
presenting	  antigenic	  peptides	   to	  T	  cells	   (adaptive	   immunity)	  and	  subsequently	  
lead	  to	  the	  activation	  of	  these	  T	  cells	  (Gordon	  et	  al.,	  2010;	  Murray	  et	  al.,	  2011).	  
In	  addition,	  they	  can	  trigger	  inflammation	  and	  recruit	  other	  macrophages	  to	  the	  
site	  of	  infection	  (Gordon	  et	  al.,	  2010;	  Murray	  et	  al.,	  2011).	  	  
	  
Granulocytes	   are	   also	   innate	   cells	   characterized	   by	   the	   presence	   of	   dense	  
granules	  inside	  their	  cytoplasm.	  There	  are	  three	  types	  of	  granulocytes	  and	  each	  
type	  performs	  different	  functions:	  
	  
Neutrophils	   are	   phagocytes	   that	   play	   an	   important	   role	   in	   the	   activation	   of	  
bactericidal	   mechanisms	   and	   the	   clearance	   of	   extracellular	   pathogens	  
(Mantovani	  et	  al.,	  2011).Recent	  evidence	  suggests	  that	  neutrophils	  can	  regulate	  
the	  effector	  functions	  of	  innate	  and	  adaptive	  immune	  cells	  via	  the	  cytokines	  and	  
other	   secreted	   effector	   molecules	   (Mantovani	   et	   al.,	   2011).	   In	   addition,	  
neutrophils	  have	  been	  shown	  to	  play	  an	  important	  role	  in	  autoimmune	  diseases	  
and	  chronic	  inflammation	  (Lande	  et	  al.,	  2011).	  Eosinophils	  and	  basophils	  are	  less	  
studied.	   They	   are	   involved	   in	   allergic	   inflammatory	   responses	   (Cheung	   et	   al.,	  
2006;	  Obata	  et	  al.,	  2007).	  	  
	  
Dendritic	   cells	   (DCs)	   are	   also	   APCs	   of	   the	   innate	   immune	   system	   present	   in	  
peripheral	   blood	   and	   tissues	   (Geissmann	   et	   al.,	   2010;	   Sixt	   et	   al.,	   2005).	   They	  
present	   antigens	   to	   T-­‐cells	   in	   the	   lymph	   nodes	   and	   express	   co-­‐stimulatory	  
molecules	   that	   bind	   to	   co-­‐receptors	   on	   T-­‐cells’	   surface	   and	   stimulate	   them	  
(Geissmann	   et	   al.,	   2010;	   Sixt	   et	   al.,	   2005).	   DCs	   play	   a	   critical	   role	   in	   the	  




establishment	   of	   immunologic	   responses	   (Geissmann	   et	   al.,	   2010).	   DCs	   have	  
been	   shown	   to	   involved	   in	   the	   induction	   of	   antibody	   responses	   via	   T	   helpers	  
(Boscardin	  et	  al.,	  2006).	  	  
	  
Other	   innate	   cells	   include	   mast	   cells.	   Although	   they	   are	   part	   of	   the	   innate	  
immune	  system,	  a	  mast	  cell’s	  origin	  is	  not	  well	  established	  but	  they	  are	  believed	  
to	   be	   involved	   in	   the	   activation	   of	   allergic	   response	   in	   tissues.	   As	   described	  
above,	   innate	   immune	   cells	   recognize	   pathogens	   through	   their	   PRRs	   that	   can	  
distinguish	   self	   from	  non–self	   (Janeway	  et	   al.,	   2008).	   Toll-­‐like	   receptors	   (TLRs)	  
are	  a	  group	  of	  PRRs	  that	  recognize	  distinct	  PAMPs	  and	  are	  important	  for	  innate	  
immune	  responses	  (Takeuchi	  et	  al.,	  2010).	  They	  are	  involved	  in	  the	  first	  line	  of	  
defense	   against	   invading	   pathogens	   and	   can	   induce	   inflammatory	   responses	  
and	  cytokines	  production	  (Kollmann	  et	  al.,	  2009).	  There	  are	  11	  members	  of	  the	  
TLR	   family	   recognizing	   different	   pathogens	   patterns	   (Takeuchi	   et	   al.,	   2010).	  
Upon	  antigen	  recognition,	  innate	  cells,	  especially	  phagocytes,	  release	  cytokines	  
and	  chemokines	  that	  play	  various	  functions	  (Iwasaki	  et	  al.,	  2010).	  For	  example,	  
they	  can	  induce	  inflammation	  at	  the	  site	  of	  infection	  (Iwasaki	  et	  al.,	  2010).	  This	  
inflammation	  subsequently	  leads	  to	  an	  increase	  in	  the	  number	  of	  effector	  cells	  
at	   the	   site	   of	   infection	   through	   chemotaxis	   (Iwasaki	   et	   al.,	   2010).	   It	   also	  
promotes	  rapid	  repair	  of	  infected	  tissues	  and	  provides	  and	  additional	  barrier	  to	  
infection.	   In	  addition,	  these	  cytokines	  and	  chemokines	  bind	  to	  T-­‐cells	  and	  lead	  
to	   the	   activation	   and	   migration	   of	   these	   T-­‐cells	   (Janeway	   et	   al.,	   2008).	  
Therefore,	   innate	   immunity	  constitutes	  the	  first	   line	  of	  defense	   in	  an	   infection	  
through	  a	  rapid,	  non-­‐specific	  response.	   Innate	  cells	  bind	  to	  pathogens	  through	  
their	   recognition	   receptors	   and	   induce	   adaptive	   immunity	   through	   antigen	  
presentation	  and	  cytokine	  release	  (Mogensen,	  2009).	  
	  
1.1.2.	  Adaptive	  Immune	  system	  
The	  adaptive	  immune	  system	  is	  activated	  by	  the	  innate	  immunity	  and	  the	  two	  
act	   synergistically	   to	   clear	   pathogen	   infection	   (Iwasaki	   et	   al.,	   2010).	   Unlike	  




induced,	   acquired,	   highly	   specific,	   and	   capable	   of	   generating	   immunological	  
memory	  (Iwasaki	  et	  al.,	  2010).	  The	  adaptive	  immune	  system	  is	  characterized	  by	  
a	  primary	   immune	   response	   several	  days	  after	  pathogen	   invasion	  and	  a	  more	  
rapid	  memory	  response	  that	  can	  be	  established	  after	  a	  second	  encounter	  with	  a	  
specific	  pathogen	   (Janeway	  et	  al.,	  2008).	  The	  adaptive	   immune	  system	  can	  be	  
divided	  into	  two	  parts	  that	  have	  different	  mechanisms	  but	  play	  complementary	  
roles:	  the	  humoral	  immune	  system	  and	  cell-­‐mediated	  immunity	  (Janeway	  et	  al.,	  
2008).	  
1.1.2.1.	  Humoral	  immune	  system	  
Humoral	   responses	   are	   initiated	   in	   the	   lymph	   nodes	   by	   naïve	   B	   cells,	   which	  
recognize	  soluble	  antigens	  and	  bind	  to	  them	  via	  their	  surface	  immunoglobulins	  
or	  B	  cell	  receptors	  (BCR)	  (Pape	  et	  al.,	  2007).	  Each	  naive	  B	  cell	  is	  characterized	  by	  
a	   unique	   surface	   antigen-­‐specific	   receptor	   and	   can	   only	   be	   activated	   after	  
encountering	   its	  specific	  antigen.	  B-­‐cell	  activation	   leads	  to	  their	  differentiation	  
into	  plasma	  cells	  and	  induction	  of	  antibody	  production	  (Janeway	  et	  al.,	  2008).	  B	  
cell	  activation	  occurs	  via	  two	  different	  mechanisms.	  In	  T-­‐cell	  dependent	  (TD)	  B	  
cell	   activation,	   B	   cells	   are	   activated	   after	   recognition	   of	   their	   specific	   antigen	  
coupled	  with	  helper	  T-­‐cell	  signalling	  (Pape	  et	  al.,	  2007).	  First,	  the	  B	  cell	  receptor	  
recognizes	  and	  binds	  to	  its	  specific	  antigen	  (Pape	  et	  al.,	  2007).	  This	  leads	  to	  an	  
internalization	  and	  degradation	  of	  the	  antigen	  into	  small	  peptides	  (Pape	  et	  al.,	  
2007).	   The	   antigenic	   peptide	   is	   then	   presented	   on	   the	   B-­‐cell	   surface	   MHCII	  
complex	  to	  a	  specific	  helper	  T-­‐cell	  in	  the	  germinal	  centers	  (Coffey	  et	  al.,	  2009).	  
Upon	  binding,	  the	  T-­‐cell	  releases	  cytokines	  that	  activates	  the	  B	  cell	  and	  leads	  to	  
its	  differentiation	  into	  plasma	  cells	  (Pape	  et	  al.,	  2007).	  	  
	  
On	  the	  other	  hand,	   in	  T-­‐cell	   independent	   (TI)	  activation,	   the	  B	  cell	  binds	  to	   its	  
specific	  antigen	  and	  is	  activated	  by	  secondary	  binding	  to	  TLRs	  such	  as	  TLR-­‐4	  or	  
TLR9	   (Pasare	   et	   al.,	   2005).	   The	   resulting	   activated	   B	   cell	   is	   restricted	   to	   IgM	  
antibodies	  (Pasare	  et	  al.,	  2005).	  T-­‐cell	  independent	  activation	  also	  occurs	  when	  




cell	   receptors	   subsequently	   takes	   place	   (Defrance	   et	   al.,	   2011),	  which	   in	   turn	  
leads	  to	  B	  cell	  activation	  and	  antibody	  secretion.	  	  
	  
In	  the	  primary	  B-­‐cell	  response,	  activated	  cells	  present	  in	  the	  lymph	  nodes	  move	  
to	  follicles	  where	  they	  undergo	  somatic	  hypermutation.	  Somatic	  hypermutation	  
improves	   B	   cells	   antigen	   specificity	   (Janeway	   et	   al.,	   2008).	   Following	   somatic	  
hypermutation,	   B	   cells	   move	   to	   the	   germinal	   centers	   where	   they	   present	  
antigens	  to	  T-­‐cells	  and	  differentiate	  into	  memory	  B-­‐cells	  or	  effector	  plasma	  cells	  
(Janeway	  et	  al.,	  2008).	  	  
	  
Once	  differentiated,	  plasma	  cells	  secrete	  antibodies,	  which	  are	  also	  referred	  to	  
as	  immunoglobulins.	  They	  are	  characterized	  by	  two	  heavy	  chains	  and	  two	  light	  
chains.	   There	   are	   different	   classes	   depending	   on	   the	   isotypes	   of	   their	   heavy	  
chains.	  Each	  class	  plays	  a	   function	  and	   is	   localized	  at	  a	   specific	   site	  within	   the	  
host	  (Janeway	  et	  al.,	  2008).	  
	  
IgM	  is	  the	  first	  antibody	  to	  be	  produced	  in	  a	  humoral	  immune	  response	  (Foote	  
et	  al.,	  1995).	  IgM	  is	  generally	  low	  affinity	  as	  it	  is	  produced	  before	  hypersomatic	  
mutation	   of	   B-­‐cells	   and	   are	   particularly	   important	   in	   the	   activation	   of	  
complement	  (Schroeder	  et	  al.,	  2010).	   In	  addition,	   IgMs	  are	  also	  present	   in	  the	  
mucosa	  where	  they	  prevent	  pathogen	  entry	  (Brandtzaeg	  et	  al.,	  1999;	  Schroeder	  
et	  al.,	  2010).	  IgG,	  IgA,	  IgE	  are	  released	  later	  in	  the	  response.	  IgG	  is	  the	  main	  class	  
of	  antibody.	  It	  has	  high	  affinity	  and	  binds	  antigen	  for	  macrophage	  ingestion,	  and	  
plays	  an	  important	  role	  in	  natural	  killer	  cell	  (NK)	  neutralization	  (Schroeder	  et	  al.,	  
2010).	  IgG	  plays	  an	  important	  role	  in	  vaccine-­‐induced	  immunity	  due	  to	  its	  high	  
blood	  concentration.	  On	  the	  other	  hand,	  the	  principal	  role	  of	  IgA	  is	  to	  transfer	  
antigenic	  proteins	  across	  the	  mucosal	  epithelium	  (Schroeder	  et	  al.,	  2010).	  IgE	  is	  
secreted	   by	  mast	   cells	   and	   is	   involved	   in	   allergic	   responses	   (Schroeder	   et	   al.,	  
2010).	  Antibodies	  have	  short	  half-­‐lives,	  the	  average	  half-­‐life	  of	   IgG	  being	  three	  
weeks	  (Foote	  et	  al.,	  1995).	  Vaccines	  help	  sustain	  long-­‐term	  antibody	  responses	  
by	   maintaining	   memory	   B	   cells	   that	   will	   later	   differentiate	   into	   antibody	  




be	   regulated	   by	   Helper	   T	   cells	   of	   the	   cellular	   immunity,	   which	   in	   return	   can	  
recognize	   antigens	  presented	  by	  B	   cell	   surface	  MHCII	  molecules	   (Mauri	   et	   al.,	  
2012).	  	  
	  
1.1.2.2.	  T-­‐cell	  mediated	  immunity	  
The	   second	   component	   of	   adaptive	   immunity	   is	   T-­‐cell	   mediated	   immunity.	   T	  
cells	  originate	   in	  the	  bone	  marrow	  and	  develop	   in	  the	  thymus	  (Janeway	  et	  al.,	  
2008).	   Once	   they	   have	   completed	   their	   development	   and	   selection	   in	   the	  
thymus,	   naïve	   T	   cells	   move	   to	   blood	   stream	   and	   peripheral	   lymphoid	   organs	  
(Burgdorf	  et	  al.,	  2007).	  They	  become	  activated	  and	  differentiate	  after	  their	  T	  cell	  
receptors	   (TCRs)	   encounter	   specific	   antigens	   presented	   on	   MHC	   complex	  
molecules	  on	  antigen-­‐presenting	  cell	   surfaces	   (Burgdorf	  et	  al.,	  2007).	  Unlike	  B	  
cells,	   T	   cellular	   main	   targets	   are	   infected	   cells	   can	   only	   recognize	   antigenic	  
peptides	   presented	   by	   Major	   Histocompatibility	   Complex	   (MHC)	   molecules	  
(Burgdorf	  et	  al.,	  2007).	  There	  are	  two	  types	  of	  TCRs:	  the	  first	  type	  is	  composed	  
of	  an	  alpha	  and	  beta	  polypeptide	  chain	  and	  represent	  approximately	  95%	  of	  the	  
TCR	  population	  (Guy	  et	  al.,	  2009).	  These	  T-­‐cells	  are	  referred	  to	  as	  conventional	  
T-­‐cells.	   The	   second	   type	   is	  made	  up	  of	  a	  gamma	  and	  delta	  polypeptide	  chain,	  
and	   are	   called	   gamma-­‐delta	   or	   non-­‐conventional	   T	   cells	   (Pennington	   et	   al.,	  
2005).	   CD3	   is	   a	   multimeric	   protein	   complex	   composed	   of	   four	   distinct	  
polypeptide	  chains	  (Guy	  et	  al.,	  2009;	  Malissen,	  2003).	  There	  are	  two	  main	  CD3+	  
T	  cells:	  helper	  T	  cells	  (CD4+)	  and	  CD8	  T-­‐cells	  (Smith-­‐Garvin	  et	  al.,	  2009).The	  CD3	  
complex	  interacts	  with	  the	  T	  cell	  receptor	  (TCR)	  at	  the	  T	  cell	  membrane	  surface	  
and	  is	  important	  for	  intracellular	  signalling	  (Guy	  et	  al.,	  2009).	  Both	  TCRs	  and	  the	  
CD3	  protein	  complex	  are	  characteristics	  of	  the	  T	  cell	  lineage	  and	  can	  be	  used	  as	  
T	  cell	  markers	  (Guy	  et	  al.,	  2009).	  	  
	  
Non-­‐conventional	  (γδ)	  and	  NK	  T	  cells	  are	  also	  present	  in	  whole	  blood	  in	  smaller	  
proportions	  (Bonneville	  et	  al.,	  2010).	  Non-­‐conventional	  T	  cells	  characterized	  by	  




(Bonneville	   et	   al.,	   2010).	   On	   the	   other	   hand,	   NK	   T	   -­‐cells	   recognize	   glycolipids	  
presented	  by	  the	  CD1d	  molecule	  on	  APC	  (Parekh	  et	  al.,	  2005).	  
	  
1.1.1.2.1.	  CD8	  T	  cells	  
After	  completing	  thymic	  maturation,	  naïve	  CD8	  T	  cells	  bear	  CD8	  co-­‐receptors	  on	  
their	   surface	   (Janeway	   et	   al.,	   2008).	   In	   the	   event	   of	   an	   invasion	   of	   the	   host	  
immune	  system	  by	  a	  virus,	  naïve	  CD8	  T-­‐cells	  express	  the	  adhesion	  molecule	  L-­‐
selectin	  and	  the	  chemokine	  receptor	  CCR7	  which	  help	  them	  migrate	  into	  lymph	  
nodes	  where	   they	   recognize	   viral	   peptides	   presented	   on	  MHC	   I	  molecules	   by	  
APCs	   (Burgdorf	   et	   al.,	   2007).	   Upon	   this	   recognition,	   CD8	   T-­‐cells	   generally	  
differentiate	  either	  into	  effector	  Cytotoxic	  T	  Lymphocytes	  (CTL)	  or	  memory	  CD8	  
T	   cells	   (Burgdorf	   et	   al.,	   2007).	   These	   two	   types	   are	   characterized	   by	   different	  
surface	  markers	  and	  secrete	  different	  molecules.	  
	  
Upon	  differentiation,	  effector	  CTL	  undergo	  some	  changes	  on	  their	  surface,	  and	  
start	  expressing	  markers	  such	  as	  CD57	  and	  CD11d	  (Hamann	  et	  al,	  1999;	  Williams	  
et	  al.,	  2007).	  These	  allow	  them	  to	  kill	  virus-­‐infected	  cells	  mediated	  by	  effector	  
molecules	  such	  as	  granzymes	  and	  perforins	  (Hamann	  et	  al,	  1999;	  Williams	  et	  al.,	  
2007).	  In	  addition,	  CTLs	  secrete	  high	  levels	  of	  IFN-­‐g	  and	  TNF-­‐alpha	  important	  for	  
control	  of	  intracellular	  pathogens	  such	  as	  Human	  Immunodeficiency	  Virus	  (HIV)	  
and	  Mycobacterium	   Tuberculosis	   (M.TB)	   (Hamann	   et	   al,	   1999;	  Williams	   et	   al.,	  
2007).	  Effector	  T	  cells,	  characterized	  by	  high	  expression	  of	  CD57,	  lack	  the	  ability	  
to	   proliferate	   and	   die	   by	   programmed	   cell	   death	   after	   long-­‐term	   antigenic	  
stimulation	  (Hamann	  et	  al,	  1999;	  Williams	  et	  al.,	  2007).	  
	  
On	   the	   other	   hand,	   memory	   CD8	   T-­‐cells	   are	   long-­‐lived	   cells	   with	   a	   strong	  
proliferative	   ability	   upon	   antigen	   re	   stimulation	   (Williams	   et	   al.,	   2007).	   As	  
shown	  in	  table	  1,	  unlike	  effector	  CD8	  T	  cells,	  memory	  CD8	  T	  cells	  are	  CD45RA-­‐	  
CD57-­‐	  cells	  and	  they	  do	  not	  secrete	  as	  much	  perforin	  and	  granzyme	  B	  (Hamann	  
et	  al,	  1999;	  Williams	  et	  al.,	  2007).	  Memory	  CD8	  T	  cells	  proliferation	  is	  mediated	  




et	   al.,	   2007).	   They	   are	   particularly	   important	   in	   vaccine-­‐induced	   immunity	  
against	  certain	  pathogens	  and	  can	  also	  express	  antiviral	  cytokines	  such	  as	  IFN-­‐g	  
(Hamann	   et	   al,	   1999;	   Williams	   et	   al.,	   2007).	   Memory	   CD8-­‐T	   cell	   activity	   is	  
regulated	   by	   CD4+	   T-­‐cells.	   Memory	   T	   cells	   have	   been	   generally	   classified	   as	  
central	  memory	  (TCM)	  and	  effector	  memory	  (TEM	  )	  (Kaech	  et	  al.,	  2007;	  Wherry	  et	  
al.,	   2003).TCM	   are	   CD62LhiCCR7+	   cells	   located	   in	   lymphoid	   organs	   and	   are	  
thought	   to	   be	   involved	   in	   secondary	   memory	   responses	   (Kaech	   et	   al.,	   2007;	  
Wherry	  et	   al.,	   2003).	   TEM	  are	  CD62LloCCR7-­‐	  found	   in	  non-­‐lymphoid	   tissues	   and	  
they	  exhibit	  express	  lytic	  activity	  (Kaech	  et	  al.,	  2007;	  Wherry	  et	  al.,	  2003).	  CD8+	  
TCM	  cells	  have	  been	  shown	  to	  induce	  greater	  protective	  immunity	  than	  TEM	  cells	  
in	   mice	   (Kaech	   et	   al.,	   2007;	  Wherry	   et	   al.,	   2003).	   In	   addition,	   CD8+	   TCM	   cells	  
exhibit	  a	  greater	  proliferative	  ability	  than	  cells	  greater	  proliferative	  burst	  of	  TCM	  
cell-­‐derived	  secondary	  effector	  T	  cells	  (Kaech	  et	  al.,	  2007;	  Wherry	  et	  al.,	  2003).	  
However,	   the	   division	   of	   CD8+	   T	   cells	   into	   TCM	   and	   TEM	   cells	   may	   be	   an	  
oversimplification	  (Badovinac	  et	  al.,	  2007;	  Wherry	  et	  al.,	  2003).	  	  




Table	   1.1:	   Properties	   of.CD8.T-­‐cell	   subsets	   (Reproduced	   from	  Hamman	  et	  al.,	  
1999	  (Hamann	  et	  al.,	  1999).	  
	  
	  
1.1.1.2.2.	  CD4+	  T-­‐cells	  
CD4+	   T-­‐cells	   complete	   their	   development	   in	   a	   similar	   fashion	   to	   CD8+	   T	   cells,	  
and	   are	   characterized	   by	   their	   CD4	   co-­‐receptor.	   After	   completing	   their	  
development,	   naïve	   CD4+	   T-­‐cells	   move	   to	   lymphoid	   tissues	   where	   they	  
recognize	  antigenic	  peptides	  presented	  by	  APCs	  on	  MHCII	  molecules	   (Janeway	  




naive	  CD4	  T	  cells	  differentiate	  into	  one	  of	  several	  lineages	  of	  T	  helper	  (Th)	  cells,	  
including	  Th1,	  Th2,	  Th17	  and	  Tregs	  (Wan	  et	  al.,	  2009;	  Zhu	  et	  al.,	  2010).Th1	  cells	  
are	   important	   in	   the	   control	   of	   intracellular	   pathogens	   such	   as	   HIV	   and	  
Mycobacterium	   Tuberculosis.	   They	   play	   an	   important	   role	   in	   phagocyte-­‐
dependent	  host	  responses	  (Romagnani,	  1997).	  Th1	  cells	  release	  cytokines	  such	  
as	  IFN-­‐g	  and	  IL-­‐2,	  which	  activate	  infected	  macrophages	  to	  promote	  the	  killing	  of	  
pathogens	  (Wan	  et	  al.,	  2009;	  Zhu	  et	  al.,	  2010).In	  addition,	  studies	  have	  shown	  
that	  Th1	  cells	  can	  lead	  to	  class	  switching	  of	  activated	  B	  cells	  (Smith	  et	  al.,	  2000;	  
Zhu	  et	   al.,	   2010).It	   has	   also	  been	  demonstrated	   that	   Th1	   cells	   are	   involved	   in	  
certain	  autoimmune	  diseases	  such	  as	  Crohn’s	  disease	  (Romagnani,	  1997).Unlike	  
Th1	   cells,	   Th2	   cells	   are	   primarily	   involved	   in	   phagocyte-­‐independent	   host	  
responses	  and	  the	  control	  of	  extracellular	  pathogens	  such	  as	  helminthes,	  toxins	  
(Janeway	  et	  al.,	  2008;	  Zhu	  et	  al.,	  2006).	  They	  release	  cytokines	  such	  as	  IL-­‐4	  and	  
IL-­‐5,	   which	   induce	   activation	   of	   B-­‐cells	   and	   the	   production	   of	   antibodies	  
(Janeway	  et	  al.,	  2008;	  Zhu	  et	  al.,	  2006).In	  addition,	  Th2	  cells	  release	  the	  cytokine	  
IL-­‐13	  which	  is	  important	  in	  allergic	  responses	  (Walter	  et	  al.,	  2001).Th2	  and	  Th1	  
cells	   are	   mutually	   inhibitory	   (Romagnani,	   1997).	   IFN-­‐g	   produced	   by	   Th1	   cells	  
was	  shown	  to	  inhibit	  the	  proliferation	  of	  Th2	  cells	  (Wan	  et	  al.,	  2009;	  Zhu	  et	  al.,	  
2010).	   Similarly,	   IL-­‐10,	   cytokine	   produced	   by	   Th2	   cells	   has	   the	   ability	   to	  
downregulate	  Th1	  cell	  cytokine	  production	  (Couper	  et	  al.,	  2008).	  This	  suggests	  
that	   the	   Th1	   and	   Th2	   responses	   should	   be	  well	   balanced	   to	   enable	   optimum	  
host	   responses	   to	   different	   types	   of	   pathogens	   (Wan	   et	   al.,	   2009;	   Zhu	   et	   al.,	  
2010).	   This	   balance	   is	   particularly	   important	   for	   vaccine	   responses,	   especially	  
for	   individuals	  whose	  immune	  systems	  are	  still	  developing	  or	  deficient	  (infants	  
or	  HIV-­‐infected	  individuals	  (Poland	  et	  al.,	  2007;	  Siegrist,	  2007).	  	  
	  
A	  third	  CD4+	  T-­‐cell	  subset	  that	  has	  recently	  been	  identified	  and	  is	  referred	  to	  as	  
Th17.	   Th17	   cells	   release	   cytokines	   such	   as	   IL-­‐17,	   IL-­‐21,	   and	   IL-­‐22	   (Korn	   et	   al.,	  
2009;	  Liang	  et	  al.,	  2006).	  IL-­‐17	  can	  induce	  inflammatory	  responses	  and	  may	  play	  
a	   protective	   role	   against	   bacterial	   infections	   at	   the	   mucosa	   (Lin	   et	   al.,	   2010;	  




correlation	   between	   a	   high	   expression	   of	   IL-­‐17	   and	   better	   protection	   against	  
mycobacteria.	  	  
	  
Regulatory	  T-­‐cells	  often	  referred	  to	  as	  Tregs,	  represent	  another	  subsets	  of	  CD4	  
T-­‐cells.	  These	  are	  CD4+	  CD25+	  T	  cells	  that	  do	  not	  proliferate	  upon	  their	  receptor	  
activation	  and	  are	   suppressive	   in	  nature	   (Mills,	  2004).	  They	  are	   thought	   to	  be	  
important	  in	  the	  prevention	  of	  autoimmune	  diseases	  (Sakaguchi	  et	  al.,	  2006).	  In	  
fact,	  studies	  have	  shown	  they	  can	  release	   IL-­‐10	  and	   inhibit	   the	  activity	  of	  self-­‐
reactive	  CD4+	  and	  CD8+	  T-­‐cells	  (Beissert	  et	  al.,	  2006;	  Kuhn	  et	  al.,	  2009).	  	  
	  
Figure	   1.1	   shows	   the	   differentiation	   of	   effector	   CD4	   T-­‐cells	   and	   the	   types	   of	  
cytokines	  they	  secrete	  and	  figure	  1.2	  shows	  these	  effector	  T-­‐cells	  interact	  with	  
other	  cells	  of	  the	  immune	  system.	  





Figure	   1.1:	   Naive	   CD4+	   T	   differentiation	   into	   Th1,	   Th2,	   Th17,	   and	   Treg	   cells.	   Upon	  
antigen	  presentation	  by	  the	  APC-­‐MHC	  complex,	  naive	  CD4	  T	  cells	  differentiate	  into	  Th1	  
cells	   through	   the	  activation	  of	   the	   regulatory	   transcription	   factor	  T-­‐bet	  via	   the	  STAT1	  
and	  STAT4	  pathways	  after	  secretion	  f	  IL-­‐12	  that	  plays	  a	  vital	  role	  in	  the	  development	  of	  
Th1	  cells.	  Th1	  cells	  secrete	  IFN-­‐γ	  which	  is	  important	  for	  protection	  against	  intracellular	  
bacteria	  and	  viruses.	  IL-­‐4	  promotes	  the	  activation	  of	  STAT6	  and	  GATA3,	  responsible	  for	  
Th2	  cell	  differentiation.	  Th2	  cells	  are	  important	  in	  humoral	  immunity	  against	  parasites,	  
and	  their	  activity	  is	  mediated	  through	  cytokines	  of	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13	  that	  they	  secrete.	  
TGF-­‐β	  and	  pro-­‐inflammatory	  cytokines,	  such	  as	  IL-­‐6	  and	  IL-­‐23,	  induce	  differentiation	  of	  
naive	   CD4+T	   cells	   differentiation	   into	   IL-­‐17-­‐producing	   Th	   cells	   (Th17)	   through	  
transcription	  factors	  STAT3	  and	  RORγt.	  Th17	  cells	   induce	   inflammatory	  responses	  and	  
may	   play	   a	   protective	   role	   against	   bacterial	   infections.	   In	   addition,	   TGF-­‐β	   can	   also	  
induce	  differentiation	  of	  naive	  CD4+T	  cells	  into	  Foxp3+Treg	  cells,	  which	  produce	  TGF-­‐β	  
and	  IL-­‐10	  and	  act	  as	  modulators	  of	  immune	  responses	  (Leung	  et	  al.,	  2010).	  	  





Figure	   1.2:	   Interaction	   between	   CD4	   T-­‐cells	   and	   other	   immune	   cells.	   Upon	   host	  
infection	  by	  a	  pathogen,	  Macrophages	  and	  Dendritic	  Cells	  (APCs)	  recognize	  pathogens	  
through	   their	   Pathogen	  Recognition	  Receptors	   (PRRs).	  Dendritic	   cells	   present	   antigen	  
to	  naive	  CD4+	  T	   cell	   via	  MHCII	  molecules.	  Upon	  antigenic	  presentation	   to	   their	  TCRs,	  
naïve	  CD4+	  T	  cells	  differentiate	  into	  Th1,	  Th2,	  Th17	  (not	  shown)	  and	  regulatory	  T	  cells	  
(T	  regs).	  Th2	  cells	  release	  cytokines	  such	  as	  IL-­‐4,	  IL-­‐6	  that	  induce	  eosinophil	  recruitment	  
and	  induce	  antibody	  production	  by	  B	  cells.	  Th1	  cells	  secrete	  mostly	  IFN-­‐γ	  that	  enhances	  
CD8+	  T	  cell	  activity.	  Regulatory	  T	  cells	  downregulate	  the	  activity	  of	  Th1,	  Th2	  and	  CD8+	  T	  
cells	  (Mills,	  2004).	  
	  
Similar	   to	  memory	  CD8+	  T	  cells,	  memory	  CD4+	  T-­‐cells	  are	   long-­‐lived	  cells	   that	  
proliferate	  after	  a	  second	  encounter	  with	  an	  antigen	  (Seder	  et	  al.,	  2003).	  Their	  
establishment	   is	  particularly	   important	  for	  protection	  against	  a	  pathogen	  after	  




As	   described	   above,	   cells	   of	   the	   immune	   system,	   particularly	   T-­‐cells,	   regulate	  




Cytokines	   are	   soluble	   effector	   molecules	   secreted	   by	   immune	   system’s	   cells,	  
especially	   T-­‐cells	   (Janeway	   et	   al.,	   2008).	   These	   cytokines	   can	   trigger	  
inflammatory	   responses	   at	   different	   sites	   of	   infection	   locally	   or	   at	   a	   distance	  
(Gouwy	   et	   al.,	   2005).	   In	   addition,	   they	   can	   regulate	   activity	   of	   some	   immune	  
cells	  by	  binding	  to	  specific	  receptors	  on	  the	  surface	  on	  these	  cells	  (Gouwy	  et	  al.,	  
2005;	  Kelso,	  1998).There	  are	  different	  groups	  of	  cytokines	  secreted	  by	  different	  
cells	  and	  each	  plays	  a	  different	  function.	  Here,	  we	  will	   focus	  only	  on	  the	  main	  
cytokines	  secreted	  by	  T-­‐cells.	  
	  
1.2.1.	  Interferons	  
There	  are	   two	   families	  of	   interferon	   cytokines	  also	   referred	   to	  as	   IFNs.	   Type	   I	  
IFNs	  (for	  example	  IFN-­‐α,	  IFN-­‐ß,	  and	  IFN-­‐ᾠ)	  are	  encoded	  by	  multiple	  genes,	  and	  
type	  II	  IFN-­‐γ	  encoded	  by	  a	  single	  gene	  (Honda	  et	  al.,	  2006;	  Theofilopoulos	  et	  al.,	  
2005).	  Even	  though	  they	  are	  not	  structurally	  related,	  they	  all	  have	  been	  shown	  
to	   have	   antiviral	   activity	   (Randall	   et	   al.,	   2008).	   In	   fact,	   mouse	   studies	   have	  
revealed	  that	  mice	  lacking	  Type	  I	  and	  II	  IFN	  genes	  are	  highly	  susceptible	  to	  viral	  
infections	   (Stetson	   et	   al.,	   2006).	   Type	   I	   IFNs	   are	   mainly	   produced	   by	  
macrophages,	   bind	   to	   specific	   receptors	   on	   macrophages,	   and	   lead	   to	   their	  
activation	   (Frucht	   et	   al.,	   2001;	   Randall	   et	   al.,	   2008).	   Besides	   their	   antiviral	  
activity,	   Type	   I	   IFNs	   affect	   the	   release	   of	   pro-­‐inflammatory	   cytokines	   or	   nitric	  
oxide	  by	  dendritic	   cells	   and	   the	   activity	   of	   type	   II	   interferon	   (IFN-­‐	   γ)	   (Bogdan,	  
2000;	  Le	  Bon	  et	  al.,	  2001).	  	  
	  
On	  the	  other	  hand,	  IFN-­‐γ	  is	  secreted	  by	  a	  few	  types	  of	  cells:	  NK	  cells,	  NK	  T-­‐cells,	  
CD4-­‐T	   cells	   and	   CTLs	   (Randall	   et	   al.,	   2008;	   Theofilopoulos	   et	   al.,	   2005).	   IFN-­‐γ	  




subsequently	   induces	   signals	   within	   these	   cells	   that	  modify	   their	   activity	   and	  
their	   function	   (Theofilopoulos	   et	   al.,	   2005).	   IFN-­‐γ	   has	   been	   demonstrated	   to	  
enhance	  macrophage	  activity	  against	  viruses	  and	  bacteria	  (Randall	  et	  al.,	  2008;	  
Theofilopoulos	   et	   al.,	   2005).	   In	   fact,	   IFN-­‐γ	   binding	   to	   macrophages	   leads	   to	  
secretion	  of	  IL-­‐12,	  important	  for	  control	  of	  mycobacteria	  Tuberculosis	  (Demissie	  
et	   al.,	   2004;	  Newport,	   1996;	   Pai	   et	   al.,	   2003).	   Furthermore,	   IFN-­‐γ	   upregulates	  
the	  expression	  of	  MHC	   I	   and	  MHC	   II	  by	  APCs	  and	   therefore	  enhances	  antigen	  
presentation	  to	  T-­‐cells	  (Janeway	  et	  al.,	  2008;	  Theofilopoulos	  et	  al.,	  2005).	  IFN-­‐γ	  
can	   modulate	   the	   permeability	   of	   epithelial	   barriers	   (Theofilopoulos	   et	   al.,	  
2005).	  IFN-­‐γ	  also	  inhibits	  Th2	  cells	  activity	  and	  promote	  the	  secretion	  of	  Ig2a	  by	  
B	  –cells	  (Janeway	  et	  al.,	  2008;	  Theofilopoulos	  et	  al.,	  2005).	  	  
	  
As	   depicted	   above,	   interferons	   modulate	   the	   activity	   of	   innate	   and	   adaptive	  
immunity	   and	   therefore	   are	   essential	   for	   protection	   against	   pathogens	  
especially	   viruses	   and	   bacteria.	   However,	   their	   overexpression	   can	   be	  
detrimental	   to	   the	   host.	   Thus,	   in	   some	   cases	   they	   are	   inhibited	   by	   other	  
cytokines	  secreted	  by	  T-­‐cells	  such	  as	  IL-­‐1	  and	  IL-­‐4	  (Dinarello,	  2009).	  	  
	  
1.2.2.	  Interleukins	  
Interleukins	  represent	  another	   family	  of	  cytokines	  secreted	  by	  effector	  T-­‐cells.	  
Within	   this	   family,	   they	   can	   be	   divided	   into	   subfamilies	   depending	   on	   their	  
functions,	  structures	  and	  the	  receptor	  they	  bind	  to	  (Dinarello,	  2009;	  Janeway	  et	  
al.,	  2008).	  Here	  we	  will	  only	  discuss	  the	  main	  interleukins	  subfamilies.	  The	  IL-­‐1	  
subfamily	  is	  made	  up	  of	  18	  cytokines	  which	  bind	  to	  IL-­‐1	  Types	  I	  and	  II	  receptors	  
and	   are	  mostly	   secreted	  by	  macrophages	   and	  T-­‐cells	   (Akdis	   et	   al.,	   2011).IL-­‐1ß	  
and	  IL-­‐1α	  are	  the	  most	  studied	  cytokines	  of	  the	  subfamily	  and	  have	  been	  shown	  
to	  induce	  systemic	  and	  local	  inflammation	  (Akdis	  et	  al.,	  2011;	  Dinarello,	  2009).	  
Furthermore,	   IL-­‐1	  cytokines	  mostly	  act	  on	  T-­‐cells	  and	  epithelial	   cells	  and	  have	  
been	   associated	   with	   autoimmune	   and	   pro-­‐inflammatory	   diseases	   such	   as	  




treated	  by	  the	  administration	  of	  IL-­‐1RA,	  an	  IL-­‐1	  receptor	  antagonist	  (Akdis	  et	  al.,	  
2011).	  
	  
IL-­‐2	  is	  a	  trimeric	  cytokine	  mainly	  secreted	  by	  Th1,	  CD8+	  and	  NKT-­‐cells	  (Akdis	  et	  
al.,	  2011).	  IL-­‐2	  has	  been	  shown	  to	  promote	  B-­‐cell	  growth	  and	  to	  enhance	  their	  
antibody	  production	   (Akdis	  et	  al.,	  2011).	  Furthermore,	   it	  enhances	   the	  growth	  
and	  cytolytic	  activity	  of	  NK	  cells	   (Akdis	  et	  al.,	  2011).	   IL-­‐2	  plays	  a	  critical	   role	   in	  
the	  function	  and	  development	  of	  Tregs	  (Furtado	  et	  al.,	  2002;	  Nelson,	  2004).	  In	  
fact,	   Furtado	   et	   al	   demonstrated	   that	   IL-­‐2	   knockout	   mice	   could	   not	   develop	  
functioning	   Tregs	   (Furtado	   et	   al.,	   2002).IL-­‐2	   has	   been	   associated	   with	   T-­‐cell	  
mediated	   autoimmune	   diseases	   (Akdis	   et	   al.,	   2011;	   Setoguchi	   et	   al.,	   2005;	  
Waldmann,	  2006)and	  some	  T-­‐cell	  lymphomas	  and	  leukemias	  have	  been	  shown	  
to	   express	   an	   IL-­‐2	   receptor	   on	   their	   surface	   (Akdis	   et	   al.,	   2011;	   Waldmann,	  
2006).	   Anti–IL-­‐2Ra	   antibodies	   are	   used	   in	   immunotherapy	   to	   inhibit	   immune	  
response	   in	   patients	   with	   autoimmune	   diseases	   and	   prevent	   transplant	  
rejection	   (Akdis	  et	  al.,	  2011;	  Waldmann,	  2006).	   In	  addition,	   they	  are	  currently	  
being	   investigated	   as	   a	   potential	   therapeutic	   for	   certain	   cancers	   (Akdis	   et	   al.,	  
2011;	  Waldmann,	  2006).	  
	  
On	   the	   other	   hand,	   IL-­‐13,	   IL-­‐4,	   and	   IL-­‐5	   bind	   to	   closely	   related	   receptors	   and	  
belong	   to	   the	   same	   subfamily	   (IL-­‐4	   subfamily)	   (Akdis	   et	   al.,	   2011).They	   are	  
produced	   by	   Th2	   cells	   and	   play	   similar	   functions	   (Akdis	   et	   al	   2009).	   They	   are	  
associated	  with	  the	  activation	  and	  recruitment	  of	  mast	  cells	  (Akdis	  et	  al	  2009).	  
In	   addition,	   IL-­‐13	   and	   IL-­‐4	   have	   been	   shown	   to	   activate	   B-­‐cells	   (Akdis	   et	   al.,	  
2011;	   Janeway	   et	   al.,	   2008).	   Furthermore,	   they	   upregulate	   the	   expression	   of	  
MHC	  II	  by	  macrophages	  and	  B-­‐cells	  and	  mediate	  class	  switching	  to	  IgG	  and	  IgE	  
(Akdis	  et	  al.,	  2011;	  Janeway	  et	  al.,	  2008).	  Roussel	  et	  al	  also	  demonstrated	  that	  
IL-­‐13	   inhibits	   pro-­‐inflammatory	   cytokines	   and	   is	   required	   for	   maintenance	   of	  
IgE-­‐mediated	  allergic	  responses	  (Roussel	  et	  al.,	  1998).	  
	  
IL-­‐17,	  IL-­‐21	  and	  IL-­‐22	  secreted	  by	  Th17	  cells	  represent	  an	  emerging	  subfamily	  of	  




cytokines	   (Stockinger	   et	   al.,	   2007).	   IL-­‐21	   and	   IL-­‐22’s	   other	   functions	   are	   still	  
being	   elucidated	   (Stockinger	   et	   al.,	   2007).	   It	   has	   been	   shown	   that	   IL-­‐17	   can	  
stimulate	   macrophages	   and	   epithelial	   cells	   to	   secrete	   pro-­‐inflammatory	  
cytokines	  such	  as	   IL-­‐1	  and	  TNF-­‐α	  (Iwakura	  et	  al.,2006;	  Stockinger	  et	  al.,	  2007).	  
Due	   to	   its	   pro-­‐inflammatory	   properties,	   IL-­‐17	   has	   been	   associated	  with	  many	  
autoimmune	  diseases	  (Komiyama	  et	  al.,	  2006;	  Nakae	  et	  al.,	  2003).	  Recent	  mice	  
studies	   showed	   that	   mice	   lacking	   IL-­‐27,	   a	   known	   IL-­‐17	   inhibitor,	   were	   more	  
susceptible	   to	   autoimmune	   diseases	   (Batten	   et	   al.,.2006).	   Despite	   these	  
negative	   effects,	   IL-­‐17	  may	   play	   an	   important	   role	   in	   host	   defense.	   In	   fact,	   it	  
induces	  recruitment	  of	  neutrophils	  at	  the	  sites	  of	   infection	  and	  therefore	   links	  
innate	  immunity	  to	  adaptive	  immunity	  (Wu	  et	  al.,	  2007).	  	  
	  
In	   summary,	   cytokines	   are	   important	   effector	   molecules.	   They	   help	   in	   the	  
recruitment	   of	   specific	   immune	   cells	   and	   play	   a	   critical	   role	   against	   some	  
pathogens.	   However,	   in	   some	   cases	   they	   can	   trigger	   inflammation	   and	   be	  
detrimental	  to	  the	  host	  (Gouwy	  et	  al.,	  2005).	  Because	  of	  their	  interplay	  on	  many	  
immune	  cells,	  cytokines	  contribute	  greatly	  to	  T	  cell	  homeostasis	  of	  the	  immune	  
system	   especially	   in	   the	   mucosa	   and	   the	   gut	   (Boyman	   et	   al.,	   2007),	   i.e.	   to	  
preserve	  normal	  T-­‐cell	  counts	  following	  T-­‐cell	  depletion	  or	  expansion	  (Boyman	  
et	  al.,	  2007).	  IL-­‐15	  and	  IL-­‐7	  are	  the	  main	  cytokines	  influencing	  T	  cell	  homeostasis	  
due	   to	   their	   effects	  on	  T	   cell	   proliferation	   (Stockinger	  et	   al.,	   2004).	   Figure	  1.3	  
shows	  the	  functions	  of	  the	  main	  cytokines	  produced	  by	  T	  cells.	  
	  
It	  is	  important	  to	  note	  that	  cytokine	  function	  and	  activity	  greatly	  depend	  on	  the	  
maturity	   of	   the	   immune	   system.	   The	   properties	   and	   mechanisms	   discussed	  
above	   are	  mostly	   observed	   in	   adults.	   Neonates	   have	   different	   immunological	  
characteristics.	  	  





Figure	   1.3:	   Function	   of	   main	   cytokines	   produced	   by	   T-­‐cells.	   Interleukins	   and	  
Interferons	  are	   the	  main	   cytokines	  produced	  by	  CD4+	  T	   cells,	   especially	   Th1	  and	  Th2	  
cells.	  Th2	  secrete	  IL-­‐5	  that	  has	  been	  shown	  to	  be	  important	  for	  eosinophil	  recruitment	  
at	   the	   site	   of	   infection.	   In	   addition,	   Th2	   cells	   also	   produce	   IL-­‐4,	   IL-­‐10	   and	   IL-­‐13.Thse	  
cytokines	  activate	  mast	  cells	  and	  also	  enhance	  B	  cell	  activity.	  In	  addition,	  IL-­‐4,	  IL-­‐10	  and	  
IL-­‐13	   inhibit	   Th1	   cells	   and	  macrophages	   and	   favor	   Th2	   differentiation.	   On	   the	   other	  
hand,	   Th1	   cells	   release	   IL-­‐2	   and	   IFN-­‐γ.	   IL-­‐2	   facilitates	  B	   cell	   activity	   and	  phagocytose-­‐
dependent	  mechanisms.	  IFN-­‐γ	  activates	  macrophages	  (Romagnani,	  1997)	  
	  
1.3.	  Immunity	  in	  early	  infancy	  
During	  the	  first	  months	  of	   life,	  an	   individual	   is	  more	  susceptible	  to	  pathogens.	  
This	   is	   partially	   due	   to	   the	   “immaturity”	   of	   the	   immune	   system	   in	   early	   life	  
(Newburg	  et	  al.,	   2007).	   In	   some	   respects,	   the	  neonatal	   immune	   system	   is	   still	  




al.,	   1997)	   (Chappuis	  et	   al	   1998,	  Kovarik	  et	   al	   1998).	  Both	  neonatal	   innate	  and	  
adaptive	   immunity	   are	   different	   from	   their	   adult	   counterparts	   (Maródi,	   2006;	  
Zaghouani	  et	  al.,	  2009).	  	  
	  
	  1.3.1.	  Innate	  immunity	  in	  infants	  
Neonates	  have	  greatly	  impaired	  neutrophil	  adherence	  and	  activity	  (Carr,	  2000).	  
Since	  neutrophils	  are	  the	  first	  line	  of	  defense	  when	  the	  host	  immune	  system	  is	  
invaded	   by	   pathogens,	   impairment	   of	   their	   function	   contributes	   to	   the	   rapid	  
spread	  of	   infections	   (Kovarik	  et	  al.,	  1997;	  Maródi,	  2006;	  Petty	  et	  al.,	  1998).	   In	  
addition	   to	   poor	   neutrophil	   function,	   Petty	   et	   al	   demonstrated	   that	   neonatal	  
dendritic	  cells	  have	  a	  limited	  ability	  to	  induce	  T-­‐cell	  proliferation	  in	  response	  to	  
different	  mitogens	   compared	   to	   adult	   dendritic	   cells	   (Petty	   et	   al.,	   1998).	   This	  
could	   partly	   be	   due	   to	   the	   reduced	   MHC	   expression	   observed	   in	   neonates	  
(Maródi,	   2006).	   Neonates	   demonstrate	   reduced	   production	   of	   some	   pro-­‐
inflammatory	   cytokines	   such	   as	   IL-­‐12,	   IL-­‐23	   and	   IFN-­‐γ	   (Kovarik	   et	   al.,	   1997).	  
These	   cytokines	   are	   important	   for	   the	   activation	   of	   mononuclear	   phagocytes	  
especially	   macrophages	   (Maródi,	   2006).	   In	   fact,	   macrophage	   responses	   are	  
often	   sub-­‐optimal	   in	   neonates	   (Maródi,	   2006).	   Many	   studies	   reveal	   that	   TLR	  
signaling	   pathways	   are	   greatly	   impaired	   in	   neonates	   (De	   Wit	   et	   al.,	   2003;	  
Kollmann	  et	  al.,	  2009).	  Kollmann	  et	  al	  recently	  demonstrated	  that	  neonatal	  TLR-­‐
mediated	   innate	  responses	  are	  different	  from	  those	   in	  adults	   (Kollmann	  et	  al.,	  
2009;	  Kollmann	  et	  al.,	  2012).	  Neonatal	  innate	  immune	  cells	  (DCs,	  macrophages)	  
secrete	  very	   small	  quantities	  of	   IFN-­‐γ	  and	   IL-­‐12p70	   in	   response	   to	  TLR	   ligands	  
compared	  to	  adult	  innate	  immune	  cells	  (Kollmann	  et	  al.,	  2009;	  Kollmann	  et	  al.,	  
2012).	  On	  the	  other	  hand,	  neonatal	  innate	  immune	  cells	  secrete	  more	  Th2	  (IL-­‐4)	  
and	   Th17	   (IL-­‐17,	   IL-­‐23)	   cytokines	   in	   response	   to	   TLR	   ligands	   than	   adult	   innate	  
immune	  cells	   (Kollmann	  et	  al.,	   2009).	  These	  differences	  explain	  why	  neonates	  
are	  more	  vulnerable	  to	  both	  viruses	  such	  as	  Cytomegalovirus	   (Kollmann	  et	  al.,	  
2009;	  Maródi,	  2006)or	  bacterial	  sepsis	  (Lavoie	  et	  al.,	  2010).	  Thus,	  their	  impaired	  




distinct	  from	  that	  of	  adults	  (Kollmann	  et	  al.,	  2009)	  and	  these	  differences	  will	  be	  
addressed	  in	  the	  following	  section.	  	  
	  
1.3.2.	  Neonatal	  T-­‐cell	  immunity	  
Table	  1.2	  shows	  the	  main	  characteristics	  of	  neonatal	   immunity.	   In	  most	  cases,	  
neonatal	  T	  cells	  preferentially	  make	  type	  2	  cytokines	  such	  as	   IL-­‐4,	   IL-­‐5,	  and	   IL-­‐
13,	   and	   therefore	   their	   immune	   responses	   are	   biased	   toward	   Th2	   responses	  
(Garcia	  et	  al.,	  2000;	  Maródi,	  2006;	  Siegrist,	  2007).	  In	  some	  cases,	  Th1	  responses	  
are	  practically	  undetectable	   in	  neonates	   (Garcia	  et	  al.,	   2000;	  Zaghouani	  et	  al.,	  
2009).	   However,	   under	   some	   circumstances,	   neonates	   can	   produce	   Th1	  
cytokines,	   such	  as	   to	  BCG	  and	  Cytomegalovirus	   (CMV)	   (Marchant	  et	  al.,	   1999;	  
Park	  et	  al.,	  2006).	  	  
	  
The	  Th1/Th2	  imbalance	  can	  be	  partially	  explained	  by	  the	  predominance	  of	  Th2	  
cytokines	   during	   pregnancy	   (Kovarik	   et	   al.,	   1997),	   and	   partly	   to	   the	   fact	   that	  
infants	  are	  deficient	   in	  production	  of	   IL-­‐12.	   It	  has	  been	  demonstrated	  that	  the	  
presence	  of	   IL-­‐4	  during	  T-­‐cell	  priming	  can	   inhibit	   IL-­‐12Rβ2	  chain	  expression	  on	  
naive	   T	   cells	   and	   therefore	  direct	   cells	   towards	   Th2	   responses	   in	  humans	   and	  
mice	   (Li	   et	   al.,	   2004;	   Ohshima	   et	   al.,	   1997).	   Lee	   et	   al	   showed	   that	   delayed	  
maturation	  of	   IL-­‐12	  producing	  dendritic	   cells	   results	   in	  a	  Th2	  bias	   in	  neonates	  
(Lee	   et	   al.,	   2008).	   In	   addition,	   as	   described	   above,	   neonatal	   deficiency	   in	   Th1	  
responses	   can	   also	   be	   attributed	   to	   the	   impaired	   TLR-­‐mediated	   innate	  
responses	  of	  APCs	  especially	  dendritic	  cells,	  which	  play	  an	  important	  role	  in	  the	  
activation	   of	   Th1	   cells	   (Kollmann	   et	   al.,	   2009).	   The	   immaturity	   of	   neonatal	  
immunity	  has	  many	   implications	   for	  neonatal	   immunization	  and	  their	   immune	  
responses	  to	  vaccines.	  	  





Table	  1.	  2:	  Main	  characteristics	  of	  neonatal	  immunity.	  
Innate	  Immunity	   	  T-­‐cell	  Immunity	  
Impairment	  of	  DC	  and	  macrophage	  activity.	  
Reduction	  of	  MHC	  molecules	  expression	  
Impairment	  of	  TLR–mediated	  immune	  responses	  
	  
Lack	  of	  pro-­‐inflammatory	  cytokines	  secreted	  by	  innate	  cells	   Downregulation	  of	  IFN-­‐g	  	  
	  
1.4.	  Vaccination	  in	  neonates	  
1.4.1.	  Vaccines,	  antigens	  and	  adjuvants	  
“A	   vaccine	   is	   a	   biological	   preparation	   that	   improves	   immunity	   to	   a	   particular	  
disease.	   A	   vaccine	   typically	   contains	   an	   agent	   that	   resembles	   the	   disease-­‐
causing	  microorganism,	  and	  is	  often	  made	  from	  weakened	  or	  killed	  forms	  of	  the	  
microbe,	  its	  toxins	  or	  one	  of	  its	  surface	  proteins.”(Stern	  et	  al.,	  2005).	  A	  vaccine	  
induces	   the	  host	   immune	   system	   to	   recognize	   foreign	   antigen,	   and	  mount	   an	  
immune	  response	  against	  it	  (Ada	  et	  al,	  2001).	  This	  leads	  to	  the	  establishment	  of	  
immunological	   memory	   that	   will	   potentially	   protect	   the	   host	   after	   later	  
encounters	  with	  the	  virulent	  form	  of	  the	  pathogen	  (Castellino	  et	  al.,.2009).	  The	  
concept	  of	  vaccination	  was	  first	  described	  by	  Edward	  Jenner	  who	  noted	  that	  an	  
8-­‐year-­‐old	  boy	  who	  he	  had	  previously	  inoculated	  with	  pus	  from	  a	  cowpox	  lesion	  
on	  a	  milkmaid’s	  hand	  was	  immune	  to	  variola	  (Stern	  et	  al.,	  2005).	  	  
	  
Most	  vaccines	  are	  prophylactic	  and	  help	  prevent	  future	  infections.	  Prophylactic	  
vaccines	  play	  an	  important	  role	  in	  protection	  against	  infectious	  diseases	  such	  as	  
Tuberculosis	  and	  Diphtheria	  and	  have	  helped	  eradicate	  others	  such	  as	  smallpox	  
(Stern	  et	  al.,	  2005).	  A	  vaccine	  could	  also	  be	  therapeutic,	  as	  is	  the	  case	  of	  cancer	  
and	  HIV	  vaccines	  that	  are	  currently	  being	  developed	  (Lu	  et	  al.,	  2004;	  Simon	  et	  





There	  are	  many	  types	  of	  vaccines;	  each	  type	  has	  different	  properties	  and	  elicits	  
different	  types	  of	  responses	  (Ada	  et	  al.,	  2001;	  Castellino	  et	  al.,	  2009;	  Liu,	  2003).	  
The	   main	   types	   of	   vaccines	   are:	   live	   attenuated	   vaccines,	   whole	   inactivated	  
vaccines,	   toxoid	   vaccines,	   subunit	   vaccines,	   conjugate	   vaccines,	   recombinant	  
vaccines	  and	  DNA	  vaccines	  (Ada	  et	  al.,	  2001;	  Castellino	  et	  al.,	  2009;	  Liu,	  2003).	  
Live	  attenuated	  and	  whole	  cell	  inactivated	  vaccines	  induce	  long-­‐lived	  immunity	  
and	   generally	   have	   higher	   efficacy	   (Belshe	   et	   al.,	   2007;	   Linhares	   et	   al.,	  
2008).However,	   attenuating	  mutations	   present	   in	   live	   vaccine	   strains	   such	   as	  
oral	   polio	   vaccine	   can	   revert	   to	   wild	   type	   and	   cause	   disease	   (Minor,	   2009).	  
Whole	  cell	   inactivated	  vaccines	   such	  as	  whole-­‐cell	  pertussis	  vaccines	  may	  also	  
be	  potentially	  harmful	  due	   to	   the	  presence	  of	   specific	   antigens	   in	   the	  vaccine	  
strains	   (Gustafsson	   et	   al.,	   1996).	   Due	   to	   these	   safety	   concerns,	   synthetic	  
vaccines	   such	   as	   recombinant	   vaccines	   and	   subunit	   vaccines	   are	   often	  
preferred.	  However,	  these	  vaccines	  are	  often	  less	  immunogenic.	  Thus,	  in	  order	  
to	   enhance	   immune	   responses	   to	   those	   vaccines,	   adjuvants	   are	   often	   used	  
(Morefield	   et	   al.,	   2005;	   Sokolovska	   et	   al.,	   2007).These	   chemical	   agents	   can	  
increase	   DC	   activity	   and	   antigen	   presentation	   (Morefield	   et	   al.,	   2005;	  
Sokolovska	  et	  al.,	   2007).	  Adjuvants	   function	   through	   the	   induction	  of	   relevant	  
cytokines	  and	  the	  regulation	  of	  co-­‐stimulatory	  molecules	  (Salerno-­‐Gonçalves	  et	  
al.,	  2006).	  Different	  adjuvants	  are	  chosen	  according	  to	  the	  type	  of	  response	  that	  
is	   desired.	   Various	   TLR	   ligands	   including	   CpG-­‐containing	   oligonucleotides	   are	  
used	   to	   induce	   CTL	   responses.	   CpG-­‐containing	   oligonucleotides,	   which	   signal	  
through	   TLR9,	   can	   induce	   strong	   CD8+	   CTL	   response	   and	   might	   allow	   a	  
reduction	  in	  the	  dose	  of	  antigen	  (Salerno-­‐Gonçalves	  et	  al.,	  2006).	  Reports	  from	  
animal	   and	   human	   studies	   indicate	   that	   they	   are	   generally	   safe	   even	   at	   high	  
doses	  (Salerno-­‐Gonçalves	  et	  al.,	  2006).	  In	  addition,	  in	  a	  recent	  clinical	  trial,	  CpG	  
was	   found	   to	   enhance	   antigen-­‐specific	   cell-­‐mediated	   immunity	   when	  
administered	   with	   hepatitis	   B	   vaccine	   in	   HIV	   infection	   (Angel	   et	   al.,	   2008).	  
Another	   example	   of	   an	   adjuvant	   is	   Aluminium	   salts	   which	   are	   used	   in	   many	  
vaccines	  where	  the	  desired	  protective	  response	  is	  antibody-­‐mediated	  such	  as	  in	  
some	   tetanus	   vaccines	   (Marrack	   et	   al.,	   2009).	   Figure	   1.4	   describes	   the	  





Figure	   1.4:	   Aluminium	   salt	   mechanism	   of	   action	   as	   a	   vaccine	   adjuvant.	   Aluminium	  
salts	  crystals	  activate	  resident	  phagocytes	  partly	  through	  the	  NLR	  family,	  pyrin	  domain	  
containing	   3	   (NLRP3;	   also	   known	   as	   NALP3).	   NLRP3	   inflammasome	   induces	   adaptive	  
Th2.cytokine	   production	   such	   as	   interleukin-­‐4	   (IL-­‐4)	   which	   enhances	   antibody	  
production.	   IL-­‐4A	   Th2	   cytokine	   downregulates	   IFN-­‐γ	   secretion	   and	   Th1	   responses	  
(Marrack	  et	  al.,	  2009).	  	  
	  
	  1.4.1.1.	  Vaccination	  
Vaccination	  is	  regarded	  as	  one	  of	  the	  greatest	  public	  health	  achievements	  of	  the	  
20th	  century	  (André,	  2003).	  Since	  the	  implementation	  of	  the	  Expanded	  Program	  
on	  Immunization	  (EPI)	  worldwide	  in	  1974,	  vaccines	  have	  saved	  over	  20	  million	  
young	   lives	   and	   greatly	   reduced	   the	   burden	   of	   major	   infectious	   diseases	   in	  
children	  such	  as	  Tuberculosis,	  Diphtheria,	  Tetanus,	  and	  Measles	  (UNICEF,	  2012).	  
Some	  countries	  have	  their	  own	  adapted	  immunization	  programs	  based	  on	  their	  
diseases	   burden	   and	   their	   economic	   resources.	   Table	   1.3	   shows	   the	   South	  
African	  EPI	  vaccination	  schedule.	  








In	  the	  next	  sections	  pertussis,	  Tetanus	  and	  BCG	  vaccines	  are	  discussed	  because	  
assessing	  infants’	  immune	  responses	  to	  those	  vaccines	  is	  the	  main	  objective	  of	  
this	  dissertation.	  	  
	  
1.4.1.1.1.	  Tetanus	  toxoid	  (TT)	  vaccine	  
Tetanus	  is	  caused	  by	  a	  bacterium	  Clostridium	  tetani.	  This	  bacterium	  is	  found	  in	  
cultivated	   soils	   and	   other	   places	   such	   as	   animal	   excrement	   and	   dust.	   The	  




(Hassel,	  2013)or	  inhalation	  in	  neonates.	  Once	  inside	  the	  host,	  it	  releases	  a	  toxin	  
called	   tetanospasmin	   into	   the	   blood	   stream	   (Hassel,	   2013).	   This	   toxin	   affects	  
nerve	   signaling	   and	   causes	   severe	   sustained	   muscle	   contractions,	   especially	  
“lockjaw”,	   with	   which	   adult	   tetanus	   is	   mostly	   associated	   (Hassel,	   2013).Even	  
though	  the	  disease	  is	  not	  spread	  from	  person	  to	  person,	  tetanus	  claims	  the	  lives	  
of	  73	  000	  children	  under	  five	  annually	  (UNICEF,	  2012).	  	  
	  
The	   main	   prevention	   against	   tetanus	   is	   the	   tetanus	   toxoid	   (TT)	   vaccine.	   The	  
vaccine	  can	  be	  administered	  alone	  as	  TT,	  or	  in	  combination	  with	  other	  vaccines	  
(CDC,	   2013).	   There	   are	   many	   formulations	   based	   on	   age	   of	   individual	   being	  
immunized.	   One	   formulation	   is	   DTaP,	   which	   is	   a	   combination	   TT	   with	   the	  
diphtheria	  and	  pertussis	  vaccines	   in	   infants	  (CDC,	  2013).	  During	  their	  first	  year	  
of	   life,	   infants	  receive	  three	  doses	  of	  DTaP	  at	  2,	  4	  and	  6	  months	  of	  age	   in	  the	  
USA	  (CDC,	  2013)	  and	  6,	  10	  and	  14	  weeks	  in	  South	  Africa	  (Department	  of	  Health,	  
2009).	  DTaP	  coverage	  worldwide	  is	  estimated	  at	  83%	  and	  the	  vaccine	  prevents	  
700	  00	  deaths	  of	  children	  under	  five	  annually	  (UNICEF,	  2012).	  TT	  induces	  a	  Th2	  
response	   and	   antibodies	   titers	   are	   good	   correlates	   protection	   for	   the	   vaccine	  
(Plotkin,	   2008).	   The	   vaccine	   is	   often	   administered	   with	   adjuvants	   such	   as	  
aluminium	  hydroxide	  to	  enhance	  T	  cell-­‐dependent	  antibody	  responses	  (Gupta,	  
1998).	  Neonatal	  tetanus	  can	  also	  arise	  in	  rural	  areas	  when	  deliveries	  are	  carried	  
out	   without	   sterile	   procedures.	   However,	   neonates	   can	   be	   protected	   from	  
tetanus	  by	  the	  TT	  antibodies	  they	  receive	  from	  their	  vaccinated	  mothers	  via	  the	  
placenta	  (Gall	  et	  al.,	  2011).	  	  
	  
1.4.1.1.2.	  Pertussis	  vaccines.	  
Pertussis	  is	  a	  contagious	  respiratory	  disease	  caused	  by	  the	  bacterium	  Bordetella	  
pertussis	   (BP).	   These	   bacteria	   release	   toxins	   which	   damage	   and	   inflame	   the	  
respiratory	   system	   (CDC,	   2013).	   The	   disease	   is	   also	   referred	   to	   as	   whooping	  
cough	  due	  to	  the	  severe	  spasmic	  coughing	  that	  it	  causes	  (CDC,	  2013).	  Pertussis	  
mostly	  affects	  children	  and	  is	  very	  lethal	  in	  neonates	  who	  can	  be	  contaminated	  




children	   under	   five	   are	   due	   to	   whooping	   cough	   worldwide	   (UNICEF,	   2012).	  
Immunization	   is	   the	   best	   prevention	   against	   pertussis,	   especially	   in	   children.	  
Similar	   to	   tetanus	   vaccines,	   pertussis	   vaccines	   are	   given	   in	   combination	   with	  
diphtheria	   and	   Tetanus	   vaccines	   in	  DTaP	   in	   children	   and	   Tdap	   in	   adults	   (CDC,	  
2013).	  As	  described	  above	  for	  tetanus,	  3	  doses	  of	  the	  vaccines	  are	  administered	  
during	  the	  first	  year	  of	  life	  (CDC,	  2013).	  However,	  unlike	  tetanus,	  two	  different	  
pertussis	  vaccines	  have	  been	  developed	  to	  this	  day	  (WHO,	  2010).	  	  
	  
	  The	   whole	   cell	   pertussis	   vaccine	   (wP)	   is	   a	   suspension	   of	   whole	   Bordetella	  
pertussis	   bacteria	   that	   have	   been	   inactivated	   and	   have	   been	   implemented	   in	  
WHO	   expanded	   immunization	   program	   since	   for	   routine	   vaccines	   since	   the	  
1940s	   (Crowcroft	  et	  al.,	  2006).	   It	  has	  been	  associated	  with	  some	  mild	  adverse	  
effects	  such	  as	  swelling,	  pain	  at	  the	  site	  of	   infection,	  drowsiness	  (Crowcroft	  et	  
al.,	   2006;	   Long	   et	   al.,	   1990).	   In	   addition,	   the	   vaccine	   can	   increase	   the	   risk	   of	  
seizures	   in	   children	   (Cody	   et	   al.,	   1981;	   Crowcroft	   et	   al.,	   2006).	   In	   order	   to	  
address	  these	  safety	  concerns,	  an	  acelluar	  pertussis	  vaccine	  (aP)	  was	  developed.	  
	  
The	   acellular	   pertussis	   vaccine	   (aP)	   is	   made	   up	   of	   one	   or	   many	   purified	  
components	   of	   Bordetella	   pertussis	   such	   as	   inactivated	   pertusiss	   toxin	   or	  
filamentous	  heamagglutinin	   (Crowcroft	  et	  al.,	  2006).	  There	  are	  different	   types	  
on	  aP	  vaccines	  depending	  on	  the	  number	  of	  purified	  components	  present	  in	  the	  
vaccine.	  Several	  studies	  confirmed	  that	  adverse	  events	  were	  less	  frequent	  after	  
administration	  of	  aP	  vaccines	  than	  with	  wP	  (Cody	  et	  al.,	  1981;	  Wintermeyer	  et	  
al.,	  1994).	  Studies	  have	  shown	  that	  aP	  and	  wP	  induce	  different	  T	  cell	  subtypes	  in	  
children(Higgins,	   Jarnicki,	   Lavelle,	  &	  Mills,	   2006;	  Ryan	  et	   al.,	   1998)	  Ryan	  et	   al.	  
demonstrated	   that	   immunization	   of	   children	   with	   wP	   vaccines	   leads	   to	  
secretion	  of	   IFN-­‐γ	  by	  T	   cells	  whereas	  T	  cells	   from	  children	   immunized	  with	  aP	  
vaccines	  secreted	  IFN-­‐γ	  and/or	  IL-­‐5	  (Higgins	  et	  al.,	  2006;	  Ryan	  et	  al.,	  1998).	  This	  
suggests	   Wp	   vaccine-­‐induced	   immunity	   is	   mediated	   by	   Th1	   cells	   while	   aP	  
vaccine-­‐induced	  immunity	  involves	  Th1	  and	  Th2	  cells	  (Ross	  et	  al.,	  2013;	  Ryan	  et	  
al.,	   1998).	   In	   addition,	   it	   has	   also	   been	   revealed	   that	   Th17	   cells	   may	   play	  




(Higgins	  et	  al.,	  2006;	  Ross	  et	  al.,	  2013).	  While	  Th2	  responses	  may	  be	  important	  
for	   the	   induction	   of	   antibodies	   in	   the	   respiratory	   tract,	  many	   studies	   suggest	  
that	  Th1	  cells	  are	  more	  important	  for	  long	  term	  protection	  against	  pertussis	  and	  
its	  spread	  throughout	  the	  body	  (Mills	  et	  al.,.1993;	  Mills	  et	  al.,	  2001;	  Warfel	  et	  
al.,	  2013).	  Warfel	  et	  al.	  recently	  demonstrated	  that	  aP	  vaccines	  protect	  against	  
the	   disease	   but	   failed	   to	   prevent	   transmission	   of	  Bordetella	   pertussis	   in	   non-­‐
primate	   models	   (Warfel	   et	   al.,	   2013).	   Thus,	   despite	   the	   adverse	   effects	  
associated	  with	   it,	  wP	  vaccine	   induces	  more	  optimal	   T	   cells	   responses	  against	  
efficient	  against	  pertussis	  than	  aP	  vaccines	  (Warfel	  et	  al.,	  2013)	  Ever	  since	  their	  
implementation	   in	   different	   immunization	   programs	   worldwide,	   aP	   and	   wP	  
vaccines	   have	  played	   considerable	   role	   in	   pertussis	   control.	   They	  prevent	   600	  
000	  thousands	  deaths	  every	  year	  (UNICEF,	  2012).	  	  
	  
1.5.	  BCG	  vaccination	  
Tuberculosis	   is	   caused	   by	   Mycobacterium	   tuberculosis,	   a	   slowly	   growing	  
bacterium	  which	  attacks	  the	  lungs	  and	  other	  parts	  of	  the	  body	  (WHO	  report	  on	  
TB,	  2013).	  The	  disease	  spreads	  through	  the	  air	  and	  can	  be	  lethal	  if	  not	  treated	  
properly	  (WHO	  report	  on	  TB,	  2013).	  Tuberculosis	  (TB)	  constitutes	  a	  major	  public	  
health	  problem	  affecting	  mostly	  Sub-­‐Saharan	  Africa	  and	  Asia.	  According	  to	  the	  
World	  Health	  Organization	   (WHO)	   report	   on	   Tuberculosis	   2013,	   there	  were	   9	  
million	  new	  TB	  cases	  in	  2012	  and	  1.4	  million	  of	  TB-­‐related	  deaths	  (WHO	  report	  
on	  TB,	  2013).	  Bacille	  Calmette-­‐Guerin	   (BCG)	   is	  currently	   the	  only	  vaccine	  used	  
for	   TB	   prevention	   (WHO	   report	   on	   TB,	   2013).	   It	   is	   a	   live	   attenuated	  
Mycobacterium	  bovis	  strain	  that	  is	  administered	  to	  almost	  100	  million	  children	  
each	   year	   (Hesseling	   et	   al.,	   2006).	   Figure	   1.5	   is	   a	   map	   of	   the	   global	   BCG	  
coverage.	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Figure	   1.5:	   Global	   coverage	   of	   BCG	   vaccination.	   A:	   Countries	   with	   universal	   BCG	  
vaccination	   programs.	   B:	   Countries	   that	   no	   longer	   recommend	   BCG	   vaccination	   for	  
everyone.	  C:	  Countries	  that	  never	  had	  universal	  BCG	  vaccination	  programs	  (Zwerling	  et	  
al.,	  2011).	  
	  
1.5.1.	  Effects	  of	  BCG	  vaccination	  in	  neonates	  
In	  TB-­‐endemic	  regions,	  BCG	   is	  generally	  given	  at	  birth.	   It	   induces	  a	  strong	  Th1	  
response	   even	   in	   neonates,	   who	   are	   notorious	   for	   their	   Th2	   biased	   immune	  
system	   (Marchant	   et	   al.,	   1999).In	   addition,	   because	   the	   neonatal	   immune	  
system	  is	  still	  immature	  at	  birth,	  BCG	  efficacy	  may	  increase	  with	  vaccination	  age	  
in	  infants	  (Hussey	  et	  al	  2012).	  In	  fact,	  Kagina	  et	  al	  showed	  in	  a	  longitudinal	  study	  
that	   delaying	   BCG	   vaccination	   from	   birth	   to	   10	   weeks	   resulted	   in	   enhanced	  




2009).	  On	  the	  other	  hand,	  two	  studies	  carried	  out	  in	  the	  Gambia	  revealed	  that	  
delaying	   BCG	   vaccination	   until	   2	   and	   4	   months	   led	   to	   a	   decrease	   in	   Th1	  
responses	  (Burl	  et	  al.,	  2010;	  Marchant	  et	  al.,	  1999).	  Therefore,	  while	  evidence	  
suggests	  that	  the	  timing	  of	  vaccination	  may	  have	  some	  effects	  on	  BCG	  efficacy	  
and	  immunogenicity	  in	  infants,	  it	  is	  not	  clear	  what	  these	  effects	  are.	  	  
	  
1.5.2.	  Effects	  of	  BCG	  vaccine	  on	  other	  vaccines	  and	  all-­‐cause	  mortality	  
BCG	   is	   cost	   effective	   and	   particularly	   efficacious	   against	   severe	   forms	   of	  
childhood	  TB	  such	  as	  TB	  meningitis	  and	  military	  TB	  in	  immunocompetent	  infants	  
(Trunz	   et	   al.,	   2006).BCG	   may	   also	   improve	   immune	   responses	   to	   other	  
unrelated	  vaccines	  and	  antigens	   (Ota	  et	  al.,	  2002).	  Ota	  et	  al	   showed	  that	  BCG	  
vaccination	   can	   boost	   antibody	   responses	   to	   OPV	   and	   HBV	   and	   increase	   the	  
production	  of	  both	  Th1	  and	  Th2	  in	  response	  to	  Tetanus	  toxoid	  (TT)	  and	  Hepatitis	  
B	  vaccines	  in	  HIV-­‐uninfected	  Gambian	  infants	  (Ota	  et	  al.,	  2002).However,	  these	  
effects	  depend	  mostly	  on	  the	  timing	  of	  the	  vaccination	  and	  the	  age	  of	  the	  infant	  
(Ota	   et	   al.,	   2002).	   Thus,	   BCG	   may	   improve	   infants’	   protection	   from	   other	  
infections.	  	  
	  
In	   fact,	   some	   studies	   also	   show	   that	   BCG	   can	   reduce	   all-­‐cause	   mortality	   in	  
infants	  (Aaby	  et	  al.,	  2011;	  Garly	  et	  al.,	  2003;	  Roth	  et	  al.,	  2006).	  In	  a	  randomized,	  
controlled	   trial	   assessing	   the	   effects	   of	   BCG	   vaccination	   in	   Low	   birth	   weight	  
children	   in	  Guinea-­‐Bissau,	  Roth	  et	  al	   showed	  that	   infants	  with	  a	  BCG	  scar	  had	  
better	   survival	   (Roth	   et	   al.,	   2004).Moulton	   et	   al	   also	   demonstrated	   that	   BCG	  
was	  associated	  with	  a	  significant	  reduction	  in	  mortality	  hazards	  in	  Indian	  infants	  
(Moulton	   et	   al.,	   2005).	   However,	   other	   studies	   have	   shown	   the	   opposite	   and	  
the	   overall	   non-­‐specific	   effects	   of	   BCG	   vaccination	   on	   all	   cause	  mortality	   are	  
subject	   to	  debate	  and	  may	  depend	  on	  other	   factors	   such	  as	  environment	  and	  
the	  implementation	  of	  other	  health	  interventions	  such	  vitamin	  A	  administration	  
(Benn	  et	  al.,	  2008;	  Roth	  et	  al.,	  2010).	  However,	  many	  of	   these	  studies	  did	  not	  





1.5.3.	  BCG	  and	  HIV	  	  
As	  shown	  in	  figure	  1.6,	  many	  TB-­‐endemic	  endemic	  regions	  such	  as	  South	  Africa	  
are	  also	  affected	  by	  HIV.	  Hesseling	  et	  al	  recently	  reported	  a	  TB	  incidence	  rate	  of	  
1596	   cases	   per	   100	   000	   population	   among	   HIV	   –infected	   infants	   versus	   65.9	  
cases	   per	   100,000	   population	   among	   HIV-­‐uninfected	   infants	   in	   South	   Africa	  
(Hesseling	   et	   al.,	   2009).Thus,	   many	   studies	   have	   investigated	   the	  
immunogenicity	  of	  BCG	   in	  HIV-­‐infected	   individuals.	  There	   is	  very	   little	  data	  on	  
the	  efficacy	  on	  BCG	  in	  HIV-­‐infected	  infants	  (Bhat	  et	  al.,1993;	  Fallo	  et	  al.,	  2005).	  
A	  Study	  carried	  out	  in	  Zambia	  showed	  that	  HIV-­‐infected	  infants	  were	  more	  likely	  
to	   be	   tuberculin	   non-­‐reactive	   and	   unable	   to	   develop	   a	   scar	   following	   BCG	  
vaccination	  compared	  to	  HIV-­‐uninfected	  infants	  (Bhat	  et	  al.,	  1993).Mansoor	  et	  
al	  recently	  showed	  that	  HIV	  infections	  greatly	  impairs	  T	  cell	  responses	  to	  BCG	  in	  
infants	  in	  their	  first	  year	  of	  life	  (Mansoor	  et	  al.,	  2009).	  In	  addition,	  BCG	  has	  also	  
been	   associated	   with	   adverse	   effects	   such	   as	   such	   as	   immune	   reconstitution	  
inflammatory	   syndrome	   (IRIS)	   and	  disseminated	  BCG	  disease	   (Hesseling	  et	  al.,	  
2009).	   IRIS	  is	  caused	  by	  the	  recovery	  of	  pathogen-­‐specific	  T-­‐cell	  responses	  and	  
disturbances	   of	   innate	   immune	   responses,	   which	   subsequently	   affect	   the	  
tissues	   infected	   by	   the	   pathogen	   (French,	   2012).	   BCG	   IRIS	   is	   very	   common	  
among	   South	   African	   HIV-­‐infected	   infants	   and	   can	   result	   in	   high	   morbidity	  
(Rabie	  et	  al.,	  2011).	  Rabie	  et	  al	  showed	  that	  low	  CD4	  counts	  and	  high	  viral	  load	  
at	   antiretroviral	   therapy	   (ART)	   initiation	  are	   strong	   risk	   factors	   for	  BCG-­‐IRIS	   in	  
South	  African	  infants	  (Rabie	  et	  al.,	  2011).	  	  
	  
In	   addition,	   T	   cell	   activation	   induced	  by	   early	  BCG	  vaccination	  of	  HIV-­‐infected	  
could	  theoretically	  lead	  to	  more	  rapid	  disease	  progression	  (Jaspan,	  AIDS	  2012).	  
Hesseling	   et	   al	   recently	   documented	   a	   considerable	   risk	   of	   disseminated	   BCG	  
disease	   of	   approximately	   1%	   in	   HIV-­‐infected	   infants,	   associated	   with	   high	  
mortality	  (Hesseling	  et	  al.,	  2009).	  Based	  partly	  on	  these	  data,	  the	  World	  Health	  
Organization	  (WHO)	  changed	  their	  recommendations	  on	  the	  routine	  vaccination	  
of	   HIV-­‐infected	   infants,	   now	   making	   infant	   HIV	   infection,	   if	   known,	   a	  
contraindication	   to	   BCG	   vaccination	   (WHO	   SAGE,	   2007).	   However,	   since	   HIV	  




continues	   in	   most	   TB	   endemic	   countries	   including	   South	   Africa	   where	   nearly	  
260	  00	  neonates	  are	  born	  to	  HIV-­‐infected	  mothers	  (Hesseling	  et	  al.,	  2006).Not	  
only	   is	   there	   no	   evidence	   of	   any	   protective	   effect	   of	   the	   BCG	   vaccine	   in	  HIV-­‐
infected	  infants	  but	  very	  little	  is	  known	  about	  BCG	  immunogenicity	  and	  efficacy	  
in	   HIV-­‐exposed,	   uninfected	   infants	   (infants	   born	   to	   HIV-­‐infected	  mothers	   but	  
who	   are	   uninfected)	   (Hesseling	   et	   al.,	   2006).	   Recent	   evidence	   suggests	   HIV-­‐
exposed	   infants	  produce	   less	   IFN-­‐Υ	  and	  TNF-­‐α	   in	  response	  to	  BCG	  (Mazzola	  et	  
al.,.2011;	  Van	  Rie	  et	  al.,	  2006)	  Hence,	  to	  inform	  future	  policy,	  there	  is	  an	  urgent	  
need	   to	   investigate	   the	   effects	   of	   delayed	   BCG	   vaccination	   in	   HIV	   –exposed	  
infants.	  Since	  there	  is	  considerable	  risk	  associated	  with	  BCG	  vaccination	  at	  birth	  
in	  HIV-­‐exposed	  infants,	  it	  is	  important	  to	  assess	  how	  immune	  responses	  to	  BCG	  




Figure	  1.6:	  Prevalence	  rates	  of	  new	  TB	  cases	  in	  HIV	  infected	  individuals	  in	  2011	  (WHO	  
Global	  TB	  report,	  2012)	  
	  
1.6.	  HIV	  prevalence	  and	  influence	  on	  the	  immune	  system	  
HIV	   remains	   a	   major	   public	   health	   problem	   with	   2.7	   million	   newly	   infected	  
people	  in	  2010	  (WHO,	  2011).	  Sub-­‐Saharan	  Africa	  is	  particularly	  affected	  by	  the	  




Paediatric	   infections	   can	   occur	   vertically	   from	   mother	   to	   child	   in	   utero,	  
perinatally	  or	  postpartum	  (from	  breastfeeding)	   (Newell	  et	  al.,	  2004;	  Thorne	  et	  
al.,	   2004).	   The	   risk	   of	   pediatric	   infections	   can	   be	   considerably	   reduced	   with	  
antiretroviral	  drugs	   (Newell	  et	  al.,	  2004).	  The	   improvement	  of	  mother	  to	  child	  
transmission	   prevention	   has	   led	   to	   increased	   numbers	   of	   HIV-­‐exposed,	  
uninfected	   infants	   in	  Sub-­‐Saharan	  Africa	  (Filteau,	  2009).	  These	  are	   infants	  that	  
are	  born	  to	  HIV-­‐infected	  mothers	  but	  are	  not	  HIV-­‐infected	  themselves.	   In	  sub-­‐
Saharan	  Africa,	   approximately	  20%	  of	   infants	   are	  HIV-­‐exposed	  and	  uninfected	  
(Filteau,	  2009).	  Hence,	  it	  is	  critical	  to	  know	  how	  HIV-­‐exposure	  affects	  the	  health	  
of	   these	   infants	  and	   their	   immune	   responses	   to	  other	  pathogens.	  Despite	   the	  
limited	   data	   availability	   on	   HIV	   exposed	   uninfected	   infants,	   it	   is	   well	  
documented	  that	  these	  infants	  are	  characterized	  by	  higher	  mortality	  than	  HIV-­‐
unexposed	  uninfected	  infants	  (Filteau,	  2009;	  L.	  Kuhn	  et	  al.,	  2005).	  	  
	  
Recent	   studies	   have	   shown	   that	   mortality	   in	   HIV-­‐exposed	   uninfected	   infants	  
was	  associated	  with	  risk	  factors	  such	  as	  low	  birth	  weight,	  maternal	  CD4	  counts	  
and	   gestational	   age	   (Filteau,	   2009;	   Wei	   et	   al.,2004).	   HIV-­‐exposed	   uninfected	  
infant	   morbidity	   is	   also	   higher	   than	   HIV-­‐unexposed	   infants	   (Filteau,	   2009;	   L.	  
Kuhn	  et	   al.,	   2005).	   In	   a	   study	   carried	  out	   in	   South	  Africa,	  HIV-­‐exposed	   infants	  
were	   found	   more	   susceptible	   to	   Pneumonia	   than	   HIV-­‐unexposed	   infants,	  
including	   pneumocystis	   jiroveci,	   an	   opportunistic	   pathogen	   (McNally	   et	   al.,	  
2007).	  In	  addition,	  HIV-­‐exposed	  uninfected	  infants	  are	  also	  more	  susceptible	  to	  
other	  vaccine	  preventable	  diseases	  (Kuhn	  et	  al.,	  2005).	  There	  are	  many	  factors	  
that	   could	   explain	   the	   increased	   susceptibility	   to	   diseases	   in	   HIV-­‐exposed	  
infants.	   It	   is	   probable	   that	   HIV	   exposure	   may	   influence	   the	   infant	   immune	  
system	  and	  hence	  immune	  responses	  to	  some	  vaccines	  (Kuhn	  et	  al.,	  2005).	  	  
	  
HIV-­‐exposed	  infants	  generally	  have	  a	  large	  number	  of	  activated	  and	  memory	  T-­‐
cells	   (Clerici	   et	   al.,	   2000).	   Jones	   et	   al	   demonstrated	   that	   HIV-­‐exposed	   infants	  
have	   low	   levels	  of	   specific	   antibodies	   at	  birth,	   but	   a	   strong	  humoral	   response	  
after	   vaccination	   (Jones	   et	   al.,	   2011).	   Some	   studies	   have	   also	   reported	  




(Chougnet	  et	   al.,	   2000;	  Rich	  et	   al.,1997).	   These	   immunological	   anomalies	  may	  
be	   due	   to	   infant	   exposure	   to	   HIV	   in	   utero	   and	   maternal	   placental	   immune	  
responses	  (Clerici	  et	  al.,	  2000;	  Kuhn	  et	  al.,	  2002).	  Nonetheless,	  it	  is	  still	  unclear	  
how	  these	  differences	  affect	  immune	  responses	  to	  other	  vaccines,	  and	  whether	  
these	   changes	   are	   responsible	   for	   the	   vulnerability	   of	   HIV-­‐exposed	   infants	  
(Filteau,	   2009).Hence,	   a	   better	   understanding	   of	   the	   immune	   system	   of	   HIV-­‐
exposed	   infants	   is	   critical	   to	   reduce	   their	   mortality	   and	   to	   inform	   new	  
prevention	  strategies	  against	  tuberculosis	  and	  other	  infectious	  diseases.	  	  
	  
1.7.	  Assays	  used	  to	  measure	  T	  cell	  vaccine	  responses	  in	  infants	  
In	   this	   section,	   the	   different	   assays	   used	   to	   measure	   vaccine	   responses	   in	  
infants	  are	  discussed.	  Table	  1.4	  below	  summarizes	   the	  main	  studies	   that	  have	  
assessed	   cellular	   immune	   responses	   to	   BCG	   in	   HIV-­‐exposed	   infants	   and	   the	  
types	  of	  assays	  they	  have	  used.	  	  
	  





Infant	  age	   Assay	   Immune	  responses	  measured	  
(Van	   Rie	  








et	   al.,	  
2009)	  
Longitudinal	   3-­‐9	  
months	  
WBA	   (12	  
h)	  
T	  cell	  proliferation/	  IFN-­‐γ,	  IL-­‐2	  and	  
TNF-­‐α	  production	  
(Mazzola	  
















CBMC	   T	  cell	  proliferation/	  IFN-­‐γ,	   IL-­‐2,	   IL-­‐






1.7.1.	  Whole	  blood	  assay	  (WBA)	  and	  its	  importance	  	  
In	  a	  WBA,	  whole	  blood	  is	  stimulated	  with	  optimized	  antigen	  concentrations	  and	  
incubated	  at	  37⁰C	  as	  soon	  as	  possible	  after	  collection.	  There	  are	  long-­‐term	  and	  
short-­‐term	   WBAs,	   ranging	   from	   12	   hours	   to	   weeks	   (Hanekom	   et	   al.,	   2004).	  
Hanekom	   et	   al	   showed	   that	   in	   short-­‐term	   assays,	   a	   delay	   in	   incubation	   was	  
associated	  with	  a	  reduction	  in	  specific	  responses	  (Hanekom	  et	  al.,	  2004).	  One	  of	  
the	  major	  advantages	  of	  the	  WBA	  is	  the	  smaller	  blood	  volume	  it	  requires	  (200-­‐
300	   µl)	   compared	   to	   peripheral	   blood	  mononuclear	   cell	   (PBMC)-­‐based	   assays	  
(Hanekom	  et	  al.,	  2004).	  This	  is	  particularly	  important	  in	  paediatric	  studies	  in	  Tb-­‐
endemic	  countries	  where	  blood	  volume	  is	  often	  a	  limiting	  factor	  (Deenadayalan	  
et	  al.,	  2013).	  Another	  advantage,	  particularly	  with	  assays	  of	  infant	  cells,	   is	  that	  
no	   additional	   serum	   is	   needed	   for	   whole	   blood.	   The	   optimal	   antigen	  
concentrations	  used	  in	  the	  WBA	  usually	  differ	  from	  those	  used	  in	  PBMC-­‐based	  
assays.	  Many	  types	  of	  antigens	  such	  as	  whole	  bacterial	  antigens,	  proteins	  and	  
peptides	   antigens	   have	  been	   tested	   successfully	   in	   the	  WBA	   (Hanekom	  et	   al.,	  
2004;	  Remick	  et	  al.,	  2000).	  	  
	  
1.7.2.	  Proliferation	  and	  Intracellular	  cytokine	  staining	  assay	  (ICS)	  
Proliferation	   is	   the	   expansion	   of	   cells	   by	   the	   division	   of	   single	   cells	   into	   two	  
daughter	   cells.	  T	   cell	  proliferation	  generally	  occurs	  before	   their	  differentiation	  
into	  different	  effectors	  (Kaech	  et	  al.,	  2001).	  As	  depicted	  in	  table	  1.5,	  there	  are	  
many	   methods	   available	   to	   measure	   conventional	   T-­‐cell	   proliferation	   and	  
activation	   in	   response	   to	   antigen	   stimulation.	   Each	   of	   these	   methods	   has	   its	  
advantages	  and	  disadvantages.	  All	  these	  methods	  are	  accurate	  and	  sensitive	  but	  
except	  for	  Ki67	  staining,	  they	  all	  require	  large	  blood	  volumes.	  In	  addition,	  strong	  
correlation	  between	  Ki67	  staining	  and	  CFSE	  staining	  have	  been	  shown	  (Soares	  
et	  al.,	  2010).	  
.	  




Table	  1.5:	  Different	  methods	  used	  to	  measure	  antigen-­‐specific	  responses	  
Method	   Immune	  response	  
measured	  
Advantages	   Disadvantages	  	  
3H-­‐thymidine	  	  
incorporation	  	  
(Soares	  et	  al.,	  2010)	  
	  
	  
T	  cell	  proliferation	   Used	   with	  
peripheral	  blood	  	  
mononuclear	   cells	  
(PBMC)	  	  
	  






et	  al.,	  2010)	  




-­‐Flow	  cytometry	  	  
-­‐Co-­‐staining	   with	  
other	  markers	  	  
-­‐Used	  with	  	  
(PBMC)	  
Large	   blood	  
volumes	  required	  
Cannot	  use	  whole	  
blood	  
Carboxyfluorescein	  	  
Succinimidyl	  Ester	  	  
(CFSE)	  staining	  	  
(Soares	  et	  al.,	  2010)	  	  
	  
-­‐T	  cell	  proliferation	  	  




-­‐Flow	  cytometry	  	  
-­‐Co-­‐staining	   with	  
other	  markers	  	  
-­‐Used	  with	  PBMC	  	  
	  
Large	   blood	  
volumes	   are	  
required.	  






(Soares	  et	  al.	  2010)	  	  
	  	  
-­‐T	  cell	  proliferation	  	  
-­‐Identification	   of	  
cellular	   sub-­‐
populations	  	  
Flow	  cytometry	  	  
-­‐Co-­‐staining	   with	  
other	  markers	  	  
-­‐Used	  with	  PBMC	  
Large	  blood	  	  
Volumes	   are	  
required	  
Cannot	   use	   whole	  
blood	  
Ki-­‐67	  staining	  	  
	  (Soares	  et	  al.,	  2010)	  	  
(Soares	  et	  al.,	  2013)	  	  
	  (Hanekom	   et	   al.,	  
2004)	  	  
	  
-­‐T	  cell	  proliferation	  	  




-­‐Flow	  cytometry	  	  
-­‐Co-­‐staining	   with	  
other	  markers	  	  
-­‐Used	  with	  PBMC	  	  
-­‐Use	  whole	  blood	  	  
-­‐sensitive.	  
-­‐Small	   blood	  
volumes	  required	  
Does	   not	   help	  
determine	   the	  
number	   of	  
proliferation	  cycles	  
Low	   detection	   of	  





1.8.	  Aims	  and	  objectives	  of	  the	  study	  
The	  aim	  of	  dissertation	  was	  to	  assess	  how	  delaying	  BCG	  vaccination	  from	  birth	  
to	  8	  weeks	  affects	  immune	  responses	  to	  BCG,	  other	  vaccines,	  and	  superantigen	  
in	  HIV-­‐exposed	  infants.	  In	  order	  to	  achieve	  this,	  there	  are	  two	  specific	  aims:	  
	  
1)	   To	   compare	   CD4+	   and	   CD8+	   T-­‐cell	   proliferative	   responses	   and	   intracellular	  
cytokine	  responses	  to	  BCG	  at	  6,	  8	  and	  14	  weeks	  between	  infants	  who	  received	  
BCG	  at	  birth	  and	  those	  who	  received	  it	  at	  8	  weeks	  of	  age.	  Our	  hypothesis	  is	  that	  
delaying	   BCG	   vaccination	   from	   birth	   to	   8	   weeks	   results	   in	   an	   altered	  
proliferative	  and	  cytokine	  CD4	  T-­‐cell	  response	  to	  BCG	  at	  14	  weeks	  of	  age	  
	  
	  2)	  To	  compare	  CD4+	  and	  CD8+	  T-­‐cell	   proliferative	   responses	  and	   intracellular	  
cytokine	   responses	   to	   Pertussis,	   Tetanus	   (TT),	   and	   SEB	   at	   6,	   8	   and	   14	   weeks	  
between	   infants	   who	   received	   BCG	   at	   birth	   and	   those	   who	   received	   it	   at	   8	  
weeks	  of	  age.	  The	  hypothesis	   is	   that	  delaying	  BCG	  vaccination	   from	  birth	   to	  8	  
weeks	  results	  in	  an	  altered	  proliferative	  and	  Th2	  or	  Tc2	  skewed	  cytokine	  T-­‐cell	  
response	  to	  other	  antigens.	  
	  
1.8.1.	  Rationale	  
There	  are	  few	  studies	  assessing	  how	  delayed	  BCG	  vaccination	  (from	  birth	  to	  8	  
weeks)	   affects	   cellular	   responses	   to	   BCG	   in	   HIV-­‐exposed	   infants,	   a	   highly	  
relevant	   group	   for	   such	   a	   vaccine	   strategy.	   In	   addition,	   there	   are	   no	   studies	  
assessing	  how	  delayed	  BCG	  vaccination	  affects	  cytokine	  and	  proliferative	  T-­‐cell	  
responses	   to	   tetanus	   and	   pertussis	   vaccination	   in	   HIV-­‐exposed	   infants.	   Since	  
there	   is	   a	   considerable	   risk	   associated	   with	   BCG	   vaccination	   in	   HIV-­‐exposed	  
infants	   at	   birth,	   understanding	   how	   delayed	   BCG	   vaccination	   would	   affect	  
immune	   responses	   to	   EPI	   vaccines	   in	   HIV-­‐exposed	   infants	   will	   help	   inform	  
policies	   on	   the	   appropriate	   timing	   for	   BCG	   vaccination	   for	   these	   infants,	   and	  
help	   in	   the	   implementation	   of	   new	   prevention	   strategies	   against	   tuberculosis	  




Chapter	  2.	  Cohort	  Characteristics,	  Materials	  
and	  Methods	  
	  
2.1.	  Cohort	  characteristics	  and	  recruitment	  	  
2.1.1.	  Study	  design	  	  
This	  thesis	  describes	  a	  substudy	  of	  a	  longitudinal,	  randomized	  controlled	  trial	  of	  
BCG	  vaccination	  at	  birth	  versus	  at	  8	  weeks	  of	  age	   in	  HIV-­‐exposed	   infants.	  The	  
primary	   outcome	   measure	   for	   this	   substudy	   was	   the	   difference	   in	   CD4+	  
proliferation	   in	   response	   to	   BCG	   between	   the	   early	   and	   delayed	   arms	   at	   6	  
weeks	   of	   age	   (baseline)	   and	   at	   14	  weeks	   of	   age.	   The	   sample	   size	   and	   power	  
calculations	  were	  based	  on	  the	  comparison	  of	  the	  median	  number	  of	  CD4+ki67+	  
cells	   per	   µl	   in	   HIV-­‐unexposed	   infants	   in	   response	   to	   TT	   at	   14	   weeks	   of	   age	  
calculated	  using	  previously	  published	  data	  (Kidzeru	  et	  al	  2014).	  This	  sample	  size	  
(n	   =	   28)	   allowed	   80%	   power	   to	   detect	   a	   5%	   difference	   in	   the	   frequency	   of	  
CD4+ki67+	  cells	  per	  µl	  (2-­‐tailed	  test	  at	  P=0.05,	  assuming	  a	  5%	  loss-­‐to-­‐follow	  up)	  	  
	  
2.1.1.1.	  Recruitment	  of	  participants	  
HIV-­‐exposed	   infants	   were	   recruited	   from	   the	   Midwife	   Obstetric	   Unit	   at	  
Khayelitsha	  Site	  B,	  Western	  Cape,	  South	  Africa.	  Consent	  forms	  were	  provided	  in	  
English,	   Xhosa	   and	   Afrikaans	   and	   the	   consent	   process	   was	   conducted	   in	   the	  
preferred	   language	   of	   the	   participant	   according	   to	   Good	   Clinical	   Practice	  
guidelines.	  	  
	  
2.1.1.2.	  Participants	  and	  blood	  collection	  	  
Infants	  were	   recruited	  within	   24	  hours	   of	   delivery	   and	   randomized	   to	   receive	  
BCG	  vaccine	  at	  birth	  (early	  arm)	  versus	  BCG	  vaccine	  at	  8	  weeks	  of	  age	  (delayed	  
arm).	  Infants	  were	  enrolled	  at	  birth,	  and	  follow-­‐up	  visits	  were	  conducted	  at	  6,	  8,	  




tested	  at	  birth	  and	  if	  negative;	  were	  eligible	  for	  randomization.	  For	  this	  study,	  a	  
total	  of	  91	  infants	  were	  selected	  from	  the	  122	  that	  completed	  the	  study:	  41	  in	  
the	  delayed	  arm	  and	  50	  in	  the	  early	  arm.	  Infants	  in	  the	  early	  arm	  received	  BCG	  
at	  days	  2-­‐3,	  when	  the	  results	  of	  the	  HIV	  DNA	  PCR	  were	  available.	  The	  delayed	  
arm	  received	  their	  BCG	  vaccination	  at	  week	  8,	  after	  the	  results	  of	  the	  standard	  
of	  care	  HIV	  DNA	  PCR	  at	  6	  weeks	  were	  available.	  
	  
	  
Figure	  2.1:	  Study	  design.	  
	  
2.1.1.3.	  Study	  Setting	  
Khayelitsha	  is	  an	  informal	  settlement	  with	  an	  antenatal	  HIV	  prevalence	  of	  30.1%	  
in	  2011	  (City	  of	  Cape	  Town	  Department	  of	  health,	  2011).	  Site	  B	  has	  established	  
pMTCT	  and	  pediatric	  ARV	  clinics.	  The	  Western	  Cape	  has	  one	  of	  the	  highest	  TB	  
rates	   globally,	   with	   an	   infant	   TB	   rate	   estimated	   (culture-­‐confirmed)	   at	   1596	  
cases	  per	  100,000	  population	  among	  HIV-­‐infected	   infants	   (95%	  CI,	  1151-­‐2132)	  
and	  66	  cases	  per	  100,000	  population	  among	  HIV-­‐uninfected	  infants	  (95%	  CI,	  56-­‐
75)	   (Madhi	   et	   al.,	   2011).	   infants	   receive	   three	   doses	   of	   Diphtheria-­‐Tetanus-­‐




conjugate	   (PCV7)	   vaccinations	   at	   6,	   10	   and	   14	   weeks	   of	   age	   (Department	   of	  
Health,	  2009)	  (Table	  1.3	  in	  chapter	  1).	  
	  
Exclusion	  criteria:	  
Infants	  were	  excluded	  if	  they	  met	  the	  following	  criteria:	  
1. Mother	  was	  not	  willing	  and	  able	  to	  give	  consent	  
2. Baby	  weighed	  less	  than	  2.4kg	  at	  birth	  
3. Mother	  had	  cough	  for	  more	  than	  two	  weeks,	   fevers	  or	  weight	   loss,	   for	  
which	  she	  was	  then	  refered	  to	  the	  TB	  Clinic	  
	  
4. Baby	   unhealthy:	   sepsis/	   convulsions/	   asphyxia/	   severe	   respiratory	  
distress/	  severe	  congenital	  abnormality	  
5. Mothers	  HIV	  test	  in	  pregnancy	  was	  negative	  
6. Mother	  or	   infant	  were	  planning	   to	  move	  away	   from	  Khayelitsha	   in	   the	  
following	  4	  months	  
7. Prematurity	  (i.e.	  <36	  weeks)	  
8. Mother	  was	  younger	  than	  18	  years	  
9. Infant	  tested	  HIV	  DNA	  PCR	  positive	  (for	  which	  immediate	  referral	  to	  the	  
ARV	  clinic	  occurred.)	  
	  
HIV	  testing	  
Blood	  collection	   for	  HIV	  DNA	  PCR	  testing	  was	  done	  at	  birth	  through	  the	  study	  
and	   six	   weeks	   of	   age	   through	   the	   routine	   pMTCT	   programme.	   Infants	   were	  
excluded	  if	  they	  tested	  positive	  for	  HIV	  infection.	  
	  
2.1.2	  Characteristics	  of	  the	  cohort	  	  
We	   compared	   the	   characteristics	   of	   the	   two	   groups.	   As	   shown	   in	   table	   2.1,	  
there	   were	   no	   significant	   differences	   in	   baseline	   characteristics	   between	   the	  
early	   and	   delayed	   arms,	   including	   birth	   weight	   (3.12	   kg	   vs.	   3.05	   kg	   p=0.407,	  
maternal	  CD4	  counts	  (388	  cells/mm3	  vs.	  358	  cells/mm3	  p=0.107),	  breastfeeding	  
(17%	  vs.	  10%	  p=0.469),	  sex	  (48%	  versus	  60%;	  p=0.140),	  and	  median	  gestational	  

















2.2.	  Laboratory	  materials	  and	  methods	  	  
The	  main	  objective	  of	  this	  dissertation	  was	  to	  assess	  cellular	  immune	  responses	  
to	   EPI	   vaccines	   as	   well	   as	   SEB	   in	   early	   (birth)	   versus	   delayed	   (8	   weeks)	  
vaccinated	   infants.	  To	   this	  end,	  we	  utilized	   several	   techniques	  and	   the	  overall	  
process	  involved	  two	  main	  assays:	  	  
	  
2.2.1.	  Whole	  blood	  assay	  (WBA).	  
The	   whole	   blood	   assay	   used	   was	   adapted	   from	   that	   previously	   described	   by	  
Soares	  et	  al.	  Between	  1-­‐3mL	  of	  whole	  blood	  was	  collected	  from	  infants	  at	  6,	  8	  
and	  14	  weeks	  of	  age	  into	  a	  preservative-­‐free	  heparinised	  tube	  and	  transported	  
to	   the	   laboratory	  within	   6	   hours	   of	   blood	  draw.	  Whole	   blood	  was	  mixed	   in	   a	  
1:10	   dilution	  with	  warm	  Roswell	   Park	  Memorial	   Institute	   (RPMI)	   1640	   culture	  
medium	   (Sigma	  Aldrich)	  without	   additives	   or	   antibiotics,	   and	   1200ul/well	  was	  
placed	   into	   a	   24	  well	   culture	   plate	   and	   incubated	   at	   37⁰C	  with	   5%	   CO2	  with	  
1x105	  cfu/ml	  Danish	  BCG	  and	  a	  negative	  control	   (media	  alone).	  The	   following	  
antigens	   were	   added:.1x105	   cfu/mL	   Mycobacterium	   bovis	   Bacille	   Calmette-­‐
Guérin	   (BCG).[Danish	   strain	   1331;.SSI],.0.16.IU	   Tetanus	   toxoid	   (TT).[TETAVAX,	  
Aventis	   Pharma	   (Pty)	   Ltd],.0.16.IU	   whole	   cell	   inactivated	   Pertussis	   antigen	  
Characteristic* Early*(n=63)* Delayed*(n=59)* P*value*
Median'age'of'BCG'vaccination'(days)'(IQR)' 3'(2:4)' 58'(56:62)' <0.001'
Median'maternal'CD4'count,'cells/mm3'(IQR)' 388'(276:477)' 358'(254:548)' 0.103'
Mean'birth'weight,'kg'(s.d.)' 3.12'(0.39)' 3.05'(0.41)' 0.407''
Mean'gestational'age'(weeks)' 39'' 39' 0.653'
Male'gender'n'(%)' '24(48)' 24'(60)' 0.140'




(PERTUSSIS).[DifcoTM	  Bordetella	  Pertussis	  Antigen,	  BD]	  and	  a	  negative	  control	  
(medium	  alone).	  The	  different	  antigens	  and	  vaccines	  were	  diluted	  to	  the	  specific	  
concentration	  using	  warm	  RPMI	  1640	  culture	  medium	  (Sigma	  Aldrich)	  without	  
additives	  or	  antibiotics.	  	  
	  
After	  24	  hours,	  100ul	  of	  supernatant	  was	  removed	  and	  1	  ug/ml	  Staphylococcal	  
enterotoxin	   B	   (SEB)	   was	   added	   to	   its	   required	   positive	   control	   well	   and	   cells	  
were	  placed	  back	  at	  37⁰C	  for	  a	  further	  5	  days.	  On	  the	  6th	  day,	  1ug/ml	  of	  phorbol	  
12-­‐myristate	  13-­‐acetate	   (PMA)	  and	  5ug/ml	   Ionomycin	  was	  added	   to	  stimulate	  
intracellular	   production	   of	   cytokines	   by	   cells	   non-­‐specifically	   (Hanekom	   et	   al.,	  
2004;	  Soares	  et	  al.,	  2013;	  Soares	  et	  al.,	  2010),along	  with	  5ug/ml	  Brefeldin	  A,	  to	  
prevent	   extracellular	   cytokine	   secretion,	   for	   the	   last	   4	   hours	   of	   stimulation.	  
Negative	  control	  cells	  were	  stimulated	  in	  the	  same	  manner	  with	  media	  alone	  on	  
day	  0	  and	  with	   Ionomycin	  and	  PMA	  on	  day	  6.	  Cells	  were	  harvested	   in	  20	  Mm	  
EDTA	   to	   dissociate	   them	   from	   the	   plate.	   Red	   blood	   cells	   were	   lysed	   and	  
remaining	   white	   cells	   were	   stained	   with	   Pacific	   Blue	   Live/Dead	   stain	   [violet	  
viability	  dye	  (VIVID)],	  fixed	  with	  FACS	  Lysing	  Solution	  (BD)	  and	  cryopreserved	  in	  
a	   10%	   dimethyl	   sulfoxide	   (DMSO)	   freezing	   solution	   for	   storage	   at	   -­‐80oC	   until	  
analysis.	  
	  
2.2.2.	  Ki67	  Proliferation	  and	  Intracellular	  cytokine	  staining	  assay	  (ICS)	  
The	   frozen	   fixed	  cells	  were	   then	   thawed	  and	   stained	  with	  a	  Ki67	  Proliferation	  
and	  Intracellular	  cytokine	  staining	  (ICS)	  panel.	  Ki67	  was	  used	  to	  measure	  T	  cell	  
proliferative	   responses	   to	  antigen	   stimulation.	  Ki67	   is	   a	  human	  protein	   that	   is	  
strictly	  associated	  with	  cell	  proliferation.	  Ki67	  protein	   is	  present	  during	  all	   the	  
division	  stages	  of	  the	  cell	  and	  absent	   in	  resting.	  This	  characteristic	  makes	  it	  an	  
excellent	   marker	   for	   cell	   growth	   and	   proliferation	   (Scholzen	   et	   al.,	   2000).	   In	  
addition	  Ki67	  can	  be	  co-­‐stained	  with	  other	  cellular	  markers,	   is	  highly	   sensitive	  
and	  requires	  only	  small	  blood	  volumes	  (Soares	  et	  al	  2010).	  Thereafter,	  ICS	  was	  
used	  to	  quantify	  the	  proportions	  of	  cytokines	  expressed	  by	  these	  proliferating	  T	  




37°C	  water	   bath,	   permeabilized	   in	   100	   ul	   of	   Cytofix/Cytoperm™	   solution	   (BD)	  
and	   stained	   for	   cellular	   markers	   (CD3	   and	   CD8),	   intracellular	   cytokines	   (ICS):	  
INF-­‐γ,	  IL-­‐2,	  IL-­‐13	  and	  IL-­‐17	  and	  as	  well	  as	  for	  proliferation	  marker	  Ki67	  (Soares	  et	  
al.,	   2010)	   with	   optimized	   volumes	   of	   fluorescence-­‐conjugated	   antibodies	  
(Soares	   et	   al.,	   2013)(table	   2.2).	   Samples	  were	   acquired	   on	   a	   BD	   LSR	   Fortessa	  
flow	  cytometer	  (BD	  Biosciences,	  San	  Jose,	  CA).	  	  
	  




Table	  2.2:	  Flow	  cytometry	  panel:	  8-­‐colour	  flow	  cytometry	  panel	  used	  with	  the	  
different	  fluorochromes,	  markers	  and	  their	  functions	  in	  the	  immune	  system	  	  
FLUOROCHROME	   MARKER	   MARKER’S	  FUNCTION	   CLONE	   SUPPLIER	  
Pacific	  blue	   VIVID	   Live/Dead	  cell	  marker	   	   Invitrogen	  
APC-­‐Cy7	   CD3	   T-­‐Lymphocytes	  marker	   UCHT1	   Biolegend	  
PerCP-­‐Cy5.5.	  	   CD8	   Cytotoxic	   lymphocytes,	   kill	  
infected	  cells	  
SK1	   BD	  
Biosciences	  	  
FITC.	   Ki67	   Marker	  of	  T	  cell	  proliferation	   B56	   BD	  
Biosciences	  	  
AlexaFluor-­‐700.	   IFN-­‐γ.	   Th1	   cytokine	   important	   for	   the	  
control	  of	  intracellular	  pathogens	  	  
	  
B27	   Biolegend.	  
	  APC.	   IL-­‐2	   Th1	   cytokine	   important	   for	   the	  
growth	  of	  T-­‐cells	  
5344.111.	  	   BD	  
Biosciences.	  
	  
PE	   IL-­‐13.	   Th2	   cytokine	   important	   for	   the	  
control	  of	  extracellular	  pathogens	  
and	   antibody	   production	   by	   B	  
cells	  
JES10-­‐5A2.	  	   BD	  
Biosciences	  	  
	  PE-­‐Cy7.	   IL-­‐17	   Th17	   cytokine	   that	   helps	   in	   the	  
recruitment	   of	   Th1	   cells	   and	  
neutrophils.	  
BL168	   Biolegend	  
	  
2.2.3.	  Flow	  cytometry	  data	  analysis	  	  
Following	   acquisition,	   colour	   compensation	   was	   performed	   using	   FlowJo	   v9.4	  
(Treestar,	  Ashland	  OR	  USA)	  to	  account	  for	  the	  spectral	  overlap,	  and	  perform	  a	  




singlets	  (single	  cells	  that	  are	  not	  aggregated	  with	  others),	  live	  CD3+	  cells,	  CD8+	  
cells	   and	   CD8-­‐	   cells	   were	   gated	   (considered	   as	   CD4+	   cells	   as	   PMA-­‐Ionomycin	  
lead	   to	   CD4	   down-­‐regulation	   in	   T	   cells)	   (Rueggs	   et	   al.,	   1992)(Figure	   2.2).	  
Furthermore,	   Ki67+	   proliferating	   cells	   were	   gated	   on	   CD8-­‐	   (CD4+)	   and	   CD8+	  
populations	   (Figure	   2.2).	   We	   then	   assessed	   IFN-­‐γ	   and	   IL-­‐2	   (Th1/	   Tc1),	   IL-­‐17	  
(Th17,	   Tc17)	   and	   IL-­‐13	   (Th2/	   Tc2)	   expression	  by	   gating	   these	   cytokines	  within	  
CD8-­‐	  Ki67+.	  (CD4+	  Ki67+)	  and	  CD8+Ki67+	  cells	  (Figure	  2.3).	  Boolean	  gating	  was	  
used	   to	   determine	   the	  proportion	  of	   CD4+	   and	  CD8+	   cells	   expressing	  none,	   a	  
single	  or	  a	  combination	  of	  multiple	  cytokines.	  Boolean	  gates	  reflect	  any	  changes	  
to	  the	  gates	  on	  which	  they	  depend.	  Figures	  2.2	  and	  2.3	  below	  describe	  how	  the	  
gates	   were	   established,	   from	   the	   time	   gates	   for	   including	   consistent	  
fluorescence	   over	   time	   and	   exclusion	   of	   doublets	   using	   forward	   scatter-­‐area	  
and	   forward	  scatter-­‐height	  parameters	   in	  a	  singlets	  gate;	   to	  exclusion	  of	  dead	  
cells	  [violet	  viability	  dye	  positive	  cells	  (VIVID+)]	  gating	  live	  CD3+	  cells	  and	  gating	  
CD8-­‐	  (CD4+)	  and	  CD8+	  T	  cells	  and	  finally	  Ki67-­‐incorporated	  T	  cells.	  	  





Figure	   2.2a:	  Gating	   strategy,	   a	   representative	   flow	   cytometry	   plot	   of	   a	   response	   to	  
Staphylococcal	  enterotoxin	  B.[SEB]	  (Positive	  control):	  After	  gating	  on	  singlets,	  live	  CD3+	  
cells,	  CD3+CD8-­‐	  (CD4+)	  (A),	  CD3+CD8+(CD8+)	  T	  cells	  were	  gated	  on,	  and	  consequently	  
Ki67+	   proliferating	   T	   cells	   (CD4+Ki67+)	   (B).	   The	   values	   represent	   the	   percentage	   of	   T	  
































































































Figure	   2.2b:	  Gating	   strategy,	   a	   representative	   flow	   cytometry	   plot	   of	   a	   response	   to	  
negative	   control	   (medium	   only):	   After	   gating	   on	   singlets,	   live	   CD3+	   cells,	   CD3+CD8-­‐	  
(CD4+)	   (A),	   CD3+CD8+(CD8+)	   T	   cells	   were	   gated	   on,	   and	   consequently	   Ki67+	  
proliferating	  T	  cells	  (CD4+Ki67+)	  (B).	  The	  values	  represent	  the	  percentage	  of	  T	  cells	  that	  















































Figure	   2.3a:	   Gating	   of	   CD8-­‐Ki67+(CD4+Ki67+)	   cytokine	   producing	   T	   cells.	   A	  
representative	   flow	   cytometry	   plot	   of	   CD4+Ki67+	   proliferating	   cells	   expressing	  
intracellular	   cytokines;	   IFN-­‐Ƴ,	   IL-­‐2	   (Th1),	   IL-­‐17	   (Th17)	   and	   IL-­‐13	   (Th2)	   in	   response	   to	  
Staphylococcal	  enterotoxin	  B	  [SEB]	  (positive	  control).	  Similar	  gates	  were	  laced	  for	  CD8+	  















Figure	   2.3b:	   Gating	   of	   CD8-­‐Ki67+(CD4+Ki67+)	   cytokine	   producing	   T	   cells.	   A	  
representative	   flow	   cytometry	   plot	   of	   CD4+Ki67+	   proliferating	   cells	   expressing	  
intracellular	   cytokines;	   IFN-­‐Ƴ,	   IL-­‐2	   (Th1),	   IL-­‐17	   (Th17)	   and	   IL-­‐13	   (Th2)	   in	   response	   to	  

















2.2.3.1.	  Pass/	  Fail	  criteria,	  cut-­‐offs	  and	  controls	  for	  the	  flow	  cytometry	  data	  	  
Following	   analysis	   by	   FlowJo,	   the	   data	   was	   exported	   into	   spice	   and	   pestle	   in	  
order	   to	   perform	   background	   subtraction.	   To	   ensure	   no	   bias,	   we	   applied	   the	  
following	  criteria:	  	  
	  
a.)	  Assay	  validity	  and	  positivity	  (before	  background	  subtraction)	  	  
The	   frequency	   of	   proliferating	   cells	   in	   response	   to	   SEB	   stimulation	   (positive	  
control)	   had	   to	   be	   greater	   than	   the	   median	   plus	   three	   times	   the	   Median	  
Absolute	  Deviation	  (MAD)	  of	  the	  negative	  control	  (Median	  alone)	  as	  indicated	  in	  
formula	   below.	   If	   not,	   the	   sample	  was	   excluded.	  MAD	   is	   an	   estimator	   of	   the	  
median	   defined	   as	   the	   deviations	   of	   each	   sample	   negative	   control	   frequency	  
from	   the	   negative	   control’s	   median,	   the	  MAD	   is	   the	   median	   of	   the	   absolute	  
values	  of	  the	  deviation	  (Rousseeuwa	  et	  al.,	  1993).	  
	  
Assay	  validity	  formula:	  Frequency	  of	  CD4+	  proliferating	  cells	  	  
%	  Ki67+CD4+	  [SEB]	  >	  %	  Ki67+CD4+	  (Median	  +	  3MAD)	  [Media]	  
	  
b.)	  Proportion	  of	  proliferating	  cells	  (Ki67+)	  	  
The	   frequency	   of	   CD4+	   and	   CD8+	   T	   cells	   expressing	   Ki67	   (i.e.	   CD4+Ki67+	   and	  
CD8+Ki67+	   T	   cells)	   of	   the	   test	   antigens	   (BCG,	   pertussis,	   TT,	   and	   SEB)	   minus	  
background	  (%	  of	  Ki67+CD4+	  and	  CD8+	  T	  cells	  in	  the	  media	  control)	  	  
i.e.:	   (i)	   [(BCG,	   pertussis,	   TT	   and	   SEB	   induced	   %Ki67+CD4+	   cells)	   –	   (Induced	  
%Ki67+CD4+	  cells	  in	  the	  media)]	  	  
	  
c.)	  Cut	  off	  for	  cytokine	  responses	  For	  single	  cytokine	  analyses	  data	  is	  reported	  




was	   the	   frequency	  of	   total	  CD4+	  and	  CD8+	  T	   cells	   that	  were	  proliferating	  and	  
producing	   cytokines	   (the	   ratio	   of	   CD4+Ki67+	   and	  CD8+Ki67+	   T	   cells	   producing	  
cytokines	   over	   the	   total	   CD4+	   and	   CD8+	   T	   cell	   population).	   For	   the	   multiple	  
cytokine	   analysis,	   data	   is	   reported	   as	   the	   frequency	   of	   proliferating	   T	   cells	  
producing	  cytokines	  and	  the	  denominator	  is	  proliferating	  cells	  only.	  	  
	  
i)	   The	   test	  antigens	   (i.e.	  BCG,	  pertussis,	   TT,	  and	  SEB)	   cytokine	   responses	  were	  
only	  quantified	  if	  the	  event	  counts	  of	  proliferating	  T	  cells	  (i.e.	  CD4+Ki67+	  T	  cells)	  
were	   ≥	   20.	   An	   average	   of	   200	   000	   cells	   were	   acquired.	   Using	   this	   filter,20	  
samples	  out	  of	  the	  168	  analysed	  were	  excluded.	  
ii)	   In	  addition,	  background	  subtraction	  of	   the	  %	  of	   total	  CD4+	  and	  CD8+	  T	  cell	  
cytokine	   production	   in	   the	   media	   from	   the	   %	   of	   total	   CD4+	   and	   CD8+	   T	   cell	  
cytokine	  production	  due	  to	  the	  specific	  test	  antigens	  i.e.	  BCG,	  pertussis,	  TT,	  and	  
SEB	  (Figure	  3.3)	  was	  performed.	  	  
	  
Figure	   2.4:	   Schematic	   description	   of	   the	   frequencies	   of	   total	   CD4+	   and	   CD8+	   cells	  




































population)	   and	   antigen	   specific	   total	   CD4+	   and	   CD8+	   cytokine	   producing	   cells	  
(daughter	  population).	  	  
	  
2.2.4.	  Statistical	  considerations	  	  
Different	  statistical	  software	  was	  used	  to	  perform	  data	  analysis	  after	  collecting	  
data	  from	  flow	  cytometry.	  These	  software	  and	  their	  functions	  are	   listed	   in	  the	  
table	  2.3	  below.	  	  




Table	  2.3:	  Statistical	  software	  used	  for	  data	  analysis	  
Software	  Program	   Type	  of	  analysis	  
FLOWJO	   v9.4.7	   (for	   MAC,	   Stanford	  
University,	   1995-­‐96;.TreeStar,	   Inc.	   1997-­‐
2012)	  
Flow	  cytometric	  data	  analysis	  after	  acquisition	  
Microsoft	  Excel	  2007	   Data	  cleaning	  
Pestle	   v1.7	   (for	   MAC,	   Mario	   Roederer,	  
National	   Institute	   of	   Allergy	   &	   Infectious	  
Diseases,	  2004-­‐2011)	  
To	   perform	   background	   subtraction	   on	   flow	  
cytometry	  data	  and	  import	  them	  into	  SPICE	  
SPICE	   v5.22	   (for	   MAC,	   Mario	   Roederer-­‐
Joshua	  Nozzi,	  National	   Institute	  of	  Allergy	  
&Infectious	  Diseases,2004-­‐2011)	  
Generate	  and	  analyze	  intracellular	  cytokine	  	  
Polyfunctionality	  data	  between	  groups	  
GraphPad	  Prism	  v5	  (for	  Windows,	  	  
GraphPad	   Software,	   San	   Diego	   California	  
USA)	  
To	   analyze	   and	   compare	   differences	   in	   proliferation	  
and	   absolute	   cytokine	   expression	   by	   cells	   between	  
groups	  
STATA	   v11	   (for	   windows,	   StataCorp	   LP,	  
College	  station,	  TX77845,	  USA)	  
To	   perform	   inferential	   statistics	   analyses	   and	  
evaluate	  the	  validity	  of	  data	  
	  
	  
2.2.4.1.	  Statistical	  Tests	  
Many	   statistical	   tests	   were	   applied	   to	   complete	   the	   data	   analysis	   as	   listed	   in	  
table	  2.4:	  




Table	  2.4:	  List	  of	  statistical	  tests	  applied	  for	  data	  analysis	  
Statistical	  Test	   Rationale	   Type	  of	  Data	   Software	  
Shapiro-­‐Wilk	  
test	  
Confirm	   normality	   of.	   data	  
distribution.	   If	   not	   normally	  
distributed	   then	   data	   was	   log	  
transformed	   for	   normal	  
distribution	  
-­‐Cohort	  description	  	  
-­‐	  T	  cell	  proliferation.	  
-­‐T	   cell	   cytokine	  
production	  	  
-­‐T	  cell	  polyfunctional	  	  
cytokine	  responses	  	  
	  
STATA	  v11	  
Wilcoxon	  rank	  	  
sum	  test	  (Mann-­‐	  
Whitney	  test)	  	  
	  
	  
Compare	   continuous	   data	  
between	   two	   categories	   not	  
normally	  distributed.	  	  
	  
T	  cell	  proliferation.	  
-­‐T	   cell	   cytokine	  
production	  	  
-­‐T	  cell	  polyfunctional	  	  
cytokine	  responses	  	  
(Early	  arm	  vs.	  Delayed	  
arm)	  	  
	  
STATA	  v11	  	  
GraphPad	  Prism	  v5	  	  
SPICE	  v5.22	  
	  
ANOVA	  test	   analyze	   the	   differences	  
between	  group	  means	  and	  their	  
associated	   procedures	   (such	   as	  
"variation"	  among	  and	  between	  
groups).	  
T	   cell	   polyfunctional	  
cytokine	  responses	  




Affect	   the	   effects	   of	   one	  
outcome	  on	  another	  	  







The	   similar	   baseline	   characteristics	   of	   the	   two	   groups	   confirmed	   that	   due	   to	  
randomization	   there	   were	   no	   major	   differences	   between	   the	   two	   groups	   of	  
infants	  other	   than	   the	   timing	   at	  which	  BCG	  was	   administered.	   Thus,	   although	  
many	   factors	   could	   influence	   vaccine	   responses,	   these	   were	   well	   balanced	  
between	  groups.	  No	   information	  on	   the	   socioeconomic	   status	  of	   the	  mothers	  
was	  collected	  but	  we	  know	  overall	  31.4%	  of	  mothers	   lived	   in	  brick	   structures,	  
60.8%	   in	   shacks	   and	   7.8%	   lived	   in	   another	   form	   of	   habitat	   not	   specified.	  
Additionally,	   viral	   load	   was	   not	   routinely	   available	   for	   all	   the	   mothers.	   This	  
constitutes	   one	   of	   the	   limitations	   of	   our	   study.	   Nonetheless,	   CD4	   counts	   are	  
good	   indicators	   of	   the	  maternal	   health	   status	   and	   how	   they	   respond	   to	   ARV	  
therapy.	   Although	   not	   without	   limitations	   such	   as	   the	   need	   for	   non-­‐specific	  
stimulation	   on	   Day	   6,	   the	   assay	   used	   in	   this	   thesis	   have	   been	   validated	  
previously	   (Soares	   et	   al.,	   2010)	   as	   an	   excellent	   method	   for	   obtaining	   large	  
amounts	  of	  data	  from	  small	  blood	  volumes.	  Ki67+	  proliferation	  is	  as	  good	  if	  not	  
better	  than	  other	  proliferation	  markers	  such	  as	  5-­‐Bromo-­‐2-­‐Deoxyuridine	  (BrdU)	  
and	  Carboxyfluorescein	  diacetate	  succinimidyl	  ester	  (CFSE)	  (Soares	  et	  al.,	  2010).	  
Ki67	  can	  also	  be	  used	  in	  conjunction	  with	  other	  markers.	  Recent	  vaccine	  studies	  
have	   used	   Ki67	   in	   conjunction	   with	   anti-­‐apoptic	   marker	   bcl-­‐2	   (Soares	   et	   al.,	  
2013;	  Mc	  Elrath	  et	  al.,	  2008).	  Bcl-­‐2	  has	  been	  extensively	  used	  in	  mice	  studies	  to	  
assess	  T	  cell	  activation	  and	  apoptosis	   following	  viral	   infection	   (Blattman	  et	  al.,	  
2003;	  Sarkar	  et	  al.,	  2008).	  However,	  due	  to	  the	  small	  blood	  volumes	  collected	  in	  
this	  study	  and	  large	  number	  of	  fluorochromes	  already	  being	  used	  in	  our	  panel,	  
bcl-­‐2	  was	  not	  used	  in	  this	  panel.	  Thus,	  in	  future	  studies,	  it	  would	  be	  very	  useful	  
to	   use	   bcl-­‐2	   and	   Ki-­‐67	   markers	   to	   assess	   T	   cell	   proliferation	   and	   apoptosis	  
following	  vaccination.	  	  
In	   addition,	   T	   cell	   cytokine	   expression	   and	   polyfunctionality	   figures	   show	   two	  
different	  types	  of	  data.	  The	  data	  reported	  in	  T	  cell	  cytokine	  expression	  figures	  is	  
dependent	  on	  the	  proliferation	  response	  (antigen-­‐specific)	  T	  cells	  reported	  as	  a	  
frequency	  of	  total	  CD4+	  and	  CD8+	  T	  cells,	  whereas	  T	  cell	  polyfunctionality	  data	  





Chapter	  3.	  Effects	  of	  Delayed	  BCG	  Vaccination	  
on	  Cellular	  Responses	  to	  BCG	  
	  
3.1.	  Introduction	  	  
Recent	   studies	  have	   shown	   that	  delaying	  BCG	  vaccination	  may	  affect	   immune	  
responses	   to	   BCG	   in	  HIV–unexposed	   infants	   (Burl	   et	   al.,	   2010;	   Kagina	   et	   al.,	  
2009;	  Lutwama	  et	  al.,	  2013).	  However,	  very	  little	  is	  known	  about	  the	  effects	  of	  
delayed	  BCG	  vaccination	   in	  HIV-­‐exposed	   infants.	   In	   this	   chapter,	  we	  aimed	   to	  
investigate	   how	   delaying	   BCG	   vaccination	   from	   birth	   to	   8	   weeks,	   when	  
perinatally	  acquired	  HIV	  is	  ruled	  out,	  affects	  immune	  responses	  to	  BCG	  in	  HIV-­‐
exposed	   infants.	   In	  order	  to	  achieve	  this,	  we	  first	  compared	  CD4+	  and	  CD8+	  T	  
cell	  proliferative	  responses	  to	  BCG	  between	  birth-­‐vaccinated	  (early	  arm)	  and	  8	  
week-­‐vaccinated	   (delayed	   arm)	   HIV-­‐exposed	   infants.	   This	   was	   done	   by	  
measuring	   the	   frequency	   of	   Ki-­‐67-­‐expressing	   CD4+and	   CD8+	   T-­‐cells	   in	   6-­‐day	  
whole	   blood	   assay	   cultures	   described	   in	   the	  methods	   (see	   section	   2.2.1)	  with	  
samples	  collected	  at	  six,	  eight	  and	  14	  weeks	  of	  age.	  Furthermore,	  using	  ICS,	  we	  
assessed	   the	   effects	   of	   delayed	   BCG	   vaccination	   on	   T	   cellular	   cytokine	  
expression	   and	   co-­‐expression	   (polyfunctionality)	   at	   6,	   8	   and	   14	  weeks	   of	   age.	  
The	  cytokines	  of	  interest	  were	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐17	  and	  IL-­‐13.	  IL-­‐2	  and	  IFN-­‐γ	  are	  Th1	  
cytokines	   and	  play	   an	   important	   role	   in	   the	   control	   of	   intracellular	   pathogens	  
such	  as	  M.TB	  (Manca	  et	  al.,	  2001).IL-­‐17	  belongs	  to	  Th17	  cytokines	  that	  has	  been	  
shown	   to	   induce	   pro-­‐inflammatory	   responses	   and	   relate	   to	   mycobacterial	  
protection	   (refer	   to	   properties	   of	   IL-­‐17	   in	   chapter	   1).	   IL-­‐13	   is	   a	   Th2	   cytokine	  
associated	   with	  mast	   cell	   activity	   and	   B	   cell	   production	   of	   antibodies	   against	  






3.2	   T-­‐cell	   proliferative	   responses	   to	   BCG	   in	   early	   versus	   delayed-­‐BCG-­‐
vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  age	  	  
The	   proliferative	   responses	   to	   BCG	   were	   compared	   between	   HIV-­‐exposed	  
infants	   in	   the	  early	  arm	  (receiving	  BCG	  at	  birth)	  and	  those	   in	   the	  delayed	  arm	  
(receiving	  BCG	  arm	  at	  8	  weeks)	  using	  Ki67,	  a	  cell	  cycle	  marker	  (refer	  to	  chapter	  
2).	   Table	  3.1	  describes	   the	  different	   time	  points	  at	  which	  blood	  was	   collected	  
and	  at	  which	  infants	  received	  the	  main	  vaccines	  studied	  in	  this	  dissertation.	  
	  




Early	  arm	   Delayed	  arm	  
0	  weeks	   BCG	   administered	   and	   blood	  
collected	  
Blood	  collected	  
6	  weeks	   Blood	  collected,	  pertussis	  and	  TT	  
vaccines	  administered	  
Blood	   collected,	   pertussis	   and	   TT	  
vaccines	  administered	  
8	  weeks	   Blood	  collected	  	   BCG	   vaccine	   administered,	   blood	  
collected	  
10	  weeks	   Pertussis	   and	   TT	   vaccines	  
administered	  
Pertussis	   and	   TT	   vaccines	  
administered	  
14	  weeks	   Blood	  collected	   Blood	  collected	  
	  
3.2.1.	  CD4+	  proliferative	  responses	  to	  BCG	  at	  weeks	  6,	  8	  and	  14	  
At	  6	  weeks	  of	  age,	   infants	   in	  the	  birth	  BCG	  vaccination	  group	  exhibited	  higher	  
CD4+	  T	  cell	  proliferation	  in	  response	  to	  BCG	  than	  those	  given	  delayed	  BCG	  (early	  
arm	  median=20.5%)	  versus	  delayed	  arm	  (median=1.89%;	  p<0.001)	  (Figure	  3.1a).	  
Similarly,	  at	  8	  weeks	  of	  age,	  infants	  in	  the	  birth	  BCG	  vaccination	  group	  also	  had	  
higher	   CD4+	   T	   cell	   proliferation	   in	   response	   to	   BCG	   than	   those	   given	   delayed	  
BCG	  (early	  arm	  median=28.6%	  versus	  delayed	  arm	  median=1.99%	  and	  p<0.001).	  
These	   findings	   were	   expected	   given	   that	   the	   delayed	   BCG	   arm	   received	   BCG	  
vaccination	  only	  at	  8	  weeks	  of	  age.	  On	   the	  other	  hand,	  at	  week	  14,	   infants	   in	  
both	   arms	   had	   similar	   proliferative	   CD4+	   responses	   (early	   arm	  median=17.8%	  




responses	  to	  BCG	  were	  compared	  6	  weeks	  post	  vaccination	  (week	  6	  for	  infants	  
vaccinated	  at	  birth	  and	  week	  14	  for	  infants	  vaccinated	  at	  week	  8),	  no	  significant	  
difference	  was	  found	  (20.5%	  versus	  22.4%,	  p=0.881)	  (Figure	  3.1b).	  	  
	  






Figure	   3.1:	   a).	   Frequency	   of	   CD4+	   T	   cells	   expressing	   Ki67+	   in	   response	   to	   BCG	  
stimulation	   determined	   by	   flow	   cytometry	   in	   the	   early	   (blue)	   versus	   delayed	   (red)	  
BCG	   vaccinees	   at	   6,	   8,	   and	   14	   weeks.	   Lines	   represent	   medians	   and	   whiskers	  
interquartile	   ranges.	   p<0.05	   significant	   level	   (unadjusted)	   and	   statistical	   significance	  
was	  obtained	  using	  Mann-­‐Whitney	  U	  test.	  b).	  Longitudinal	  assessment	  of	  the	  median	  









































































































3.2.2.	  CD8+	  proliferative	  responses	  to	  BCG	  at	  weeks	  6,	  8	  and	  14	  
Similar	   to	   CD4+	   T	   cells,	   infants	   in	   the	   early	   arm	   had	   higher	   CD8+	   T	   cell	  
proliferation	   in	   response	   to	  BCG	  compared	   to	   infants	   in	   the	  delayed	  arm	  at	  6	  
weeks	  of	  age	  (early	  arm	  median=18.5%	  versus	  delayed	  arm	  median	  =3.61%	  and	  
p=0.0363)(figure	   3.2.a).	   At	   8	   weeks	   of	   age,	   infants	   in	   the	   early	   arm	   also	   had	  
higher	  CD8+	  T	  cell	  proliferation	  in	  response	  to	  BCG	  compared	  to	  infants	   in	  the	  
delayed	  arm	  (early	  arm	  median=21.5%	  versus	  delayed	  arm	  median=4.61%	  and	  
p=0.0184)	   (figures	   3.2a	   and	   3.2.b).	   At	   week	   14,	   there	   was	   no	   difference	   in	  
proliferative	   CD8+	   proliferative	   responses	   between	   infants	   in	   the	   two	   arms	  
(early	  arm	  median=9.5%	  versus	  delayed	  arm	  median=8.61%	  and	  p=0.8241).	  	  
	  
When	   CD8+	   proliferative	   responses	   to	   BCG	   were	   compared	   at	   6	   weeks	   post	  
vaccination	  (week	  6	  for	  early	  arm-­‐infants	  and	  week	  14	  for	  delayed	  arm-­‐infants	  
vaccinated	  at	  week	  8),	  no	  significant	  difference	  was	  found	  (figure	  3.2.a).	  




BCG-­‐induced	  CD8+	  Ki67+	  T	  cells	  
	  
	  
Figure	   3.2:	   a).	   Frequency	   of	   CD8+	   T	   cells	   expressing	   Ki67+	   in	   response	   to	   BCG	  
stimulation	   determined	   by	   flow	   cytometry	   in	   the	   early	   (blue)	   versus	   delayed	   (red)	  
BCG	   vaccinees	   at	   6,	   8,	   and	   14	   weeks.	   Lines	   represent	   medians	   and	   whiskers	  
interquartile	   ranges.	   p<0.05	   significant	   level	   (unadjusted)	   and	   statistical	   significance	  
was	  obtained	  using	  Mann-­‐Whitney	  U	  test.	  b).	  Longitudinal	  assessment	  of	  the	  median	  
frequency	   of	   CD8+Ki67+	   cells.	   Whiskers	   represent	   interquartile	   ranges.	   *p<0.05;	  
**p<0.01.	  	  
	  
3.2.3.	   Effects	   of	   pre	   vaccination	   responses	   on	   post	   vaccination	   responses	   in	  
the	  delayed	  arm	  	  
At	  6	  and	  8	  weeks	  of	  age,	  3	  of	  the	  28	  infants	  in	  the	  delayed	  group	  possessed	  high	  
levels	  of	  BCG-­‐specific	  CD4+	  proliferation.	  (15-­‐30%)	  despite	  not	  having	  yet	  been	  
BCG	   vaccinated	   possibly	   a	   consequence	   of	   environmental	   Mycobacteria	  

























































































to	   impact	   post-­‐vaccination	   proliferative	   responses	   in	   infants	   who	   received	  
delayed	   vaccination,	   the	  effects	   of	   pre-­‐vaccination	   responses	   (weeks	  6	   and	  8)	  
on	   post	   vaccination	   proliferative	   responses	   (weeks	   14)	   were	   assessed.	   There	  
was	   no	   correlation	   between	   BCG-­‐specific	   CD4	   proliferative	   responses	   pre-­‐
vaccination	   in	   the	   delayed	   BCG	   arm	   at	   week	   6	   and	   their	   responses	   post-­‐
vaccination	   at	   week	   14	   (r=0.027;	   p=0.946)	   (figure	   3.3.a).	   Similarly,	   CD4+	  
proliferative	   responses	   at	   week	   8	   did	   not	   correlate	   with	   CD4+	   proliferative	  
responses	  at	  week	  14	  (r=0.393;	  p=0.261)	  (figure	  3.3.a)	  
	  
In	   addition,	   there	   was	   no	   correlation	   between	   BCG-­‐specific	   CD8+	   T	   cell	  
proliferative	  responses	  pre-­‐vaccination	   in	   the	  delayed	  BCG	  arm	  at	  week	  6	  and	  
their	   responses	   post-­‐vaccination	   at	   week	   14	   (r=0.427;	   p=0.234).	   CD8+	  
proliferative	  responses	  at	  week	  8	  also	  did	  not	  correlate	  with	  CD4+	  proliferative	  
responses	  at	  week	  14	  (r=-­‐0.259;	  p=0.4933)	  (figure	  3.3.b)	  






Figure	  3.3:	  a).	  Spearman	  Correlation	  between	  CD4+	  proliferative	  responses	  at	  week	  6	  
(left),	  week.8	  (right)	  and	  CD4	  proliferative	  responses	  at	  week	  14.	  p	  values	  were	  0.946	  
and	   0.261	   respectively.	   b).	   Spearman	   correlation	   between	   CD8+	   proliferative	  
responses	  at	  week	  6	  (left),	  week	  8	  (right)	  and	  CD8	  proliferative	  responses	  at	  week	  14.	  
p	   values	   were	   0.259	   and	   0.493	   respectively.	   A	   Spearman	   correlation	   analysis	   was	  
performed	  using	  STATAv11	  and	  Graph	  pad	  Prism	  V5.	  
	  
3.3.	   T	   cell	   intracellular	   cytokine	   expression	   in	   response	   to	  BCG	   in	  
HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  	  
After	   assessing	   T	   cell	   proliferative	   responses,	   T	   cell	   cytokine	   expression	   in	  
response	  to	  BCG	  were	  compared	  between	  birth-­‐vaccinated	   infants	   (early	  arm)	  
and	  8	  week-­‐vaccinated	  (Delayed	  arm)	  HIV-­‐exposed	  infants.	  	  
	  























































































3.3.1.	   IFN-­‐g	   and	   IL-­‐2	   (Th1/	   Tc1)	   expression	   in	   response	   to	   BCG	   in	   early	   vs.	  
delayed	  arms	  at	  6,	  8	  and	  14	  weeks	  of	  age	  
3.3.1.1.	   Frequency	   of	   CD4+	   proliferating	   T	   cell	   expressing	   IL-­‐2	   or	   IFN-­‐γ	   (Th1	  
cytokines)	  at	  weeks	  6,	  8	  and	  14.	  
Figure	  3.4a	  shows	  that	  as	  hypothesized,	  infants	  in	  the	  early	  arm	  (receiving	  BCG	  
at	   birth)	   had	   a	   higher	   proportion	   of	   CD4+	   T	   cells	   secreting	   IFN-­‐	   and	   IL-­‐2	  
compared	  to	  infants	  in	  the	  delayed	  BCG	  arm	  (receiving	  BCG	  at	  week	  8)	  at	  weeks	  
6	  and	  8	   (p<0.001).	  At	  week	  14,	   infants	   in	   the	  delayed	  arm	  (receiving	  BCG	  at	  8	  
weeks)	  had	  a	  larger	  proportion	  of	  CD4+	  T-­‐cells	  expressing	  IFN-­‐γ	  (p<0.001)	  when	  
compared	  to	  infants	  in	  the	  early	  arm.	  There	  was	  no	  difference	  in	  IL-­‐2	  expression	  
by	  CD4+	  proliferating	  cells	  between	  the	  two	  groups	  at	  week	  14.	  	  
	  
Figure	   3.4a:	   Frequency	   of	   CD4+Ki67+	   cells	   expressing	   IFN-­‐γ+	   and	   IL-­‐2+	   in	   the	   early	  
(blue)	  versus	  delayed	  (red)	  HIV-­‐exposed	  infants	  after	  BCG	  stimulation	  for	  six	  days	  in	  
the	  whole	  blood	  assay	  measured	  by	  flow	  cytometry.	  Frequencies	  reported	  are	  of	  total	  
CD4+	   T	   cells.	   Bars	   indicate	   medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	  
was	  tested	  using	  Mann-­‐Whitney	  U	  test.	  	  
	  
	  3.3.1.1.Frequency	   of	   CD8+	   proliferating	   T	   cell	   expressing	   IL-­‐2	   or	   IFN-­‐γ	   (Tc1	  
cytokines)	  at	  weeks	  6,	  8	  and	  14.	  
Similarly	   to	   CD4+Ki67,	   infants	   in	   the	   early	   arm	   (receiving	   BCG	   at	   birth)	   had	   a	  































































































































and	   p=	   0.028	   respectively)	   (figure	   3.4b).	   At	   week	   8,	   infants	   in	   the	   early	   arm	  
(receiving	   BCG	   at	   birth)	   had	   higher	   frequencies	   of	   IFN-­‐γ	   –expressing	  
proliferating	  CD8	  cells	  (p<0.001)	  and	  there	  was	  no	  difference	  in	  IL-­‐2	  expression	  
by	  proliferating	  CD8+	  cells.	  At	  week	  14,	   infants	   in	  both	  arms	  had	  similar	   levels	  
IL-­‐2	  and	  IFN-­‐γ-­‐expressing	  CD8+	  cells	  (figure	  3.4b).	  
	  
Figure	   3.4b:	   Frequency	   of	   CD8+Ki67+	   cells	   expressing	   IFN-­‐γ+	   and	   IL-­‐2+	   in	   the	   early	  
(blue)	  versus	  delayed	  (red)	  HIV-­‐exposed	  infants	  after	  BCG	  stimulation	  for	  six	  days	  in	  
the	  whole	  blood	  assay	  measured	  by	  flow	  cytometry.	  Frequencies	  reported	  are	  of	  total	  
CD8+	   T	   cells.	   Bars	   indicate	   medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	  
was	  tested	  using	  Mann-­‐Whitney	  U	  test.	  	  
	  
3.3.2.	  IL-­‐17	  (Th17)	  expression	  in	  response	  to	  BCG	  in	  early	  vs.	  delayed	  arm	  at	  6,	  
8	  and	  14	  weeks	  age.	  
3.3.2.1.	  Frequency	  of	  CD4+	  proliferating	  T	  cell	  expressing	  IL-­‐17	  (Th17)	  at	  weeks	  
6,	  8	  and	  14.	  
At	  6	  weeks	  of	  age,	  early-­‐vaccinated	  infants	  had	  significantly	  higher	  frequencies	  
o	  f	   IL-­‐17-­‐expressing	  CD4	  proliferating	  cells	   in	  response	  to	  BCG	  at	  6	  weeks	  than	  































































































































differences	   in	   IL-­‐17	  expression	  were	  observed	  between	  the	  two	  groups	  (figure	  
3.5a).	  	  
	  
Figure	  3.5a:	  Frequency	  of	  CD4+Ki67+	  cells	  expressing	  IL-­‐17+	  in	  the	  early	  (blue)	  versus	  
delayed	   (red)	   HIV-­‐exposed	   infants	   after	   BCG	   stimulation	   for	   six	   days	   in	   the	   whole	  
blood	   assay	  measured	   by	   flow	   cytometry.	   Frequencies	   reported	  are	  of	   total	  CD4+	  T	  
cells.	  Bars	  indicate	  medians;	  alpha=0.05	  (unadjusted);	  statistical	  significance	  was	  tested	  
using	  Mann-­‐Whitney	  U	  test.	  	  
	  
3.3.2.1.	  Frequency	  of	  CD8+	  proliferating	  T	  cell	  expressing	  IL-­‐17	  (Tc17)	  at	  weeks	  
6,	  8	  and	  14.	  
Early-­‐vaccinated	  infants	  had	  significantly	  higher	  frequencies	  of	  IL-­‐17-­‐expressing	  
CD8	  proliferating	  cells	  in	  response	  to	  BCG	  at	  6	  weeks	  than	  those	  in	  the	  delayed	  
arm	  (p=0.0089).	  On	  the	  other	  hand,	  at	  8	  and	  14	  weeks	  of	  age,	   infants	   in	  both	  
arms	  had	  similar	  level	  of	  IL-­‐17-­‐expressing	  CD8+	  proliferating	  cells	  in	  response	  to	  

















































































Figure	  3.5b:	  Frequency	  of	  CD8+Ki67+	  cells	  expressing	  IL-­‐17+	  in	  the	  early	  (blue)	  versus	  
delayed	   (red)	   HIV-­‐exposed	   infants	   after	   BCG	   stimulation	   for	   six	   days	   in	   the	   whole	  
blood	   assay	  measured	   by	   flow	   cytometry.	   Frequencies	   reported	  are	  of	   total	  CD8+	  T	  
cells.	  Bars	  indicate	  medians;	  alpha=0.05	  (unadjusted);	  statistical	  significance	  was	  tested	  
using	  Mann-­‐Whitney	  U	  test.	  
	  
4.3.2.	   IL-­‐13	  (Th2/	  Tc2)	  expression	   in	  response	  to	  BCG	  in	  Birth-­‐	  versus	  8	  week	  
vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  age.	  
4.3.2.1.	  Frequency	  of	  CD4+	  proliferating	  T	  cell	  expressing	  IL-­‐13	  (Th2)	  at	  weeks	  
6,	  8	  and	  14.	  
Early-­‐vaccinated	   infants	   at	   higher	   frequencies	   of	   IL-­‐13-­‐expressing	   CD4+	  
proliferating	  cells	  in	  response	  to	  BCG	  at	  week	  6	  than	  those	  in	  the	  delayed	  arm	  
(p=	  0.0091)	  (figure	  3.6a).	  This	  was	  no	  longer	  the	  case	  at	  weeks	  8	  and	  14	  when	  
infants	   in	   the	   two	   arms	   had	   similar	   frequencies	   of	   IL-­‐13-­‐expressing	   CD4	  
proliferating	  cells	  in	  response	  to	  BCG	  (figure	  3.6a).	  




















































Figure	  3.6a:	  Frequency	  of	  CD4+Ki67+	  cells	  expressing	  IL-­‐13+	  in	  the	  early	  (blue)	  versus	  
delayed	   (red)	   HIV-­‐exposed	   infants	   after	   BCG	   stimulation	   for	   six	   days	   in	   the	   whole	  
blood	   assay	  measured	   by	   flow	   cytometry.	   Frequencies	   reported	  are	  of	   total	  CD4+	  T	  
cells.	  Bars	  indicate	  medians;	  alpha=0.05	  (unadjusted);	  statistical	  significance	  was	  tested	  
using	  Mann-­‐Whitney	  U	  test.	  	  
	  
4.3.2.1.	  Frequency	  of	  CD8+	  proliferating	  T	  cell	  expressing	  IL-­‐13	  (Tc2)	  at	  weeks	  
6,	  8	  and	  14.	  
Early-­‐vaccinated	   infants	   demonstrated	   higher	   frequencies	   of	   IL-­‐13-­‐expressing	  
CD8+	  proliferating	  cells	  in	  response	  to	  BCG	  at	  week	  6	  than	  those	  in	  the	  delayed	  
arm	   (p=<0.001).	   At	   weeks	   8	   and	   14,	   infants	   in	   the	   two	   arms	   had	   similar	  




Figure	  3.6b:	  Frequency	  of	  CD4+Ki67+	  cells	  expressing	  IL-­‐13+	  in	  the	  early	  (blue)	  versus	  
delayed	   (red)	   HIV-­‐exposed	   infants	   after	   BCG	   stimulation	   for	   six	   days	   in	   the	   whole	  
blood	   assay	  measured	   by	   flow	   cytometry.	   Frequencies	   reported	  are	  of	   total	  CD4+	  T	  
cells.	  Bars	  indicate	  medians;	  alpha=0.05	  (unadjusted);	  statistical	  significance	  was	  tested	  
























































































3.4.	  T-­‐cell	  polyfunctional	  responses	  to	  BCG	  in	  early	  versus	  delayed-­‐
BCG	  vaccinated	  infants	  at	  6,	  and	  14	  weeks	  of	  life	  
Co-­‐expression	  of	  cytokines	  by	  specific	  T	  cells	  (polyfunctionaility)	  in	  response	  to	  
antigen	  stimulation	  is	  often	  a	  measure	  of	  T	  cell	  function.	  	  
	  
3.4.1.	  Polyfunctionality	  of	  T	  cell	  responses	  to	  BCG	  stimulation	  at	  6	  weeks	  post-­‐
vaccination	  	  
	  T	   cell	   polyfunctional	   responses	   to	   BCG	   between	   early	   and	   delayed	   BCG-­‐
vaccinated	  infants	  were	  compared	  after	  all	  the	  infants	  had	  received	  BCG	  i.e.	  at	  
14	  weeks.	  Additionally,	   T	   cell	  polyfunctionality	   to	  BCG	  at	  6	  weeks	   in	   the	  early	  
arm	  were	   compared	   to	  T	   cell	   polyfunctional	   responses	   to	  BCG	  at	  14	  weeks	   in	  
the	   delayed	   arm.	   The	   aim	   was	   to	   determine	   whether	   T	   cell	   polyfunctional	  
responses	   to	   BCG	   are	   the	   same	   between	   the	   two-­‐arms	   6	   weeks	   post-­‐
vaccination.	  	  
	  
3.4.1.1.	   Polyfunctionality	   of	   CD4+	   T	   cell	   responses	   to	   BCG	   stimulation	   at	   6	  
weeks	  post-­‐vaccination	  
Figure	   3.7	   shows	   the	   breadth	   of	   CD4+	   T	   cell	   cytokine	   responses	   to	   BCG	   at	   6	  
weeks	   post-­‐vaccination	   (6	   weeks	   for	   early	   arm	   versus	   14	   weeks	   for	   delayed	  
arm).	  The	   frequency	  of	  proliferating	  cells	   that	  were	  making	  none,	  any	  one,	  or	  
any	  combination	  of	  cytokines,	  between	   infants	   in	  the	  delayed	  BCG	  arm	  versus	  
the	  early	  BCG	  arm	  at	  6	  weeks	  post	  BCG	  vaccination	  were	  compared.	  As	  seen	  in	  
the	   top	   graph,	   when	   comparing	   all	   the	   different	   combinations	   of	   cytokines,	  
infants	   in	   the	   early	   and	   delayed	   arms	   had	   comparable	   frequencies	   of	  
proliferating	   CD4+	   cells	   expressing	   zero,	   one,	   two	   or	   three	   cytokines	   (figure	  
3.7.a).	  There	  was	  no	  significant	  difference	   for	   the	  expression	  of	  any	  particular	  
cytokine	   combination	   between	   the	   early	   and	   delayed	   arms	   6-­‐weeks	   post-­‐
vaccination.	   Overall	   infants	   in	   the	   two	   arms	   had	   similar	   CD4+Ki67+	  







Figure	   3.7:	   Proportions	   of	   BCG-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  6	  weeks	  post	  vaccination	  (6	  weeks	  for	  early	  arm	  and	  14weeks	  for	  
delayed	  arm)	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  delayed-­‐vaccinated	  HIV-­‐
exposed	  infants.	  Comparison	  of	  the	  proportion	  of	  cells	  expressing	  no	  cytokine,	  one	  or	  
a	  combination	  of	  intracellular	  cytokine(s)	  by	  proliferating	  CD4+	  T	  cells	  in	  infants	  in	  the	  
early	  arm	  (blue	  dots)	  versus	   infants	   in	   the	  delayed	  arm	  (red	  dots).	   (a)	  Represents	   the	  
possible	   combination	   of	   the	   responses	   shown	   versus	   the	   proportions	   of	   the	  
functionally	   distinct	   cell	   populations	   within	   the	   responding	   CD4+	   T	   cells	   shown.	  
Responses	   are	   grouped	   and	   colour-­‐coded	   on	   the	   basis	   of	   the	   combinations	   of	   the	  
cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	   functionally	   distinct	   T	   cell	  
populations	  within	  the	  proliferating	  CD4+	  T	  cells.	  Bars	  correspond	  to	  medians;	  p-­‐value	  
indicates	   significant	   difference	   in	   the	   combination	   of	   cytokine	   production	   by	   CD4+	   T	  
cells	  between	  the	  two	  groups.	  Statistical	  analysis	  was	  performed	  using	  Wilcoxon	  signed	  
rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  the	  data	  with	  the	  pie	  slice	  legend	  
on	  the	  graph	  showing	  the	  colours	  of	  the	  various	  cytokine	  combinations	  and	  the	  p-­‐value	  
showing	  the	  overall	  significance	  of	  the	  total	  magnitude	  of	  the	  combinations	  of	  cytokine	  
responses.	  



























































































3.4.1.2.	   Polyfunctionality	   of	   CD8+	   T	   cell	   responses	   to	   BCG	   stimulation	   at	   6	  
weeks	  post	  vaccination	  
At	  6	  weeks	  post	  vaccination,	  when	  comparing	  all	  the	  different	  combinations	  of	  
cytokines,	   infants	   in	   the	   early	   BCG	   arm	   had	   significantly	   higher	   proliferating	  
CD8+	  T	  cells	  expressing	  IL-­‐13	  alone	  than	  infants	  in	  the	  delayed	  arm	  (p=	  0.049).	  
However,	  after	  adjusting	  for	  multiple	  comparisons,	  the	  difference	  was	  no	  longer	  
significant	   (p=0.784	   not	   shown).	   Other	   than	   IL-­‐13	   expression	   by	   proliferating	  
CD8+	   cells,	   there	   was	   no	   difference	   in	   the	   frequencies	   of	   CD8Ki67+	   cells	  
expressing	   zero,	   one,	   two	   or	   three	   cytokines	   and	   any	   other	   specific	   cytokine	  
combination	  (figure	  3.8a).	  Overall,	  there	  was	  no	  difference	  in	  proliferating	  CD8+	  
T	   cell	   polyfunctionality	   between	   infants	   in	   the	   early	   and	   those	   in	   the	   delayed	  






Figure	   3.8:	   Proportions	   of	   BCG-­‐specific	   proliferating	   CD8+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  6	  weeks	  post	  vaccination	  (6	  weeks	  for	  early	  arm	  and	  14weeks	  for	  
delayed	   arm)	   in	   birth-­‐vaccinated	   (early	   group)	   infants	   versus	   8-­‐week-­‐vaccinated	  
(delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  of	  cells	  expressing	  
no	  cytokine,	  one	  or	  a	   combination	  of	   intracellular	   cytokine(s)	  by	  proliferating	  CD8+	  T	  
cells	  in	  infants	  in	  the	  early	  arm	  (blue	  dots)	  versus	  infants	  in	  the	  delayed	  arm	  (red	  dots)	  
(a)	   Represents	   the	   possible	   combination	   of	   the	   responses	   shown	   versus	   the	  
proportions	  of	   the	   functionally	  distinct	  cell	  populations	  within	  the	  responding	  CD8+	  T	  
cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  of	  the	  combinations	  
of	  the	  cytokines	  produced.	  Spots	  correspond	  to	  the	  fractions	  of	  functionally	  distinct	  T	  
cell	  populations	  within	  the	  proliferating	  CD8+	  T	  cells.	  bars	  correspond	  to	  medians	  and;	  
p-­‐value	   indicates	   significant	   difference	   in	   the	   combination	   of	   cytokine	   production	   by	  
CD8+	   T	   cells	   between	   the	   two	   groups.	   Statistical	   analysis	   was	   performed	   using	  
Wilcoxon	  signed	  rank	   test.	   (b)	  The	  pie	  charts	  at	   the	  bottom	  summarise	   the	  data	  with	  
the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	   cytokine	  
combinations	  and	  the	  p-­‐value	  showing	  the	  overall	  significance	  of	   the	  total	  magnitude	  
of	  the	  combinations	  of	  cytokine	  responses.	  	  




























































































3.4.2.	  Polyfunctionality	  of	  T	  cell	  responses	  to	  BCG	  stimulation	  at	  14	  weeks	  of	  
age	  
3.4.2.1.	   Polyfunctionality	   of	   CD4+	   T	   cell	   responses	   to	   BCG	   stimulation	   at	   14	  
weeks	  of	  age	  
At	  week	   14,	   infants	   in	   the	   delayed	   BCG	   arm,	  who	   had	   received	   BCG	   6	  weeks	  
prior,	   had	   significantly	   higher	   frequency	   of	   proliferating	   CD4+	   T	   cells	   that	  
produced	   at	   least	   one	   cytokine	   in	   response	   to	   BCG,	   and	   significantly	   higher	  
frequency	  of	  cells	  making	  IFN-­‐γ	  than	  those	  the	  early	  arm	  who	  had	  received	  BCG	  
14	  weeks	  prior	  (p=0.024	  and	  0.012	  respectively)	  (figure	  3.9a).	  Neither	  of	  these	  
differences	   remained	   significant	   after	   adjustment	   for	   multiple	   comparisons.	  
Overall,	   CD4+	   T	   cells	   from	   infants	   in	   the	   delayed	   arm	  were	   significantly	  more	  
polyfunctional	   in	   response	   to	   BCG	   stimulation	   than	   those	   in	   the	   early	   arm	  





Figure	   3.9:	   Proportions	   of	   BCG-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  14	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (Early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (Delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	   early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
correspond	   to	   medians	   ranges;	   p-­‐value	   indicates	   significant	   difference	   in	   the	  
combination	  of	  cytokine	  production	  by	  CD4+	  T	  cells	  between	  the	  two	  groups.	  Statistical	  
analysis	   was	   performed	   using	  Wilcoxon	   signed	   rank	   test.	   (b)	   The	   pie	   charts	   at	   the	  
bottom	  summarise	  the	  data	  with	  the	  pie	  slice	  legend	  on	  the	  graph	  showing	  the	  colours	  
of	  the	  various	  cytokine	  combinations	  and	  the	  p-­‐value	  showing	  the	  overall	  significance	  































































































3.4.2.2.	   Polyfunctionality	   of	   CD8+	   T	   cell	   responses	   to	   BCG	   stimulation	   at	   14	  
weeks	  of	  age	  
As	   shown	   in	   figure	   3.10a,	   when	   comparing	   each	   combination	   of	   cytokines	  
individually,	   there	  were	  no	  significant	  differences	  between	   infants	   in	   the	  early	  
and	   delayed	   arms.	   There	   was	   also	   no	   difference	   in	   the	   overall	   CD8+	   T-­‐cell	  
polyfunctionality	   between	   infants	   in	   the	   early	   and	   delayed	   arms	   at	   week	   14	  
(p=0.111)(figure	  3.10b).	  





Figure	   3.10:	   Proportions	   of	   BCG-­‐specific	   proliferating	   CD8+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  6	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (Early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (Delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD8+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
































































































In	  this	  chapter,	  the	  effects	  of	  delaying	  BCG	  vaccination	  from	  birth	  to	  8	  weeks	  on	  
CD4+and	  CD8+T	  cell	  proliferative	  and	  cytokine	  responses	  to	  BCG	  in	  HIV-­‐exposed	  
infants	  was	  assessed.	  These	  responses	  would	  help	  us	  determine	  the	   impact	  of	  
delaying	   BCG	   vaccination	   on	   the	   vaccine	   immunogenicity	   in	   HIV-­‐exposed	  
infants,	  a	  strategy	  that	  may	  allow	  for	   infant	  BCG	  vaccination	   in	   line	  with	  WHO	  
guidelines.	  Few	  studies	  have	  investigated	  the	  effects	  of	  delayed	  BCG	  vaccination	  
in	  infants	  (Burl	  et	  al.,	  2010;	  Kagina	  et	  al.,	  2009;	  Marchant	  et	  al.,	  1999).	  However,	  
all	  this	  studies	  were	  carried	  out	  in	  HIV-­‐unexposed	  infants.	  This	  is	  one	  of	  the	  first	  
studies	  to	  examine	  the	  effects	  of	  delaying	  BCG	  vaccination	  on	  T	  cell	  responses	  in	  
HIV-­‐exposed,	  uninfected	  infants,	  a	  group	  highly	  relevant	  for	  such	  a	  vaccination	  
strategy.	  	  
	  
In	  this	  chapter,	  the	  main	  result	  showed	  that	  delaying	  BCG	  vaccination	  from	  birth	  
to	  8	  weeks	  did	  not	  alter	  CD4+	  and	  CD8+	  T	  cell	  proliferation	  to	  BCG	  6-­‐weeks	  post	  
vaccination.	   These	   findings	   are	   consistent	   with	   reports	   of	   proliferative	   in	  
responses	  in	  HIV-­‐unexposed	  infants	  following	  delayed	  BCG	  vaccination	  in	  South	  
Africa,	  Uganda	  and	  The	  Gambia	  (Burl	  et	  al.,	  2010;	  Kagina	  et	  al.,	  2009;	  Lutwama	  
et	   al.,	   2013).	   In	   all	   these	   previous	   studies,	   BCG	   vaccination	  was	   delayed	   from	  
birth	  to	  10,	  6	  and	  8	  weeks	  of	  age	  in	  HIV-­‐unexposed	  infants	  respectively	  (Burl	  et	  
al.,	  2010;	  Kagina	  et	  al.,	  2009;	  Lutwama	  et	  al.,	  2013).	  Thus,	  it	  seems	  as	  if	  delayed	  
BCG	  vaccination	  does	  not	  have	  any	  effect	  on	  CD4+	  and	  CD8+	  T	  cell	  proliferation	  
regardless	  of	  HIV	  exposure.	  	  
	  
Furthermore,	  this	  chapter	  showed	  that	  at	  14	  weeks	  of	  age,	  HIV-­‐exposed	  infants	  
who	   were	   vaccinated	   with	   BCG	   at	   8	   weeks	   of	   age	   had	   significantly	   higher	  
frequencies	   of	   IFN-­‐γ–secreting	   CD4+	   T	   cells	   compared	   to	   birth-­‐vaccinated	  
infants.	  Delaying	  BCG	  resulted	  in	  greater	  polyfunctionality	  of	  CD4+	  and	  CD8+	  T	  
cell	   as	   measured	   by	   cytokine	   response	   at	   14	   weeks.	   Whilst	   the	   immune	  
correlates	  of	  protection	  against	  TB	  are	  unknown,	  studies	  have	  shown	  that	  IFN-­‐γ-­‐




(Flynn	   et	   al.,	   1993;	   Reed	   et	   al.,	   2009).	   In	   addition,	   higher	   frequencies	   of	  
polyfunctional	  CD4+	  T-­‐cells	  expressing	  many	  Th1	  cytokines	  such	  as	  IL-­‐2	  and	  IFN-­‐
γ+	  are	  generally	  recognized	  as	  an	  increase	  in	  quality	  of	  response	  (Beveridge	  et	  
al.,	  2007;	  Mueller	  et	  al.,	  2008).	  	  
	  
Neonates	   are	   characterized	   by	   an	   “immature”	   immune	   system	  and	  defects	   in	  
antigen	  presentation	  and	   IL-­‐12	  production	   (Marodi,	   2002;	  Velilla	   et	   al.,	   2007).	  
As	  a	  result,	  their	  immunity	  is	  generally	  skewed	  towards	  Th2	  responses	  (Marodi,	  
2002;	   Rose	   et	   al.,	   2007;	   Velilla	   et	   al.,	   2007).	   However,	   it	   has	   been	   well	  
established	   that	  Th1	   responses	   improve	  with	  age	   (Marodi,	  2002),	  which	  could	  
explain	  the	  higher	  frequencies	  of	  BCG	  specific	   IFN-­‐γ	  secreting	  CD4+	  T-­‐cells	  and	  
polyfunctional	  CD4+	  T-­‐cells	  in	  infants	  given	  BCG	  a	  few	  weeks	  after	  birth.	  	  
	  
Previous	   studies	   of	   the	   effects	   of	   delayed	   BCG	   on	   cytokine	   responses	   in	   HIV-­‐
unexposed	   infants	   have	   shown	   variable	   results.	   In	   a	   study	   from	   the	   Gambia,	  
delaying	  BCG	  vaccination	  to	  two	  and	  four	  months	  resulted	  in	  lower	  IFN-­‐γ	  and	  IL-­‐
17	   responses	   in	   the	   delayed	   BCG	   vaccinated	   group	   compared	   to	   those	  
vaccinated	  at	  birth,	  when	  assessed	  at	  two	  months	  post	  vaccination	  (Burl	  et	  al.,	  
2010;	  Marchant	  et	  al.,	  1999).In	  a	  non-­‐randomised,	  observational	  study	  carried	  
out	  in	  Uganda,	  infants	  who	  inadvertently	  received	  delayed	  BCG	  vaccination	  at	  6	  
weeks	  of	  age	  also	  produced	  lower	  IFN-­‐γ	  responses	  when	  measured	  at	  9	  months	  
(Lutwama	   et	   al.,	   2013).	   On	   the	   other	   hand,	   similar	   to	   our	   findings	   in	   HIV-­‐
exposed	  infants,	  Kagina	  et	  al.	  found	  that	  delaying	  BCG	  vaccination	  to	  10	  weeks	  
of	  age	  resulted	  in	  higher	  frequencies	  of	  BCG-­‐specific	  IFN-­‐γ-­‐secreting	  CD4	  T-­‐cells	  
and	   IFN-­‐γ+IL-­‐2+	   CD4	   T	   cells	   subset	   at	   in	   the	   delayed	   vaccination	   group	   at	   20	  
weeks	   of	   age	   (Kagina	   et	   al.,	   2009).	   Finally,	   we	   also	   observed	   low	   IL-­‐17	  
expression	  by	  all	  the	  infants	  following	  BCG	  vaccination.	  This	  is	  consistent	  with	  a	  
recent	   study	   carried	   out	   in	   South	   Africa	   that	   examined	   T	   cell	   cytokine	  
production	   over	   time	   following	   BCG	   vaccination	   in	   HIV-­‐unexposed	   infants	  





One	  of	   the	  main	   limitations	  of	   this	   study	  was	   the	  short	  duration	  of	   follow-­‐up,	  
therefore	   the	   long-­‐term	   effects	   of	   delaying	   BCG	   in	   HIV-­‐exposed	   infants	   could	  
not	  be	  assessed.	  This	  was	  due	  to	  the	  nature	  of	  the	  study	  design	  and	  the	  setting	  
in	   which	   the	   samples	   were	   obtained.	   Another	   limitation	   is	   that	   cells	   were	  
restimulated	   with	   mitogens	   on	   day	   6	   to	   measure	   intracellular	   cytokine	  
production,	  and	  these	  cytokines	  may	  not	  be	  the	  same	  as	  the	  cells	  would	  have	  
made	   on	   day	   1.	   It	   is	   also	   possible	   that	   using	   a	   shorter	   12-­‐hour	   whole	   blood	  
assay	   rather	   than	   a	   six-­‐day	   whole	   blood	   assay	   would	   have	   led	   to	   different	  
outcomes.	   Despite	   these	   limitations,	   we	   were	   able	   to	   assess	   the	   effect	   of	  
delayed	  BCG	  vaccination	  on	  BCG	   immunogenicity	   in	  HIV	  exposed	   infants	  at	  an	  
age	  when	  most	   infants	  begin	   to	  be	  exposed	  to	  TB.	  On	  the	  other	  hand,	  one	  of	  
the	   strengths	   of	   this	   study	   was	   that	   it	   was	   randomized	   and	   the	   two	   group	  
characteristics	  were	  balanced	  except	   for	   the	  age	  of	  BCG	  vaccination,	   it	   is	  very	  
unlikely	   that	   the	   differences	   observed	   in	   the	   two	   groups	   be	   due	   to	   other	  
confounders.	  	  
	  
In	  settings	   like	  South	  Africa,	  where	  TB	  and	  HIV	  co-­‐infection	   is	  high,	  BCG	   is	  still	  
routinely	  administered	  at	  birth	  to	  infants	  born	  to	  HIV-­‐infected	  mothers	  despite	  
all	  the	  risks	  in	  HIV-­‐infected	  individuals.	  For	  optimal	  safety	  reasons,	  BCG	  should	  
be	  administered	  only	  after	  HIV	  status	   is	  confirmed	  negative	  and	  excluded.	  The	  
findings	  of	  this	  chapter	  suggest	  that	  delaying	  BGG	  vaccination	  to	  8	  weeks	  of	  age	  
in	  HIV-­‐exposed	  uninfected	  infants	  does	  not	  impinge	  on	  vaccine	  immunogenicity	  
and	  may	  even	   improve	  Th1	   responses.	  Thus,	  delaying	  BCG	  vaccination	   in	  HIV-­‐
exposed	   infants	   appears	   to	   be	   a	  worth	   further	   exploration	   for	   TB	   prevention	  




Chapter	  4.	  Effects	  of	  Delayed	  BCG	  Vaccination	  




Acellular	   pertussis	   and	   tetanus	   toxoid	   (TT)	   are	   antigens	   included	   in	   the	  
combined	  vaccine	  DTap	  (CDC,	  2013).	  DTap	  is	  made	  up	  of	  TT,	  acellular	  pertussis	  
and	   diphtheria	   vaccines.	   In	   South	   Africa,	   this	   vaccine	   is	   first	   administered	   to	  
infants	   at	   6	  weeks	   of	   age	   as	   opposed	   to	   BCG,	  which	   is	   administered	   at	   birth	  
(Department	  of	  Health,	  2009)	  and	  is	  boosted	  at	  10	  and	  14	  weeks.	  Pertussis	  uses	  
extracellular	   and	   intracellular	  pathways	   to	   avoid	   immune	   responses	  especially	  
in	  the	  respiratory	  tract	  (Mills,	  2001).	  Th1	  responses	  are	  important	  in	  the	  control	  
of	   pertussis	   infection	  especially	   in	   the	   lungs	   (Mills,	   2001).	  On	   the	  other	  hand,	  
Th2	  cytkoines	  have	  been	   shown	   to	   induce	  antibody	   responses	   to	  extracellular	  
pertussis	  (Higgs	  et	  al.,2012).	  TT	  is	  the	  vaccine	  against	  tetanus	  and	  is	  made	  up	  of	  
deactivated	  Tetanus	  toxin	  produced	  by	  Clostridum	  tetani,	  (CDC,	  2013).	  Th2	  and	  
antibody	  responses	  are	  thought	  to	  be	  important	  for	  control	  of	  Tetanus	  (Poulsen	  
et	  al.,	  2007).In	  this	  chapter,	  the	  effects	  of	  BCG,	  a	  strong	  Th1	  response	  inducer,	  
on	  T	  cell	  responses	  to	  pertussis	  and	  TT	  in	  HIV-­‐exposed	  infants	  are	  investigated.	  
We	   hypothesized	   that	   HIV-­‐exposed	   infants	   who	   received	   BCG	   at	   birth	   (early	  
arm)	   would	   have	   lower	   Th2	   responses	   to	   TT	   and	   pertussis	   due	   to	  
downregulation	   of	   Th2	   by	   Th1	   cytokine	   production	   enhanced	   by	   early	   BCG	  
vaccination.	   To	   achieve	   this	   aim,	   we	   first	   compared	   CD4+	   and	   CD8+	   T	   cell	  
proliferative	  responses	  to	  pertussis	  and	  TT	  between	  HIV–exposed	  infants	  in	  the	  
early	   and	   delayed	   arms	   at	   weeks	   8	   and	   14.	   This	   was	   done	   by	   measuring	  
frequency	  of	  Ki67-­‐expressing	  CD4+	  and	  CD8+	  T	   cell	   in	   a	  whole	  blood	  assay	  as	  
described	   in	   chapter	   3.	   Furthermore,	  we	   assessed	   the	   effects	   of	   delayed	  BCG	  
vaccination	   on	   CD4+	   and	   CD8+	   T	   cell	   expression	   of	   Th1/	   Tc1	   (IFNγ	   and	   IL-­‐2),	  




TT	  stimulation	  in	  the	  two	  arms.	  These	  responses	  as	  well	  as	  T	  cell	  polyfunctional	  
responses	  to	  TT	  and	  pertussis	  were	  also	  measured	  at	  8	  and	  14	  weeks.	  
	  
4.2.	   T-­‐cell	   proliferative	   responses	   to	   pertussis	   and	   TT	   in	   early	  
versus	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
4.2.1.	   CD4+	   and	   CD8+	   proliferative	   responses	   to	   pertussis	   in	   early	   versus	  
delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
The	   CD4+and	   CD8+	   T	   cell	   proliferative	   responses	   to	   pertussis	  were	   compared	  
between	  birth-­‐vaccinated	  (early	  arm)	  and	  8-­‐week-­‐vaccinated	  (delayed	  arm)	  HIV	  
exposed	  infants	  at	  weeks	  8	  and	  14.	  	  
	  
As	  shown	  in	  figure	  4.1,	  at	  8	  weeks	  of	  age,	  before	  the	  delayed	  BCG	  arm	  had	  been	  
BCG	  vaccinated,	  there	  was	  no	  difference	  in	  CD4+	  T	  cell	  proliferation	  in	  response	  
to	   pertussis	   between	   HIV-­‐exposed	   infants	   in	   the	   early	   arm	   and	   those	   in	   the	  
delayed	   arm	   (3.4%	   vs.	   3.1%	   p=	   0.361).	   Similar	   to	   CD4+	   T	   cells,	   there	   was	   no	  
significant	   difference	   in	   the	   frequencies	   CD8+Ki67+	   between	   HIV-­‐exposed	  
infants	   in	   the	   early	   arm	   and	   those	   in	   the	   delayed	   arm	   following	   pertussis	  
stimulation	  (8.6%	  vs.	  7.3%,	  p=0.555).	  
	  
At	   14	   weeks	   of	   age,	   as	   indicated	   in	   figure	   4.1,	   in	   response	   to	   pertussis	  
stimulation,	   there	   was	   no	   difference	   in	   the	   frequencies	   of	   proliferating	   CD4+	  
cells	  between	  HIV-­‐exposed	  infants	  in	  the	  early	  arm	  and	  those	  in	  the	  delayed	  am	  
(2.72%	  vs.	  0.929%,	  p=	  0.161).	  Furthermore,	  as	  observed	  at	  week	  8,	  there	  was	  no	  
also	  no	  difference	  in	  CD8+	  T	  cell	  proliferative	  responses	  to	  pertussis	  at	  week	  14.	  
Infants	  who	   received	  BCG	  at	   birth	   (early	   arm)	   had	   comparable	   frequencies	   of	  
CD8+Ki67+	  cells	  as	   infants	  who	  received	  BCG	  at	  8	  weeks	  of	  age	   (delayed	  arm)	  





Figure	   4.1:	   Frequency	   of	   CD4	   and	   CD8+T	   cells	   expressing	   Ki67+	   in	   response	   to	  
pertussis	  stimulation	  determined	  by	  flow	  cytometry	  in	  the	  early	  (blue)	  versus	  delayed	  
(red)	   BCG	   vaccinees	   at	   8	   and	   14	   weeks.	   Lines	   represent	   medians	   and	   whiskers	  
interquartile	   ranges.	   p<0.05	   significant	   level	   (unadjusted)	   and	   statistical	   significance	  
was	  obtained	  using	  Mann-­‐Whitney	  U	  test.	  
	  
4.2.1.CD4+	  and	  CD8+	  proliferative	  responses	  to	  TT	  
T	   cell	   proliferative	   responses	   to	   TT	   in	   birth	   BCG-­‐vaccinated	   and	   8-­‐week	   BCG-­‐
vaccinated	  HIV-­‐exposed	   infants	  were	   compared	   at	   8	   and	   14	  weeks	   of	   age.	   At	  
week	  8,	   in	   response	   to	  TT	   stimulation,	   there	  was	  no	   significance	  difference	   in	  
frequencies	   of	   CD4+Ki67+	   cells	   between	   infants	   in	   the	   early	   arm	   and	   delayed	  
BCG	   arms	   (1.04%	   vs.	   1.03%,	   p=	   0.793)	   as	   shown	   in	   figure	   4.2.	  We	   also	   noted	  
very	  comparable	  levels	  of	  CD8+Ki67+	  cells	  between	  birth	  and	  8	  week-­‐vaccinated	  
HIV-­‐exposed	  infants	  (1.03%	  vs.	  1.09%,	  p=0.700)	  (figure	  4.2).	  	  
	  
At	   14	   weeks	   of	   age,	   infants	   in	   the	   early	   and	   delayed	   BCG	   arms	   had	   similar	  
frequencies	  of	  proliferating	  CD4+	  cells	  in	  response	  to	  TT	  stimulation	  (2.02%	  vs.	  
1.43%,	  p=0.488).	  In	  addition,	  there	  was	  no	  difference	  in	  CD8+	  T	  cell	  proliferative	  
responses	   to	   TT	   between	   birth-­‐vaccinated	   (early	   arm)	   and	   8	  week-­‐vaccinated	  
(delayed	   arm)	   infants	   at	   14	   weeks	   of	   age	   as	   shown	   in	   figure	   4.2	   (1.30%	   vs.	  
3.13%,	  p=0.850).	  However,	  we	  only	  had	  three	  blood	  samples	  at	  14	  weeks	  of	  age	  









































Figure	   4.2:	   Frequency	   of	   CD4	   and	   CD8+T	   cells	   expressing	   Ki67+	   in	   response	   to	   TT	  
stimulation	   determined	   by	   flow	   cytometry	   in	   the	   early	   (blue)	   versus	   delayed	   (red)	  
BCG	  vaccinees	  at	  8	  (left)	  and	  14	  (right)	  weeks.	  Lines	  represent	  medians	  and	  whiskers	  
interquartile	   ranges.	   p<0.05	   significant	   level	   (unadjusted)	   and	   statistical	   significance	  
was	  obtained	  using	  Mann-­‐Whitney	  U	  test.	  	  
	  
4.3.	   T	   cell	   cytokine	   expression	   in	   response	   to	   pertussis	   and	   TT	   in	  
early-­‐BCG	  vs.	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  
age	  
4.3.1.	   IFNγ	   and	   IL-­‐2	   (Th1/Tc1)	   expression	   in	   response	   to	   pertussis	   and	   TT	   in	  
early	  versus	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
4.3.1.1.	   IFNγ	   and	   IL-­‐2	   (Th1/Tc1)	   expression	   in	   response	   to	   pertussis	   in	   early	  
versus	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
Using	   ICS,	   we	   first	   measured	   the	   levels	   of	   IFN-­‐γ	   and	   IL-­‐2	   expression	   by	  
proliferating	  CD4+	  and	  CD8+	  cells	  following	  pertussis	  stimulation	  at	  weeks	  8	  and	  
14.	   At	   week	   8,	   there	  was	   no	   significant	   difference	   in	   the	   frequency	   of	   IFN-­‐γ-­‐
expressing	  CD4+Ki67+	  cells	   in	  response	  to	  pertussis	  between	  birth-­‐and	  8	  week	  
BCG-­‐vaccinated	  infants	  (0.278%	  vs.	  0.687%	  respectively,	  p=0.639)	  (figure	  6.3).	  In	  
addition,	   there	  was	   also	   no	   difference	   IFN-­‐γ	   expression	   by	   proliferating	   CD8+	  
cells	  between	  infants	  in	  the	  early	  arm	  and	  those	  in	  the	  delayed	  arm	  (3.92%	  vs.	  



































Infants	   the	   in	   the	   early	   and	   delayed	   BCG	   arms	   also	   had	   similar	   levels	   of	   IL-­‐2	  
expression	  by	  CD4+	  proliferating	  cells	  following	  pertussis	  stimulation	  at	  week	  8	  
(0.274%	   vs.	   0.096%	   respectively,	   p=0.541).	   On	   the	   other	   hand,	   as	   shown	   in	  
figure	   4.3,	   infants	   vaccinated	   with	   BCG	   at	   birth	   (early	   BCG	   arm)	   had	   higher	  
frequencies	   of	   IL-­‐2	   expressing	   CD8+Ki67+	   cells	   compared	   to	   infants	   in	   the	  
delayed	   BCG	   arm	   (who	   had	   not	   yet	   received	   BCG	   vaccination)	   (4.012%	   vs.	  
0.244%	   respectively,	   p=0.044).	   This	   difference	   was	   no	   longer	   statistically	  
significant	  after	  adjusting	  for	  multiple	  comparisons.	  	  
	  
At	   14	   weeks	   of	   age,	   following	   pertussis	   stimulation,	   infants	   in	   the	   early	   and	  
delayed	   BCG	   arms	   had	   similar	   levels	   of	   IFN-­‐γ	   –expressing	   CD4+Ki67+	   cells	  
(0.504%	  vs.	  0.378%	  respectively,	  p=0.254).	  A	  similar	  outcome	  was	  also	  observed	  
for	  IFN-­‐γ	  expression	  by	  CD8+	  proliferating	  cells	  between	  birth-­‐and	  8-­‐week	  BCG-­‐
vaccinated	   infants	   (1.50%	   vs.	   1.54%	   respectively,	   p=0.275).	   Furthermore,	   no	  
difference	   was	   found	   in	   IL-­‐2	   expression	   in	   response	   to	   pertussis	   at	   week	   14,	  
(CD4+Ki67+	  0.119%	  vs.	  0.105%,	  p=0.401	  and	  CD8+Ki67+	  cells	  2.39%	  vs.	  0.394%,	  




Figure	  4.3:	  The	  frequency	  of	  T	  cells	  producing	  IFNγ	  and	  IL-­‐2	  at	  8	  and	  14	  weeks	  of	  life	  
after	   pertussis	   stimulation	   for	   6	   days	   in	   whole	   blood	   assay	   measured	   by	   flow	  
cytometry.	   Frequency	  of	  antigen	  specific	   IFN-­‐γ	  and	   IL-­‐2	  producing	  T	  cells	  out	  of	   total	  
CD4+	  (on	  the	  left	  side	  of	  each	  graph)	  and	  CD8+	  (on	  the	  right	  side	  of	  each	  graph)	  T	  cells,	  
determined	   by	   flow	   cytometry	   of	   pertussis-­‐stimulated	   whole	   blood	   of	   HIV-­‐exposed	  
infants	  vaccinated	  with	  BCG	  at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  
infants	   vaccinated	  with	  BCG	  at	  8	  weeks	  of	   age	   (delayed	  arm)	   (red	  dots).	   Frequencies	  
reported	   as	   frequency	   of	   proliferating	   cytokine	   producing	   cells	   out	   of	   total	   CD4+	   or	  
CD8+	   T	   cells.	   Bars	   indicate	   medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	  
was	  tested	  using	  Mann-­‐Whitney	  U	  test.	  	  
	  
4.3.1.2.	  IFNγ	  and	  IL-­‐2	  (Th1/Tc1)	  expression	  in	  response	  to	  TT	  in	  early-­‐BCG	  vs.	  
delayed-­‐BCG	  vaccinated	  infants	  8	  and	  14	  weeks	  of	  age	  
At	  week	  8,	  in	  response	  to	  TT,	  there	  was	  no	  difference	  in	  the	  frequencies	  of	  IFNγ-­‐
expressing-­‐CD4+Ki67+	  between	   infants	   in	   the	  early	  BCG	  arm	  and	   those	   in	   the	  
delayed	   BCG	   arm	   as	   shown	   in	   figure	   4.4	   (0.187%	   vs.	   0.343%,	   p=0.928).	   In	  
addition,	   infants	   in	   early	   and	   delayed	   arms	   also	   had	   similar	   levels	   of	   IFNγ-­‐

















































































p=0.479)	  (figure	  4.4).	  Furthermore,	  at	  week	  8,	   infants	   in	  the	  early	  and	  delayed	  
exhibited	   similar	   levels	   of	   IL-­‐2	   expression	   by	   proliferating	   CD4+	   (0.027%	   vs.	  
0.82%,	  p=0.109)	  and	  CD8+-­‐cells	  (0.223%	  vs.0.544%,	  p=0.889)	  (figure	  4.4).	  	  
	  
At	   week	   14,	   following	   TT	   stimulation,	   birth	   BCG-­‐vaccinated	   and	   8	   week-­‐
vaccinated	   infants	   had	   similar	   frequencies	   of	   IFNγ-­‐expressing-­‐CD4Ki67+cells	  
(0.03%	   vs.	   0.02%,	   p=0.506)	   and	   IFNγ-­‐expressing-­‐CD8+Ki67+cells	   (0.05%	   vs.	  
0.16%,	  p=0.867)	  (figure	  4.4).	  Like	  with	  IFN-­‐γ	  expression,	  infants	  in	  the	  two	  arms	  
also	   had	   similar	   levels	   of	   IL-­‐2	   expression	   by	   CD4+Ki67+	   (0.436%	   vs.	   0.141%,	  
p=0.897)	  and	  CD8+Ki67+	   (0.015%	  vs.	   0.207%,	  p=0.605)	   cells	   in	   response	   to	  TT	  
(figure	  4.4.)	  However,	  due	  to	  the	  very	  small	  sample	  size	  of	  samples	  stimulated	  
with	  TT	  at	  week	  14	  in	  the	  early	  arm,	  it	  is	  possible	  that	  this	  does	  not	  reflect	  the	  
true	  effects	  of	  TT	  stimulation	  on	  cytokine	  responses.	  




Figure	  4.4:	  The	  frequency	  of	  T	  cells	  producing	  IFNγ	  and	  IL-­‐2	  at	  8	  and	  14	  weeks	  of	  life	  
after	   TT	   stimulation	   for	   6	   days	   in	  whole	   blood	   assay	  measured	   by	   flow	   cytometry.	  
Frequency	  of	  antigen	  specific	  IFNγ	  and	  IL-­‐2	  producing	  T	  cells	  out	  of	  total	  CD4+	  (on	  the	  
left	  side	  of	  each	  graph)	  and	  CD8+	  (on	  the	  right	  side	  of	  each	  graph)	  T	  cells,	  determined	  
by	   flow	   cytometry	   of	   TT-­‐stimulated	   whole	   blood	   of	   HIV-­‐exposed	   infants	   vaccinated	  
with	  BCG	  at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  
with	   BCG	   at	   8	   weeks	   of	   age	   (delayed	   arm)	   (red	   dots).	   Frequencies	   reported	   as	   the	  
frequency	  of	   proliferating	   cytokine	  producing	   cells	   out	  of	   total	   CD4+	  or	  CD8+	  T	   cells.	  
Bars	  indicate	  medians;	  alpha=0.05	  (unadjusted);	  statistical	  significance	  was	  tested	  using	  
Mann-­‐Whitney	  U	  test.	  	  
	  
4.3.2.	   IL-­‐17	   (Th17/	  Tc17)	  expression	   in	   response	  to	  pertussis	  and	  TT	   in	  early-­‐
BCG	  vs.	  delayed-­‐BCG	  vaccinated	  infants	  8	  and	  14	  weeks	  of	  age	  
After	   assessing	   Th1/	   Tc1	   (IFNγ	   and	   IL-­‐2)	   cytokine	   expression	   by	   proliferative	  
CD4+	  and	  CD8+	  cells,	  IL-­‐17	  (Th17/	  Tc17	  cytokine)	  expression	  by	  CD4+	  and	  CD8+	  






























































4.3.2.1.	  IL-­‐17	  (Th17/Tc17)	  expression	  in	  response	  to	  pertussis	  in	  early-­‐BCG	  vs.	  
delayed-­‐BCG	  vaccinated	  infants	  8	  and	  14	  weeks	  of	  age	  
At	   week	   8,	   following	   pertussis	   stimulation,	   there	   was	   no	   difference	   in	   IL-­‐17	  
expression	   by	   CD4+	   proliferating	   cells	   between	   birth-­‐vaccinated	   infants	   (early	  
arm)	   and	   8	   week-­‐vaccinated	   infants	   (delayed	   arm)	   (1.03%	   vs.	   2.03%	  
respectively,	  p=0.755).	  Similar	  to	  CD4+	  cells,	  there	  was	  also	  no	  difference	  IL-­‐17	  
expressing-­‐CD8+Ki67+	  cells	  between	  birth-­‐	  and	  8	  week-­‐vaccinated	   infants	  at	  8	  
weeks	  of	  age	  (22,7%	  vs.	  16.4%	  p=0.255)	  (figure	  4.5).	  	  
	  
At	   week	   14,	   following	   pertussis	   stimulation,	   infants	   in	   the	   early	   and	   delayed	  
arms	   had	   similar	   levels	   of	   IL-­‐17-­‐expressing	   CD4+Ki67+	   (0.115%	   vs.	   0.112%	  
respectively,	   p=0.069)	   and	   CD8+Ki67+	   cells	   (1.85%	   vs.	   1.98%	   respectively,	  
p=0.782)	  (figure	  4.5).	  
	  
	  
Figure	  4.5:	  The	  frequency	  of	  T	  cells	  producing	  IL-­‐17	  at	  8	  and	  14	  weeks	  of	  life	  after	  CpG	  
stimulation	  for	  6	  days	  in	  whole	  blood	  assay	  measured	  by	  flow	  cytometry.	  Frequency	  
of	   antigen	   specific	   IL-­‐17	  producing	   T	   cells	   out	   of	   total	   CD4+	   (on	   the	   left	   side	  of	   each	  
graph)	   and	   CD8+	   (on	   the	   right	   side	   of	   each	   graph)	   T	   cells,	   determined	   by	   flow	  
cytometry	  of	  pertussis-­‐stimulated	  whole	  blood	  of	  HIV-­‐exposed	  infants	  vaccinated	  with	  
BCG	  at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  with	  
BCG	  at	  8	  weeks	  of	  age	  (delayed	  arm)	  (red	  dots).	  Frequencies	  reported	  as	  the	  frequency	  
of	  proliferating	  cytokine	  producing	  cells	  out	  of	  total	  CD4+	  or	  CD8+	  T	  cells.	  Bars	  indicate	  
medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	   was	   tested	   using	   Mann-­‐











































4.3.2.2.	  IL-­‐17	  (Th17)	  expression	  in	  response	  to	  TT	  in	  early-­‐BCG	  vs.	  delayed-­‐BCG	  
vaccinated	  infants	  8	  and	  14	  weeks	  of	  age	  
In	  response	  to	  TT	  stimulation	  at	  week	  8,	  birth	  BCG-­‐vaccinated	  (early	  arm)	  and	  8	  
week	   BCG-­‐vaccinated	   infants	   had	   similar	   levels	   of	   IL-­‐17	   expression	   by	  
CD4+Ki67+	   cells	   (0.156%	   vs.	   0.252%,	   p=0.875)	   (figure	   4.6).	   Levels	   of	   IL-­‐17	  
expression	  by	  CD8+	  proliferating	  cells	  were	  also	  comparable	  between	  birth-­‐	  and	  
8-­‐week	  BCG-­‐vaccinated	  infants	  (1.45&	  vs.3.29%,	  p=0.332)	  (figure	  4.6).	  	  
	  
At	  week	   14,	   in	   response	   to	   TT	   stimulation,	   birth-­‐	   and	   8	  week	  BCG-­‐vaccinated	  
infants	  exhibited	  comparable	  frequencies	  of	  IL-­‐17-­‐expressing	  CD4+	  proliferating	  
cells	   (p=0.394).	   They	   also	   had	   similar	   frequencies	   of	   IL-­‐17	   expressing-­‐CD8+	  
proliferating	  cells	  (p=0.721)	  (figure	  4.6).	  	  
	  
	  
Figure	  4.6:	  The	  frequency	  of	  T	  cells	  producing	  IL-­‐17	  at	  8	  and	  14	  weeks	  of	  life	  after	  TT	  
stimulation	  for	  6	  days	  in	  whole	  blood	  assay	  measured	  by	  flow	  cytometry.	  Frequency	  
of	   antigen	   specific	   IL-­‐17	  producing	   T	   cells	   out	   of	   total	   CD4+	   (on	   the	   left	   side	  of	   each	  
graph)	   and	   CD8+	   (on	   the	   right	   side	   of	   each	   graph)	   T	   cells,	   determined	   by	   flow	  
cytometry	  of	  TT-­‐stimulated	  whole	  blood	  of	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  at	  
birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  at	  8	  
weeks	   of	   age	   (delayed	   arm)	   (red	   dots).	   Frequencies	   reported	   as	   the	   frequency	   of	  
proliferating	   cytokine	  producing	   cells	  out	  of	   total	  CD4+	  or	  CD8+	  T	   cells.	  Bars	   indicate	  
medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	   was	   tested	   using	   Mann-­‐





































4.3.3.	  IL-­‐13	  (Th2/Tc2)	  expression	  in	  response	  to	  pertussis	  and	  TT	  in	  early-­‐BCG	  
vs.	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
Finally,	   IL-­‐13	   (Th2/Tc2)	   expression	   by	   proliferating	   CD4+	   and	   CD8+	   cells	   in	  
response	  to	  pertussis	  and	  TT	  was	  assessed	  at	  weeks	  8	  and	  14	  stimulation	  using	  
ICS.	  	  
	  
4.3.3.1.	   IL-­‐13	   (Th2/Tc2)	   expression	   in	   response	   to	   pertussis	   in	   early-­‐BCG	   vs.	  
delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
At	  week	  8,	  in	  response	  to	  pertussis	  stimulation,	  no	  difference	  was	  found	  in	  the	  
frequencies	  of	   IL-­‐13-­‐expressing-­‐CD4+Ki67+	  cells	  between	   infants	  the	  early	  arm	  
and	   infants	   in	   the	   delayed	   arm	   (0.01%	   vs.	   0.081%	   respectively,	   p=0.984)	   as	  
shown	  in	  figure	  4.7.	  We	  also	  found	  no	  difference	  in	  the	  frequencies	  of	  and	  IL-­‐13	  
expressing-­‐CD8+Ki67+	  cells	  between	  the	  early	  and	  delayed	  arms	  (4.4%	  vs.	  2.69%	  
respectively,	  p=0.446).	  	  
	  
On	   the	  other	  hand,	  at	  week	  14,	   infants	   in	   the	  early	  BCG	  arm	  had	  significantly	  
higher	   IL-­‐13	   expression	   by	   CD4+	   proliferating	   cells	   in	   response	   to	   pertussis	  
compared	   to	   those	   in	   the	   delayed	   BCG	   arm	   (0.158%	   vs.0.024%	   respectively,	  
p=0.038).	  This	  difference	  was	  no	  longer	  significant	  after	  adjustment	  for	  multiple	  
comparisons.	   In	  addition,	  birth-­‐vaccinated	   infants	  exhibited	  higher	  frequencies	  
of	  IL-­‐13-­‐expressing-­‐CD8+Ki67+	  in	  response	  to	  pertussis	  than	  8	  week=vaccinated	  
infants	   (2.11%	   vs.	   0.879%	   respectively,	   p=0.0035)	   (figure	   4.7).	   This	   difference	  





Figure	   4.7:	  The	   frequency	   of	   T	   cells	   producing	   IL-­‐13	   at	   8	   and	   14	  weeks	   of	   life	   after	  
pertussis	   stimulation	   for	  6	  days	   in	  whole	  blood	  assay	  measured	  by	   flow	  cytometry.	  
Frequency	  of	  antigen	  specific	  IL-­‐13	  producing	  T	  cells	  out	  of	  total	  CD4+	  (on	  the	  left	  side	  
of	  each	  graph)	  and	  CD8+	  (on	  the	  right	  side	  of	  each	  graph)	  T	  cells,	  determined	  by	  flow	  
cytometry	  of	  pertussis-­‐stimulated	  whole	  blood	  of	  HIV-­‐exposed	  infants	  vaccinated	  with	  
BCG	  at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  with	  
BCG	  at	  8	  weeks	  of	  age	  (delayed	  arm)	  (red	  dots).	  Frequencies	  reported	  as	  the	  frequency	  
of	  proliferating	  cytokine	  producing	  cells	  out	  of	  total	  CD4+	  or	  CD8+	  T	  cells.	  Bars	  indicate	  
medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	   was	   tested	   using	   Mann-­‐
Whitney	  U	  test.	  
	  
4.3.3.2.	  IL-­‐13	  (Th2/Tc2)	  expression	  in	  response	  to	  TT	  in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
Infants	  in	  the	  early	  and	  delayed	  arms	  had	  similar	  levels	  of	  IL-­‐13-­‐expressing	  CD4+	  
proliferating	   cells	   following	   TT	   stimulation	   at	   week	   8	   (0.352%	   vs.	   0.999%,	  
p=0.488).	  In	  addition,	  at	  week	  8,	  we	  observed	  no	  difference	  in	  the	  levels	  of	  IL-­‐
13-­‐expressing-­‐CD8+Ki67+	   cells	   between	   birth-­‐	   and	   8	   week-­‐vaccinated	   infants	  
(0.627%	  vs.2.37%,	  p=0.185)	  (figure	  4.8).	  
	  
At	   week	   14,	   infants	   in	   the	   two	   arms	   (early	   and	   delayed	   BCG)	   also	   had	  
comparable	   levels	  of	   IL-­‐13-­‐expressing-­‐CD4+Ki67+	  cells	   following	  TT	  stimulation	  
(0.005%	   vs.	   0.08%,	   p=0.945).	   We	   observed	   a	   similar	   outcome	   for	   CD8+	  
















































Figure	  4.8:	  The	  frequency	  of	  T	  cells	  producing	  IL-­‐13	  at	  6,8	  and	  14	  weeks	  of	  life	  after	  TT	  
stimulation	  for	  6	  days	  in	  whole	  blood	  assay	  measured	  by	  flow	  cytometry.	  Frequency	  
of	   antigen	   specific	   IL-­‐13	  producing	   T	   cells	   out	   of	   total	   CD4+	   (on	   the	   left	   side	  of	   each	  
graph)	   and	   CD8+	   (on	   the	   right	   side	   of	   each	   graph)	   T	   cells,	   determined	   by	   flow	  
cytometry	  of	  TT-­‐stimulated	  whole	  blood	  of	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  at	  
birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  at	  8	  
weeks	   of	   age	   (delayed	   arm)	   (red	   dots).	   Frequencies	   reported	   as	   the	   frequency	   of	  
proliferating	   cytokine	  producing	   cells	  out	  of	   total	  CD4+	  or	  CD8+	  T	   cells.	  Bars	   indicate	  
medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	   was	   tested	   using	   Mann-­‐
Whitney	  U	  test.	  
	  
4.4.	   T-­‐cell	   polyfunctional	   responses	   to	   pertussis	   and	   TT	   in	   early-­‐
BCG	  vs.	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  of	  age	  
In	   this	   chapter,	   we	   assessed	   the	   frequencies	   of	   CD4+	   and	   CD8+	   proliferating	  
cells	  expressing	  any	  zero,	  one,	  two,	  three	  or	  more	  cytokines	  simultaneously	   in	  
early-­‐BCG	  vs.	  delayed-­‐BCG	  vaccinated	  infants	  at	  8	  and	  14	  weeks	  in	  response	  to	  
pertussis	  and	  TT.	  
4.4.1.	   T-­‐cell	   polyfunctional	   responses	   to	   pertussis	   in	   early-­‐BCG	   vs.	   delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  8	  
4.4.1.1.	   CD4+	   T	   cell	   polyfunctional	   responses	   to	   pertussis	   in	   early-­‐BCG	   vs.	  
delayed-­‐BCG	  vaccinated	  infants	  at	  week	  8.	  
	  The	  ability	  of	  proliferating	  T	   cells	   to	  make	  at	   least	  one,	  a	   combination	  of	  any	  
two,	   three,	   or	   all	   four	   cytokines	   in	   response	   to	   pertussis	   at	   week	   8	   was	  





































the	   delayed	   BCG	   arm	   (not	   yet	   vaccinated).	   There	   was	   no	   difference	   in	   the	  
frequencies	  of	  CD4+	  T	  cells	  expressing	  zero,	  one,	  two,	  three	  cytokines	  between	  
infants	   in	   the	   two	   arms	   at	   8	   weeks	   of	   age.	   Overall,	   infants	   in	   the	   early	   and	  
delayed	  arms	  had	  similar	  CD4+	  T	  cell	  polyfunctionality	  (ANOVA	  p=0.269)	  (figures	  
4.9a	  and	  4.9b).	  	  





Figure	   4.9:	  Proportions	   of	   pertussis-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  8	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
whiskers	   correspond	   to	   medians;	   p-­‐value	   indicates	   significant	   difference	   in	   the	  
combination	  of	  cytokine	  production	  by	  CD4+	  T	  cells	  between	  the	  two	  groups.	  Statistical	  
analysis	   was	   performed	   using	   Wilcoxon	   signed	   rank	   test	   (b)	   The	   pie	   charts	   at	   the	  
bottom	  summarise	  the	  data	  with	  the	  pie	  slice	  legend	  on	  the	  graph	  showing	  the	  colours	  
of	  the	  various	  cytokine	  combinations	  and	  the	  p-­‐value	  showing	  the	  overall	  significance	  
of	  the	  total	  magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  



























































































4.4.1.2.	   CD8+	   T	   cell	   polyfunctional	   responses	   to	   pertussis	   in	   early	   versus	  
delayed-­‐BCG	  vaccinated	  infants	  at	  week	  8.	  
Similar	  to	  CD4+	  T	  cells,	  infants	  in	  the	  early	  and	  delayed	  had	  comparable	  levels	  of	  
CD8+	  T	   cells	   expressing	   zero,	   one,	   any	   combination	  of	   two	  or	   three	   cytokines	  
simultaneously	   (figure	   4.10a).	   Overall,	   there	   was	   no	   difference	   CD8+	   T	   cell	  
polyfunctionality	   between	  birth-­‐	   (early	   arm)	   and	   8	  week-­‐vaccinated	   infants	   at	  
week	  8	  (ANOVA	  p=0.769)	  (figure	  4.10.b)	  





Figure	  4.10:	  Proportions	  of	  pertussis-­‐specific	  proliferating	  CD8+	  T	  cells	  producing	  no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at.8	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD8+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  



























































































4.4.2.	   T-­‐cell	   polyfunctional	   responses	   to	   pertussis	   in	   early-­‐BCG	   vs.	   delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  14	  
4.4.2.1.	   CD4+	   T	   cell	   polyfunctional	   responses	   to	   pertussis	   in	   early-­‐BCG	   vs.	  
delayed-­‐BCG	  vaccinated	  infants	  at	  week	  14.	  
At	  14	  weeks	  of	  age,	  in	  response	  to	  pertussis	  stimulation,	  infants	  in	  the	  early	  BCG	  
arm	   and	   those	   in	   the	   delayed	   BCG	   arm	   had	   comparable	   frequencies	   of	   CD8+	  
cells	  expressing	  zero,	  one,	  two	  or	  three	  cytokines	  as	  shown	  in	  figure	  4.11.a.	   In	  
addition,	   there	   was	   no	   difference	   between	   the	   two	   arms	   for	   any	   particular	  
cytokine	   and	   the	  overall	   levels	   CD4+	  T	   cell	   polyfunctionality	  were	   very	   similar	  
between	  the	  two	  arms	  (ANOVA	  p=0.127)	  (figure	  4.11b).	  	  





Figure	  4.11:	  Proportions	  of	  pertussis-­‐specific	  proliferating	  CD4+	  T	  cells	  producing	  no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  14	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	   early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD4+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses	  




























































































4.4.2.2.	   CD8+	   T	   cell	   polyfunctional	   responses	   to	   pertussis	   in	   early-­‐BCG	   vs.	  
delayed-­‐BCG	  vaccinated	  infants	  at	  week	  14.	  
At	   week	   14,	   infants	   in	   the	   two	   arms	   also	   had	   similar	   levels	   of	   CD8+	   T	   cells	  
expressing	  zero,	  one,	  two	  or	  three	  cytokines	  (figure	  4.12a).	  However,	  infants	  in	  
the	   early	   BCG	   arm	   had	   significantly	   higher	   frequencies	   of	   CD8+Ki67+	   cells	  
expressing	   IL-­‐17	   and	   IL-­‐13	   simultaneously	   (p=0.047)	   (figure	   4.12a).	   This	  
difference	  was	   no	   longer	   significant	   after	   adjusting	   for	  multiple	   comparisons.	  
Nonetheless,	  overall,	   infants	   in	   the	   two	  arms	  had	   similar	   levels	  of	  CD8+	  T	   cell	  







Figure	  4	  12:	  Proportions	  of	  pertussis-­‐specific	  proliferating	  CD8+	  T	  cells	  producing	  no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at.14	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD8+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  





























































































4.4.3.	   T-­‐cell	   polyfunctional	   responses	   to	   TT	   in	   early-­‐BCG	   vs.	   delayed-­‐BCG	  
vaccinated	  infants	  at	  week	  8	  
The	  ability	  of	  proliferating	  cells	  to	  make	  at	  least	  one,	  a	  combination	  of	  any	  two,	  
three,	  or	  all	  four	  cytokines	  in	  response	  to	  TT	  at	  week	  8	  between	  infants	  in	  the	  
early	  BCG	  arm	  and	  those	  in	  the	  delayed	  BCG	  arm	  
	  
4.4.3.1.	  CD4+	  T	   cell	  polyfunctional	   responses	   to	  TT	   in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  8.	  
When	  we	  assessed	  the	  ability	  of	  proliferating	  CD4+	  T	  cells	  to	  make	  at	  least	  one,	  
a	  combination	  of	  any	  two,	  three,	  or	  all	  four	  cytokines	  in	  response	  to	  TT	  at	  week	  
8,	   infants	   in	  the	  early	  and	  delayed	  arms	  had	  comparable	  levels	  of	  CD4+	  T	  cells	  
expressing	   one,	   two	   and	   three	   cytokines	   (figure	   4.13a).	   In	   addition,	   Infants	   in	  
the	  two	  arms	  also	  had	  comparable	  frequencies	  of	  proliferating	  CD4+	  T	  cells	  not	  
expressing	  any	  cytokine	  (figure	  4.13a).	  Overall,	  there	  was	  no	  difference	  in	  CD8+	  






Figure	   4.13:	   Proportions	   of	   TT-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  8	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	   early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD4+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  



























































































4.4.3.2.	   CD8+	   T	   cell	   polyfunctional	   responses	   to	   TT	   in	   early-­‐BCG	   versus	  
delayed-­‐BCG	  vaccinated	  infants	  at	  week	  8.	  
At	   week	   8,	   infants	   in	   the	   two	   arms	   had	   similar	   proportions	   of	   CD8+	   T	   cells	  
expressing	   one,	   any	   two	   or	   three	   cytokines	   following	   pertussis	   stimulation	  
(figure	  4.14.a).	  Infants	  in	  the	  early	  BCG	  arm	  and	  those	  in	  the	  delayed	  BCG	  arm	  
also	   had	   similar	   levels	   of	   CD8+	   proliferating	   cells	   not	   expressing	   any	   cytokine	  
(p=1.00	   not	   shown)	   (figure	   4.14a).	   Finally,	   overall,	   there	  was	   no	   difference	   in	  
CD8+	   T	   cell	   polyfunctionality	   between	   the	   two	   arms	   (ANOVA	  p=0.771)	   (figure	  
4.14b).	  





Figure	   4.14:	   Proportions	   of	   TT-­‐specific	   proliferating	   CD8+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  8	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD8+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  



























































































4.4.4.	   T-­‐cell	   polyfunctional	   responses	   to	   TT	   in	   birth	   vs.	   8-­‐week	   vaccinated	  
infants	  at	  week	  14	  
Due	  to	  the	  very	  few	  number	  of	  samples	  of	  birth-­‐vaccinated	  infants	  available	  for	  
TT	  stimulation	  at	  week	  14,	  we	  were	  unable	   to	  compare	  CD4+	  and	  CD8+	  T	  cell	  
polyfunctional	  responses	  to	  TT	  between	  the	  two	  arms	  at	  week	  14.	  	  
	  
4.5.	  Discussion	  
In	  this	  chapter,	  we	  aimed	  to	  investigate	  the	  effects	  of	  delayed	  BCG	  vaccination	  
on	  T	  cell	  responses	  to	  acellular	  pertussis	  and	  TT,	  two	  vaccine	  antigens	  known	  to	  
elicit	  Th2	  responses	  in	  infants	  (Ennis	  et	  al.,	  2005;	  Mills	  et	  al.,2001;	  Rowe	  et	  al.,	  
2000).	  Few	  studies	  have	  assessed	  how	  BCG	  affects	  cellular	   responses	   to	  TT	  or	  
pertussis	   (Ota	   et	   al.,	   2002).	   This	   is	   the	   first	   study	   investigating	   the	   effects	   of	  
delayed	  BCG	  vaccination	  on	  T	  cell	  responses	  to	  pertussis	  and	  TT	  in	  HIV-­‐exposed	  
infants.	  Our	   findings	  demonstrate	   that	  delaying	  BCG	  vaccination	   from	  birth	   to	  
eight	  weeks	  of	  age	  does	  not	  affect	  pertussis-­‐	  and	  TT-­‐specific	  CD4+	  and	  CD8+	  T-­‐
cell	   polyfunctionality	   and	  proliferation	  measured	   at	   8	   and	  14	  weeks	  of	   age	   in	  
HIV-­‐exposed,	  uninfected	   infants.	  However,	  birth-­‐vaccinated	   infants	  had	  higher	  
frequencies	   of	   pertussis-­‐specific	   IL-­‐13+-­‐expressing	   CD4+	   and	   CD8+	   cells	   at	   14	  
weeks	  than	  infants	  vaccinated	  with	  BCG	  at	  8	  weeks.	  It	  is	  well	  documented	  that	  
during	  HIV	   infection,	   there	   is	   a	   change	   in	   the	  Th1/Th2	  balance	  with	  a	  gradual	  
shift	   towards	   Th2	   cytokines	   (Becker,	   2004;	   Clerici	   et	   al.,	   1994).	   Thus,	   HIV-­‐
exposed,	   uninfected	   infants	   (particularly	   those	   that	   are	   predominantly	   non-­‐
breastfed)	  may	  have	  different	  Th2	  cytokine	  profiles	  to	  pertussis	  and	  TT	  antigens	  
compared	   with	   unexposed	   infants.	   IL-­‐13	   is	   a	   Th2	   cytokine	   involved	   in	   anti-­‐
inflammatory	   responses	   and	   IgE-­‐mediated	   allergic	   responses	   (Roussel	   et	   al.,	  
1998;	   Walter	   et	   al.,	   2001)	   and	   aP	   (acellular	   pertussis)	   vaccination	   has	   been	  
shown	  to	  induce	  IL-­‐13	  production	  (Ennis	  et	  al.,	  2005;	  Rowe	  et	  al.,	  2000).	  While	  
there	  is	  debate	  about	  which	  arms	  of	  the	  cellular	  immune	  response	  to	  pertussis	  
are	  the	  best	  correlate	  of	  protection	  (Ausiello	  et	  al.,	  1997;	  De	  Gouw	  et	  al.,	  2011;	  
Ross	  et	  al.,	  2013),	  it	  is	  widely	  accepted	  that	  cellular	  immunity	  to	  pertussis	  is	  vital	  




demonstrated	   that	   aP	   vaccine	   induces	   protection	   against	   exacerbation	   of	  
allergic	  asthma	  in	  bordetella	  pertussis	  infection	  through	  IL-­‐13	  production	  (Ennis	  
et	  al.,	  2005).	  Our	  findings	  in	  this	  chapter	  suggest	  that	  early	  BCG	  vaccination	  may	  
improve	  IL-­‐13	  T	  cellular	  responses	  to	  acellular	  pertussis	  at	  week	  14.	  	  
	  
	  BCG	  has	  been	  shown	  to	  enhance	  DC	  production	  of	   IL-­‐12	   in	  response	  to	  many	  
antigens	   (Henderson	   et	   al.,1997).	   This	   subsequently	   induces	   strong	   Th1	  
responses	   in	  neonates	   (Marchant	  et	  al.,	  1999).	   It	   is	  well	  documented	  that	  and	  
that	   Th1	   and	   Th2	   cells	   reciprocally	   inhibit	   their	   function	   (Romagnani,	   1997).	  
Thus,	  observing	  that	  earlier	  BCG	  could	  improve	  Th2	  responses	  to	  pertussis	  was	  
unexpected	  and	  contrary	  to	  our	  initial	  hypothesis.	  However,	  recent	  data	  suggest	  
that	   neonatal	   DCs	   have	   a	   defective	   expression	   of	   IL-­‐12	   gene	   and	   other	   co-­‐
stimulatory	  molecules	  (Goriely	  et	  al.,	  2001;	  Ota	  et	  al.,	  2002).	  This	  leads	  neonatal	  
DCs	  to	  induce	  the	  secretion	  of	  Th1	  and	  Th2	  cytokines	  by	  neonatal	  CD4+	  T	  cells	  
upon	   BCG	   stimulation	   (Ohshima	   et	   al.,	   1997).	   In	   addition,	   the	   observed	  
difference	  was	  at	  14	  weeks	  after	  infants	  in	  the	  two	  arms	  had	  received	  BCG.	  It	  is	  
also	  possible	  that	  the	  Th1	  skewing	  effects	  of	  BCG	  may	  have	  worn	  off	  in	  the	  early	  
BCG	  arm	  and	  as	  a	  result	  higher	  Th2	  cytokine	  expression	  was	  observed.	  	  
	  
Ota	   el	   al	   showed	   that	   early	   BCG	   vaccination	   enhances	   Th2	   and	   antibody	  
responses	   to	   HBV	   in	   HIV-­‐unexposed	   infants	   (Ota	   et	   al.,	   2002).	   They	   also	  
observed	  enhanced	  IL-­‐13	  secretion	  in	  response	  to	  TT	  at	  4	  months	  of	  age	  (Ota	  et	  
al.,	   2002).	   However,	   this	   increase	   in	   Th2	   cytokine	   responses	   did	   not	   affect	  
antibody	  responses	  to	  TT	  (Ota	  et	  al.,	  2002).In	  our	  study,	  we	  did	  not	  observe	  any	  
difference	  in	  IL-­‐13	  expression	  in	  response	  to	  TT	  stimulation	  between	  birth-­‐	  and	  
8-­‐vaccinated	   infants	   at	   14	  weeks.	   This	   could	   be	   due	   to	   the	   short	   duration	   of	  
follow	  up	  (14	  weeks)	  and	  the	  small	  sample	  size	  at	  week	  14.	  In	  addition,	  contrary	  
to	  Ota	   el	   al	  who	  only	   assessed	   the	   levels	   of	   soluble	   cytokines	   secreted	   in	   the	  
plasma,	   we	   measured	   the	   proportions	   of	   cytokines	   expressed	   by	   CD4+	   and	  





Pertussiss	  and	  TT	  vaccines	  are	  administered	  at	  6	  weeks	  of	  age	  in	  neonates.	  The	  
peak	   immune	   response	   to	   TT	   vaccine	   in	   neonates	   generally	   occurs	   around	  27	  
weeks	   of	   age	   (Soares	   et	   al.,	   2013)	   and	   it	   is	   not	   well	   known	   when	   immune	  
responses	  to	  pertussis	  peak	  (Rowe	  et	  al.,	  2000).	  Thus,	   it	   is	  possible	  that	  giving	  
BCG	   two	  weeks	  only	  after	  Pertussis	  and	  TT	  could	  affect	   immune	   responses	   to	  
these	  vaccines	  in	  those	  infants.	  	  Therefore	  it	  is	  very	  possible	  that	  we	  missed	  the	  
possible	   differences	   in	   immune	   responses	   to	   pertussis	   and	   TT	   between	   the	  
groups	   due	   to	   BCG	   timing.	   Thus,	   in	   future	   delayed	   BCG	   studies,	   it	   would	   be	  
important	  to	  take	  into	  consideration	  the	  potential	  effects	  that	  BCG	  could	  have	  



























Chapter	  5.	  Effects	  of	  Delayed	  BCG	  Vaccination	  
on	  Cellular	  Responses	  to	  SEB	  
	  
5.1.	  Introduction	  	  
BCG	  has	  been	  reported	  to	  improve	  all	  cause	  mortality	  in	  Gambian	  infants	  (Aaby	  
et	  al.,	  2011;	  Garly	  et	  al.,	  2003)	  and	  Ota	  et	  al	  have	  found	  that	  BCG	  can	  improve	  
immune	   responses	   to	   certain	   other	   antigens	   and	   propose	   that	   BCG	   enhances	  
the	  maturation	  of	  the	  neonatal	  immune	  system	  (Ota	  et	  al.,	  2002).	  Kleinnijenhuis	  
propose	  that	  BCG	  may	  have	  these	  effects	  through	  inducing	  epigenetic	  changes	  
in	  the	  NOD-­‐2	  receptor	  present	  in	  monocytes	  (Kleinnijenhuis	  et	  al.,	  2012).	  Thus,	  
in	   this	   chapter,	   using	   the	   same	   assays	   as	   described	   in	   chapter	   3,	   we	   aim	   to	  
determine	  whether	  BCG	  improves	  T	  cell	  proliferative	  and	  cytokine	  responses	  to	  
the	  non-­‐recall	   antigen	  SEB	   in	  HIV-­‐exposed	   infants.	   SEB	   is	  a	   super	  antigen	   that	  
binds	   to	  MHC	  class	   II	  α-­‐chain	  and	   the	  TCR	  β-­‐chain	  and	   leads	   to	  massive	  T	  cell	  
proliferation	   (Fraser,	   2011).CD4+	   and	   CD8+	   T	   cell	   responses	   to	   SEB	   can	   help	  
determine	  their	  quality	  and	  maturity	  level	  of	  an	  immune	  response	  (Proft	  et	  al.,	  
2003).	   If	  delaying	  BCG	  vaccination	   for	  HIV-­‐exposed	   infants	   is	   to	  be	  considered	  
an	   option,	   it	   is	   important	   to	   understand	   the	   non-­‐specific	   effects	   of	   BCG,	   and	  
whether	  BCG	  vaccination	  does	  enhance	  T	  cell	  responses	  to	  unrelated	  antigens,	  





5.2.	   T-­‐cell	   proliferative	   responses	   to	   SEB	   in	   early-­‐BCG	   versus	  
delayed-­‐BCG	  vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  age	  	  
At	   6	   and	   8	   weeks	   of	   age,	   there	   was	   no	   difference	   in	   CD4+	   and	   CD8	   T	   cell	  
proliferative	   responses	   to	   SEB	   between	   HIV	   exposed	   infants	   in	   the	   early	   BCG	  
arm	  versus	  infants	  in	  the	  delayed	  BCG	  arm	  (figure	  5.1).	  However,	  at	  14	  weeks	  of	  
age,	  14	  weeks	  after	  the	  early	  arm	  infants	  received	  BCG,	  and	  6	  weeks	  after	  the	  
delayed	  arm	  was	  BCG	  vaccinated,	   infants	   vaccinated	  at	  with	  BCG	  at	  birth	  had	  
higher	  frequency	  of	  proliferating	  CD4+	  cells	  to	  SEB	  than	  infants	  vaccinated	  with	  
BCG	  at	  8	  weeks	  of	  age	  (early	  arm	  median=29,6%	  vs.	  delayed	  arm	  median=17	  %,	  
p=0.018).	  	  
	  
SEB-­‐induced	  CD4+Ki67+	  and	  CD8+Ki67+	  cells	  
	  
Figure	   5.1:	  Frequency	   of	   CD4	   and	   CD8+T	   cells	   expressing	   Ki67+	   in	   response	   to	   SEB	  
stimulation	   determined	   by	   flow	   cytometry	   in	   the	   early	   (blue)	   versus	   delayed	   (red)	  
BCG	  vaccinees	  at	  8	  and	  14	  weeks.	  Lines	  represent	  medians	  and	  whiskers	  interquartile	  
ranges.	   p<0.05	   significant	   level	   (unadjusted)	   and	   statistical	   significance	  was	   obtained	  
using	  Mann-­‐Whitney	  U	  test.	  
	  
5.3.	  T	  cell	  cytokine	  expression	   in	  response	  to	  SEB	   in	  early-­‐BCG	  vs.	  
delayed-­‐BCG	  vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  age	  
5.3.1.	   IFNγ	   and	   IL-­‐2	   (Th1/Tc1)	   expression	   in	   response	   to	   SEB	   in	   early-­‐BCG	  
versus	  delayed-­‐BCG	  vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  age	  
As	  shown	  in	  figure	  5.2,	  infants	  in	  the	  early	  BCG	  arm	  had	  a	  higher	  proportion	  of	  
















































to	  infants	  in	  the	  delayed	  BCG	  arm	  at	  8	  weeks	  (p	  =	  0.035);	  this	  difference	  was	  not	  
significant	  after	  adjustment	  for	  multiple	  comparisons.	  At	  8	  and	  14	  weeks	  of	  age,	  
infants	  in	  the	  early	  and	  delayed	  BCG	  arms	  had	  similar	  frequencies	  of	  CD4+Ki67+	  
and	  CD8+Ki67+	  cells	  expressing	  IL-­‐2	  (figure	  5.2).	  There	  was	  no	  difference	  in	  the	  
frequencies	   of	   CD4+Ki67+and	  CD8+Ki67+	   cells	   expressing	   IFN-­‐γ	   in	   response	   to	  
SEB	  stimulation	  at	  6,	  8	  and	  14	  weeks	  between	  the	  two	  arms	  (figure	  5.2).	  
Figure	  5.2:	  The	  frequency	  of	  T	  cells	  producing	  IFNγ	  and	  IL-­‐2	  at	  6,8	  and	  14	  weeks	  of	  life	  
after	  SEB	  stimulation	   for	  6	  days	   in	  whole	  blood	  assay	  measured	  by	   flow	  cytometry.	  
Frequency	  of	  antigen	  specific	  IFNγ	  and	  IL-­‐2	  producing	  T	  cells	  out	  of	  total	  CD4+	  (on	  the	  
left	  side	  of	  each	  graph)	  and	  CD8+	  (on	  the	  right	  side	  of	  each	  graph)	  T	  cells,	  determined	  
by	   flow	   cytometry	   of	   SEB-­‐stimulated	  whole	   blood	   of	   HIV-­‐exposed	   infants	   vaccinated	  
with	  BCG	  at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  
with	   BCG	   at	   8	   weeks	   of	   age	   (delayed	   arm)	   (red	   dots).	   Frequencies	   reported	   are	   the	  
frequencies	  of	  proliferating	  cytokine	  producing	  cells	  out	  of	  total	  CD4+	  or	  CD8+	  T	  cells.	  
Bars	  indicate	  medians;	  alpha=0.05	  (unadjusted);	  statistical	  significance	  was	  tested	  using	  


























































































5.3.2.	   IL-­‐17	   (Th17/	   Tc17)	   expression	   in	   response	   to	   SEB	   in	   early-­‐BCG	   versus	  
delayed-­‐BCG	  vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  age	  
When	  compared,	  there	  was	  no	  difference	  in	  the	  frequencies	  of	  CD4+Ki67+	  and	  
CD8+Ki67+	  expressing	  IL-­‐17	  in	  response	  to	  SEB	  between	  infants	  in	  the	  early	  BCG	  
arm	  and	  those	  in	  the	  delayed	  BCG	  arm	  at	  any	  of	  the	  three	  time	  points.	  Except	  
for	   CD8+Ki67+	   cells	   at	   8	  weeks	   of	   age,	   as	   it	  was	   previously	   observed	   for	   BCG	  
stimulation	  (section	  4.3.2),	  infants	  in	  the	  two	  arms	  exhibited	  very	  low	  levels	  of	  
IL-­‐17	  expression	  in	  response	  to	  SEB	  stimulation	  (Figure	  5.3).	  
Figure	  5.3:	  The	  frequency	  of	  T	  cells	  producing	  IL-­‐17	  at	  6,8	  and	  14	  weeks	  of	   life	  after	  
SEB	   stimulation	   for	   6	   days	   in	   whole	   blood	   assay	   measured	   by	   flow	   cytometry.	  
Frequency	  of	  antigen	  specific	  IL-­‐17	  producing	  T	  cells	  out	  of	  total	  CD4+	  (on	  the	  left	  side	  
of	  each	  graph)	  and	  CD8+	  (on	  the	  right	  side	  of	  each	  graph)	  T	  cells,	  determined	  by	  flow	  
cytometry	  of	  SEB-­‐stimulated	  whole	  blood	  of	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  
at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  
at	  8	  weeks	  of	  age	  (delayed	  arm)	  (red	  dots).	  Frequencies	  reported	  are	  the	  frequencies	  of	  
proliferating	   cytokine	  producing	   cells	  out	  of	   total	  CD4+	  or	  CD8+	  T	   cells.	  Bars	   indicate	  
medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	   was	   tested	   using	   Mann-­‐




















































5.3.3	   IL-­‐13	   (Th2/Tc2)	   expression	   in	   response	   to	   SEB	   in	   early-­‐BCG	   versus	  
delayed-­‐BCG	  vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  age	  
As	  indicated	  in	  figure	  5.4,	  at	  6,	  8	  and	  14	  weeks,	  infants	  in	  the	  early	  and	  delayed	  
BCG	  arms	  had	  similar	  levels	  of	  CD4+Ki67+	  and	  CD8+Ki67+	  cells	  expressing	  IL-­‐13	  
in	  response	  to	  SEB	  stimulation.	  
	  
Figure	  5.4:	  The	  frequency	  of	  T	  cells	  producing	  IL-­‐13	  at	  6,	  8	  and	  14	  weeks	  of	  life	  after	  
SEB	   stimulation	   for	   6	   days	   in	   whole	   blood	   assay	   measured	   by	   flow	   cytometry.	  
Frequency	  of	  antigen	  specific	  IL-­‐13	  producing	  T	  cells	  out	  of	  total	  CD4+	  (on	  the	  left	  side	  
of	  each	  graph)	  and	  CD8+	  (on	  the	  right	  side	  of	  each	  graph)	  T	  cells,	  determined	  by	  flow	  
cytometry	  of	  SEB-­‐stimulated	  whole	  blood	  of	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  
at	  birth	  (early	  arm)	  (blue	  dots)	  compared	  to	  HIV-­‐exposed	  infants	  vaccinated	  with	  BCG	  
at	  8	  weeks	  of	  age	  (delayed	  arm)	  (red	  dots).	  Frequencies	  reported	  are	  the	  frequencies	  of	  
proliferating	   cytokine	  producing	   cells	  out	  of	   total	  CD4+	  or	  CD8+	  T	   cells.	  Bars	   indicate	  
medians;	   alpha=0.05	   (unadjusted);	   statistical	   significance	   was	   tested	   using	   Mann-­‐
Whitney	  U	  test.	  	  
	  
5.4.	  T-­‐cell	  functional	  responses	  to	  SEB	  in	  in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  6,	  8	  and	  14	  weeks	  of	  life	  
5.4.1.1	   CD4+	   T-­‐cell	   polyfunctional	   responses	   to	   SEB	   in	   in	   early-­‐BCG	   vs.	  
delayed-­‐BCG	  vaccinated	  infants	  at	  week	  6	  
The	  ability	  of	  proliferating	  cells	  to	  make	  at	  least	  one,	  a	  combination	  of	  any	  two,	  
three,	  or	  all	  four	  cytokines	  in	  response	  to	  SEB	  at	  week	  6	  between	  infants	  in	  the	  
early	   arm	   versus	   those	   in	   the	   delayed	   arm	   were	   compared.	   There	   were	   no	  
















































cytokines	  (figure	  5.5a).	  Overall,	  there	  was	  also	  no	  significant	  difference	  in	  CD4+	  
cell	  polyfunctionality	  as	  indicated	  in	  figure	  5.5b	  (overall	  ANOVA	  p	  =	  0.216).	  
	  
Figure	   5.5:	   Proportions	   of	   SEB-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  6	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD4+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  




























































































5.4.1.2.	  CD8	  T-­‐cell	   polyfunctional	   responses	   to	  SEB	   in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  6	  
Similar	   to	   CD4+	   T	   cell	   cytokine	   responses,	   at	   week	   6,	   no	   difference	   in	   CD8+	  
polyfunctional	   cytokine	   responses	   was	   observed	   between	   early	   BCG	   and	  
delayed	  BCG-­‐vaccinated	   infants.	  There	  was	  no	  difference	   in	  the	  frequencies	  of	  
all	  the	  different	  combinations	  of	  cytokines	  expressed	  by	  CD8+	  cells	  in	  response	  
to	   SEB	   (figure	   5.6a)	   between	   infants	   in	   the	   early	   BCG	   arm	   and	   those	   in	   the	  
delayed	   BCG	   arm.	   In	   addition,	   as	   indicated	   in	   figure	   5.6b,	   there	   was	   also	  
difference	  in	  the	  overall	  CD8+	  cell	  polyfunctionality	  between	  infants	  in	  the	  two	  
arms	  (ANOVA	  p	  =	  0.264).	  	  





Figure	   5.6:	   Proportions	   of	   SEB-­‐specific	   proliferating	   CD8+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  6	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	   medians	   respectively;	   p-­‐value	   indicates	   significant	   difference	   in	   the	  
combination	  of	  cytokine	  production	  by	  CD8+	  T	  cells	  between	  the	  two	  groups.	  Statistical	  
analysis	   was	   performed	   using	  Wilcoxon	   signed	   rank	   test.	   (b)	   The	   pie	   charts	   at	   the	  
bottom	  summarise	  the	  data	  with	  the	  pie	  slice	  legend	  on	  the	  graph	  showing	  the	  colours	  
of	  the	  various	  cytokine	  combinations	  and	  the	  p-­‐value	  showing	  the	  overall	  significance	  
of	  the	  total	  magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  





























































































5.4.2.T-­‐cell	   polyfunctional	   responses	   to	   SEB	   in	   in	   early-­‐BCG	   vs.	   delayed-­‐BCG	  
vaccinated	  infants	  at	  week	  8	  
5.4.2.1	  CD4	  T-­‐cell	  polyfunctional	  responses	  to	  SEB	  in	  in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  8	  
The	  polyfunctionality	  of	  proliferating	  CD4+	  cells	   following	  SEB	  stimulation	  was	  
compared	  between	  the	  two	  BCG	  vaccination	  arms	  by	  assessing	  the	  frequencies	  
of	  cells	  making	  zero,	  any	  one,	  or	  any	  combination	  of	  two	  or	  three	  cytokines	  at	  
week	   8	   (Figure	   5.7).	   There	   was	   no	   difference	   in	   CD4+	   cytokine	   responses	  
between	   infants	   in	   the	   early	   BCG	   arm	   and	   those	   in	   the	   delayed	   arm	   (figure	  
5.7a).	  Overall,	  CD4+	  cell	  polyfunctionality	  was	  similar	  between	  the	  two	  arms	  at	  
week	  8	  (ANOVA	  p	  =0.951)	  (Figure	  5.7b).	  	  





Figure	   5.7:	   Proportions	   of	   SEB-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  8	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD4+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  



























































































5.4.2.2	  CD8	  T-­‐cell	  polyfunctional	  responses	  to	  SEB	  in	  in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  8	  
When	  the	  polyfunctionality	  of	  proliferating	  CD8+cells	  following	  SEB	  stimulation	  
was	  assessed	  in	  infants	  in	  the	  early	  and	  delayed	  BCG	  arms	  at	  8	  weeks	  of	  age,	  no	  
difference	   was	   found	   in	   CD8+	   polyfunctional	   cytokine	   responses	   after	   SEB	  
stimulation	  between	  infants	  who	  received	  BCG	  at	  birth	  and	  those	  who	  received	  
BCG	  at	  8	  weeks	  of	  age	  (ANOVA	  p	  =	  0.269)	  (figure	  5.8b).	  	  





Figure	   5.8:	   Proportions	   of	   SEB-­‐specific	   proliferating	   CD8+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  8	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD8+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  



























































































5.4.3.T-­‐cell	   polyfunctional	   response	   to	   SEB	   in	   in	   early-­‐BCG	   vs.	   delayed-­‐BCG	  
vaccinated	  infants	  at	  week	  14	  
5.4.3.1	  CD4	  T-­‐cell	  polyfunctional	  responses	  to	  SEB	  in	  in	  early-­‐BCG	  vs.	  delayed-­‐
BCG	  vaccinated	  infants	  at	  week	  14	  
At	   week	   14,	   14	   weeks	   after	   birth	   vaccination	   and	   6	   weeks	   after	   delayed	  
vaccination,	   infants	   in	   the	   early	   and	   delayed	   arms	   had	   similar	   levels	   of	   CD4+	  
cells	   expressing	  one,	   two	  and	   three	   cytokines	   in	   response	   to	   SEB	  as	   shown	   in	  
figure	  5.9a.	  In	  addition,	  frequencies	  of	  CD4+	  cells	  expressing	  zero	  cytokine	  were	  
also	   similar	   between	   the	   two	   arms.	   Overall,	   there	   was	   also	   no	   difference	   in	  
CD4+	  polyfunctionality	  between	  infants	  in	  the	  two	  arms	  (ANOVA	  p	  =	  0.676)	  (see	  






Figure	   5.9:	   Proportions	   of	   SEB-­‐specific	   proliferating	   CD4+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  14	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD4+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD4+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD4+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD4+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  




























































































5.4.3.2	   CD8+	   T-­‐cell	   polyfunctional	   responses	   to	   SEB	   in	   birth	   vs.	   8-­‐week	  
vaccinated	  infants	  at	  week	  14	  
Similar	   to	  CD4+	  cells,	   frequencies	  of	  CD8+	  cells	  expressing	  one,	   two	  and	  three	  
cytokines	   in	   response	   to	   SEB	   were	   similar	   between	   infants	   in	   the	   two	   BCG	  
vaccination	   arms	   at	   14	   weeks	   of	   age	   (figure	   5.10a).	   In	   addition,	   as	   noted	   in	  
figure	   5.10a,	   frequencies	   of	   CD8+	   cells	   expressing	   zero	   measurable	   cytokine	  
were	  also	  similar.	  Overall	  infants	  in	  the	  two	  BCG	  arms	  exhibited	  similar	  CD8+	  T	  
cell	  polyfunctionality	  (ANOVA	  p	  =0.144).	  	  





Figure	   5.10:	   Proportions	   of	   SEB-­‐specific	   proliferating	   CD8+	   T	   cells	   producing	   no	  
cytokine,	  one,	  or	  a	  combination	  of	  cytokine(s)	  based	  on	  expression	  of	  IL-­‐2,	  IFN-­‐γ,	  IL-­‐
13	  and/or	  IL-­‐17,	  at	  14	  weeks	  of	  age	  in	  birth-­‐vaccinated	  (early	  group)	  infants	  versus	  8-­‐
week-­‐vaccinated	  (delayed	  group)	  HIV-­‐exposed	  infants.	  Comparison	  of	  the	  proportion	  
of	   cells	   expressing	   no	   cytokine,	   one	   or	   a	   combination	   of	   intracellular	   cytokine(s)	   by	  
proliferating	  CD8+	  T	   cells	   in	   infants	   in	   the	  early	   arm	   (blue	  dots)	   versus	   infants	   in	   the	  
delayed	   arm	   (red	   dots).	   (a)	   Represents	   the	   possible	   combination	   of	   the	   responses	  
shown	   versus	   the	   proportions	   of	   the	   functionally	   distinct	   cell	   populations	  within	   the	  
responding	  CD8+	  T	  cells	  shown.	  Responses	  are	  grouped	  and	  colour-­‐coded	  on	  the	  basis	  
of	   the	   combinations	   of	   the	   cytokines	   produced.	   Spots	   correspond	   to	   the	   fractions	   of	  
functionally	   distinct	   T	   cell	   populations	   within	   the	   proliferating	   CD8+	   T	   cells.	   Bars	  
correspond	   to	  medians;	  p-­‐value	   indicates	   significant	  difference	   in	   the	   combination	  of	  
cytokine	  production	  by	  CD8+	  T	   cells	  between	   the	   two	  groups.	   Statistical	   analysis	  was	  
performed	  using	  Wilcoxon	  signed	  rank	  test.	  (b)	  The	  pie	  charts	  at	  the	  bottom	  summarise	  
the	   data	   with	   the	   pie	   slice	   legend	   on	   the	   graph	   showing	   the	   colours	   of	   the	   various	  
cytokine	   combinations	   and	   the	   p-­‐value	   showing	   the	   overall	   significance	   of	   the	   total	  
magnitude	  of	  the	  combinations	  of	  cytokine	  responses.	  	  
	  
	  




























































































This	   chapter	   aimed	   to	   investigate	   the	   effects	   of	   BCG	   vaccination	   on	   immune	  
responses	   to	   non-­‐vaccine	   antigens	   in	   HIV-­‐exposed	   infants,	   in	   particular,	   the	  
superantigen	   SEB.	   Few	   studies	   have	   investigated	   neonatal	   T	   cell	   responses	   to	  
SEB	   in	   HIV-­‐exposed	   infants.	   Kagina	   et	   al	   assessed	   the	   effects	   of	   delayed	   BCG	  
vaccination	  on	  CD4+	  T	  cell	  cytokine	  response	  to	  SEB	  in	  HIV-­‐unexposed	  neonates	  
(Kagina	   et	   al.,	   2009).	   Assessing	   the	   affect	   of	   BCG	   vaccination	   in	   non-­‐recall	  
antigens	  can	  help	  to	  understand	  the	  non-­‐specific	  effects	  of	  BCG	  on	  neonatal	  T	  
cell	  response	  to	  unrelated	  antigens	  and	  the	  overall	  adjuvant	  effects	  of	  BCG	  on	  
the	  immune	  system.	  Also,	  responses	  to	  SEB	  represent	  the	  full	  potential	  of	  cells	  
to	   respond	   to	   stimulation.	   In	   order	   to	   do	   this,	   the	   effects	   of	   delayed	   BCG	  
vaccination	   (from	   birth	   to	   8	   weeks)	   on	   T	   cell	   proliferative	   and	   cytokine	  
responses	  to	  SEB	  were	  assessed	  in	  HIV-­‐exposed,	  uninfected	  infants	  at	  weeks	  6,	  
8	   and	   14	   using	   intracellular	   staining	   as	   described	   in	   chapter	   3.	   Delaying	   BCG	  
vaccination	  from	  birth	  to	  8	  weeks	  does	  not	  seem	  to	  affect	  CD4+	  and	  CD8+	  T	  cell	  
proliferative	  responses	  to	  SEB	  at	  6	  and	  8	  weeks	  of	  age.	  However,	  infants	  in	  the	  
early	  BCG	  arm	  had	  higher	  CD4	  T	  cell	  proliferative	  responses	  to	  SEB	  compared	  to	  
infants	  in	  the	  delayed	  BCG	  arm	  at	  week	  14,	  after	  both	  groups	  had	  received	  BCG	  
vaccination.	  Finally,	  no	  differences	  in	  CD4+	  and	  CD8+	  cytokine	  responses	  to	  SEB	  
were	   found	   between	   infants	   in	   the	   two	   BCG	   arms.	   In	   addition,	   infants	   in	   the	  
early	   and	   delayed	   arms	   exhibited	   similar	   CD4+	   and	   CD8+	   polyfunctional	  
cytokine	  responses	  following	  SEB	  stimulation	  at	  weeks	  6,	  8	  and	  14.	  
	  
Since	   it	   was	   observed	   that	   HIV-­‐exposed	   infants	   vaccinated	   with	   BCG	   at	   birth	  
(early	  arm)	  had	  higher	  CD4	  T	  cell	  proliferative	  response	  to	  SEB	  at	  14	  weeks	  of	  
age	  than	  infants	  who	  received	  BCG	  at	  8	  weeks	  of	  age	  (i.e.	  14	  weeks	  prior	  versus	  
6	   weeks	   prior),	   it	   is	   possible	   that	   early	   BCG	   vaccination	   subtly	   enhances	   the	  
maturation	  of	  the	  neonatal	  immune	  system.	  Studies	  in	  adults	  and	  mice	  suggest	  
that	  mycobacteria	  such	  as	  BCG	  can	  enhance	  DC	  maturation	  and	  production	  of	  
IL-­‐12	  that	  subsequently	  leads	  to	  an	  increase	  in	  T	  cell	  activity	  (Henderson	  et	  al.,	  




enhanced	  in	  the	  presence	  of	  BCG	  (Larsen	  et	  al.,	  2007).	  In	  addition,	  DCs	  are	  not	  
the	   only	   APCs	   affected	   by	   BCG.	   It	   has	   also	   been	   demonstrated	   that	   BCG	  
vaccination	   increases	   monocytes	   responses	   to	   unrelated	   antigens	   in	   healthy	  
individuals	   through	   a	   mechanism	   that	   involves	   epigenetic	   changes	   in	   the	  
monocytes	   through	   their	   NOD2	   receptor	   (Kleinnijenhuis	   et	   al.,	   2012).This	  
trained	  immunity	  could	  explain	  the	  increased	  non-­‐specific	  immune	  responses	  to	  
other	   antigens	   induced	   by	   BCG.	   Thus,	   it	   is	   plausible	   that	   trained	   immunity	  
induced	  by	  BCG	  could	  enhance	  non-­‐specific	  T	  cells	  responses	  to	  SEB	  as	  observed	  
in	  this	  chapter.	  However,	  we	  observed	  very	  minor	  alterations	  in	  SEB	  responses	  
in	   this	   study.	   All	   these	   previous	   observations	   were	   made	   in	   HIV-­‐unexposed	  
individuals,	  and	  it	  is	  unclear	  whether	  the	  same	  phenomena	  are	  likely	  to	  be	  true	  
also	  in	  HIV-­‐exposed	  individuals.	  	  
	  
Finally,	  BCG	  timing	  did	  not	  seem	  to	  have	  any	  effect	  on	  CD4+	  and	  CD8+	  cytokine	  
responses	  and	  polyfunctionality.	   These	   findings	  were	   consistent	  with	  previous	  
reports	   of	   CD4+	   T	   cell	   cytokine	   responses	   to	   SEB	   following	   delayed	   BCG	  
vaccination	  in	  HIV-­‐unexposed	  infants	  (Kagina	  et	  al	  2009).	  Kagina	  et	  al	  found	  that	  
at	  20	  weeks,	  there	  was	  no	  difference	  in	  the	  frequencies	  of	  IFNγ-­‐expressing	  CD4+	  
cells	  in	  response	  to	  SEB	  stimulation	  in	  HIV-­‐unexposed	  infants	  who	  received	  BCG	  
at	  birth	  and	  those	  who	  received	   it	  at	  10	  weeks	  of	  age	   (Kagina	  et	  al.,	  2009).	   In	  
addition,	   they	   also	   observed	   no	   difference	   in	   CD4	   T	   cell	   polyfunctionality	   in	  
response	  to	  SEB	  between	  early	  and	  delayed	  arms	  at	  20	  weeks	  of	  age	  (Kagina	  et	  
al.,	   2009).	   Thus,	   BCG	   does	   not	   seem	   to	   affect	   CD4	   or	   CD8	   T	   cell	   cytokine	  
responses	  to	  SEB.	  	  
	  
The	  low	  cytokine	  responses	  to	  SEB	  in	  general	  in	  these	  infants	  may	  be	  specific	  to	  
superantigen	  responses	  in	  the	  neonatal	  period.	  In	  fact,	  Hayward	  et	  al	  reported	  
that	  Th1	  and	  Th2	  cytokine	  responses	  to	  SEB	  were	  seven	  times	  lower	  in	  human	  
neonates	  than	  in	  adults	  (Hayward	  et	  al.,	  1994).Cusumano	  et	  al	  also	  showed	  that	  
neonatal	   mice	   exhibited	   very	   low	   levels	   of	   IFNγ	   and	   IL-­‐2	   in	   response	   to	   SEB	  
stimulation	  (Cusumano	  et	  al.,	  1997).	  However,	  since	  SEB	  is	  a	  strong	  stimulus,	  it	  




experiments	  was	  exhausted.	  The	  results	  in	  this	  chapter	  are	  also	  consistent	  with	  
Islander	   et	   al	  who	   demonstrated	   that	   neonatal	   T	   cells	   express	   very	   low	   IL-­‐17	  
levels	   following	   SEB	   stimulation	   (Islander	   et	   al.,	   2010).	   A	   large	   proportion	   of	  
neonatal	  CD4+	  T	  cells	  are	  naïve	  T	  cells	  characterized	  by	  the	  high	  expression	  of	  
the	   CD45RA	   receptor	   (Storek	   J	   et	   al.,	   1995)	   and	   CD45RA	  has	   been	   associated	  
with	  low	  T	  cell	  responses	  to	  SEB	  (Hayward	  et	  al.,	  1994).	  In	  addition,	  low	  cytokine	  
responses	  to	  SEB	  may	  also	  be	  due	  to	  the	  need	  for	  additional	  stimulation	  other	  
than	  just	  cross-­‐linkage	  of	  the	  TCR	  and	  MHC	  II	  in	  infancy.	  Neonatal	  dendritic	  cells	  
and	  other	  APCs	  are	   characterized	  by	   their	   low	  expression	  of	  MHCII	  molecules	  
(Velilla	  et	  al.,	  2007)	  and	  optimal	  cross-­‐linkage	  of	  the	  MHCII	  complex	  and	  the	  TCR	  
is	  necessary	  to	  induce	  good	  cytokine	  responses	  to	  SEB	  (Fraser,	  2011).	  	  
	  
Consistent	  with	  previous	  studies	  carried	  out	  in	  neonates,	  low	  Th1,	  Th17	  and	  Th2	  
cytokine	   responses	   to	   SEB	  were	   found	   in	   these	   young	   infants	   (Islander	   et	   al.,	  
2010;	  Hayward	  et	  al.,	  1994).	  A	  longer	  duration	  of	  follow	  up	  would	  therefore	  be	  
informative	   to	   assess	   the	   longitudinal	   effects	   of	   delayed	   BCG	   vaccination	   on	  
cytokine	  responses	  to	  SEB.	  Despite	  these	  limitations,	  the	  findings	  in	  this	  chapter	  
show	  that	  early	  BCG	  vaccination	  may	  have	  some	  limited	  non-­‐specific	  effects	  on	  
the	  neonatal	  immune	  system.	  As	  a	  result,	  it	  is	  important	  to	  weigh	  the	  risks	  and	  
benefits	  of	  delayed	  BCG	  vaccination	  in	  neonates.	  	  




Chapter	  6.	  Conclusion	  
	  
Bacille	  Calmette-­‐Guerin	  (BCG),	  a	  live	  attenuated	  Mycobacterium	  bovis	  strain,	  is	  
administered	   to	  almost	  100	  million	  children	  at	  birth	  annually	  and	   remains	   the	  
only	  licensed	  vaccine	  for	  TB	  prevention	  (WHO	  epidemiologic	  report,	  2004)..	  BCG	  
induces	   strong	   Th-­‐1	   responses	   even	   in	   neonates,	   who	   have	   a	   Th-­‐2	   biased	  
immune	  system,	  and	  protects	  against	  severe	  forms	  of	  childhood	  TB	  such	  as	  TB	  
meningitis	   and	   miliary	   TB	   in	   immunocompetent	   children	   (Marchant	   et	   al.,	  
1999).	   In	   addition	   BCG	   immunogenicity	  may	   increase	  with	   vaccination	   age	   as	  
the	   neonatal	   immune	   system	  develops	   (Hussey	   et	   al.,	   2002).	   In	   fact,	   delaying	  
BCG	  vaccination	   from	  birth	   to	  10	  weeks	  has	  been	  shown	   to	  enhance	  memory	  
CD4	   T-­‐cells	   in	   South	   African	   HIV-­‐unexposed,	   uninfected	   infants	   (Kagina	   et	   al.,	  
2009).	   Furthermore,	   data	   suggest	   that	   early	   BCG	   vaccination	   may	   improve	  
immune	   responses	   to	  other	  antigens	  and	  unrelated	  vaccines	   such	  as	  OPV	  and	  
HBV	  (Ota	  et	  al.,	  2002).	  	  
	  
Many	   TB-­‐endemic	   endemic	   regions	   such	   as	   South	   Africa	   are	   also	   affected	   by	  
HIV.	  BCG	  has	  been	  associated	  with	  serious	  adverse	  events	  due	  to	  BCG	  immune	  
reconstitution	  inflammatory	  syndrome	  (BCG	  IRIS)	  and	  disseminated	  BCG	  disease	  
in	   HIV-­‐infected	   infants.	   Although,	   HIV-­‐infection	   is	   a	   contraindication	   to	   BCG	  
vaccination,	   the	   vaccine	   continues	   to	   be	   administered	   to	   HIV-­‐exposed,	  
uninfected	   neonates.	   Very	   little	   is	   known	   about	   BCG	   immunogenicity	   in	   HIV-­‐
exposed	   infants	   (Hesseling	   et	   al.,	   2006;	   Rabie	   et	   al.,	   2011).Recent	   studies	  
demonstrate	   reduced	   IFN-­‐γ	   and	   TNF-­‐α	   production	   by	   HIV-­‐exposed	   infants	   in	  
response	  to	  BCG	  (Mazzola	  et	  al.,	  2011;	  Van	  Rie	  et	  al.,	  2006).In	  addition,	  to	  the	  
previously	  observed	  altered	  immune	  features	  of	  the	  HEU	  infants	  in	  response	  to	  
BCG	  vaccination,	  this	  dissertation	  has	  shown	  that:	  
	  
(i)	  Delaying	  BCG	  vaccination	  from	  birth	  to	  8	  weeks	  of	  age	  results	  in	  improved	  T	  




response	  to	  BCG	  in	  HIV-­‐exposed	  infants	  at	  14	  weeks	  of	  age.	  
(ii)	  Early	  BCG	  vaccination	  induces	  higher	  CD4+	  T	  cell	  proliferation	  in	  response	  to	  
SEB	  in	  HIV-­‐exposed	  infants	  at	  14	  weeks	  of	  age.	  
	  (iii)	  Early	  BCG	  vaccination	  leads	  to	  higher	  frequencies	  of	  IL-­‐13-­‐expressing	  CD4+	  
and	  CD8+	  T	  cells	   in	   response	   to	  pertussis	  at	  14	  weeks	  of	  age.	  Thus,	  early	  BCG	  
vaccination	  may	  alter	   immune	   responses	   to	  acellular	  pertussis	   in	  HIV-­‐exposed	  
infants.	  	  
	  
In	  chapter	  3,	  when	   the	  effects	  of	  delayed	  BCG	  vaccination	  on	  CD4+	  and	  CD8+	  
proliferative	   and	   cytokine	   responses	   to	   BCG	   were	   assessed,	   delayed	   BCG	  
vaccination	  did	  not	  seem	  to	  have	  any	  effect	  on	  T	  cell	  proliferation.	  This	  finding	  
was	  in	  close	  agreement	  with	  other	  infant	  studies	  which	  show	  that	  delaying	  BCG	  
vaccination	   from	   birth	   to	   six	   or	   ten	  weeks	   does	   not	   affect	   T	   cell	   proliferative	  
responses	  in	  HIV-­‐unexposed	  infants	  (Kagina	  et	  al.,	  2009;	  Lutwama	  et	  al.,	  2013).	  
On	   the	  other	  hand,	   still	   in	   chapter	   3,	   following	  BCG	   stimulation,	  we	  observed	  
that	   infants	   in	   the	   delayed	   BCG	   arm	   (receiving	   BCG	   at	   8	   weeks)	   had	   higher	  
frequencies	   of	   IFN-­‐γ-­‐expressing	   CD4+	   T	   cells	   compared	   to	   infants	   in	   the	   early	  
BCG	   arm	   at	   14	   weeks	   of	   age.	   Kagina	   et	   al.	   also	   observed	   increased	   in	  
frequencies	  of	   IFN-­‐γ-­‐expressing	  CD4+	  T	  cells	  at	  20	  weeks	   in	  South	  African	  HIV-­‐
unexposed	   infants	   who	   received	   BCG	   at	   10	   weeks	   (Kagina	   et	   al.,	   2009).	   As	  
discussed	  in	  chapter	  3,	  it	  is	  well	  documented	  that	  Th1	  responses	  increase	  with	  
time	  (Marodi,	  2002).	  Therefore,	  it	  is	  possible	  that	  the	  increase	  in	  Th1	  cytokines	  
(especially	   IFN-­‐γ-­‐)	  be	  due	  to	  the	  more	  developed	   immune	  system	  of	   infants	   in	  
the	   delayed	  BCG	   arm	  at	   the	   time	   they	   received	   their	   BCG	   vaccine.	   This	   could	  
also	   explain	   why	   infants	   in	   the	   delayed	   BCG	   arm	   exhibited	   higher	   CD4+	   and	  
CD8+	   T	   cell	   polyfunctionality	   in	   response	   to	   BCG	   at	   14	   weeks	   of	   age.	  
Furthermore,	   the	   effects	   observed	   at	   week	   14	   could	   simply	   be	   due	   to	   the	  
waning	  of	  the	  response	  to	  BCG	  in	  the	  early	  BCG	  arm.	  The	  immune	  correlates	  of	  




cytokines	  and	  T	  cell	  polyfunctionality	  in	  the	  delayed	  BCG	  arm	  affect	  BCG	  efficacy	  
but	  it	  is	  thought	  that	  increased	  CD4+	  T	  cell	  polyfunctionality	  and	  Th1	  cytokines	  
are	  important	  for	  TB	  control	  (Beveridge	  et	  al.,	  2007;	  Mueller	  et	  al.,	  2008).	  
	  
In	   chapters	   4	   and	   5,	   the	   non-­‐specific	   effects	   of	   BCG	   were	   determined	   by	  
assessing	   T	   cells	   responses	   to	  pertussis	   and	  TT	   vaccines	   and	   the	   superantigen	  
SEB.	   At	   week	   14,	   infants	   in	   the	   early	   BCG	   arm	   had	   higher	   CD4+	   proliferative	  
responses	  to	  SEB.	  SEB	  is	  a	  super	  antigen	  that	  binds	  to	  MHC	  class	  II	  α-­‐chain	  and	  
the	   TCR	   β-­‐chain	   and	   leads	   to	   massive	   T	   cell	   proliferation	   (Fraser,	   2011).	  
Responses	  to	  SEB	  can	  be	  used	  to	  determine	  the	  maturity	  of	  the	  immune	  system.	  
Thus,	  the	  higher	  CD4+	  proliferative	  responses	  to	  SEB	  observed	  in	  infants	  in	  the	  
early	  BCG	  arm	  may	  imply	  that	  BCG	  vaccine	  can	  enhance	  the	  neonatal	   immune	  
system.	  It	  is	  not	  clear	  how	  BCG	  enhances	  the	  immune	  system	  maturity	  but	  in	  a	  
recent	   study	  Kleinnijenhuis	   et	   al.,	   showed	   that	   early	  BCG	  vaccination	   leads	   to	  
the	   reprogramming	   and	   increased	   activity	   in	  monocytes	   (Kleinnijenhuis	   et	   al.,	  
2012).	  Thus,	  BCG	  can	  enhance	  APCs	  activity	  and	  subsequently	  lead	  to	  improved	  
T	   cell	   proliferative	   responses.	   These	   BCG	   non-­‐specific	   effects	   could	   lead	   to	  
improved	  mortality	  in	  infants	  as	  shown	  in	  a	  randomized	  controlled	  cohort	  in	  the	  
Gambia	   (Roth	   et	   al.,	   2006)	   as	   well	   as	   enhanced	   immune	   responses	   to	   other	  
unrelated	   vaccines	   (Ota	   et	   al.,	   2002).	   When	   assessing	   whether	   early	   BCG	  
vaccination	  could	  affect	  T	  cell	  responses	  to	  pertussis	  and	  TT	  vaccines,	  except	  for	  
IL-­‐13-­‐expressing	   CD4+	   cells,	   BCG	   timing	   had	   very	   little	   effect	   on	   immune	  
responses	  to	  pertussis	  and	  TT.	  The	  higher	  frequencies	  of	  IL-­‐13-­‐expressing	  CD4+	  
cells	  observed	  at	  week	  14	  in	  response	  to	  pertussis	  stimulation	  could	  be	  due	  to	  
the	   immaturity	   of	   the	   neonatal	   immune	   system	   or	   simply	   due	   to	   the	  waning	  
effects	   of	   BCG	   in	   the	   early	   arm	   (Ota	   et	   al.,	   2002).Ota	   et	   al.,	   also	   observed	  
frequencies	   IL-­‐13-­‐expressing	   CD4+	   cells	   in	   BCG	   vaccinated	   infants	   at	   two	  
months	  of	  age	  (Ota	  et	  al.,	  2002).	  IL-­‐13	  is	  a	  Th2	  cytokine	  especially	  important	  in	  
IgE-­‐mediated	   allergic	   responses	   (Roussel	   et	   al.,1998;	  Walter	   et	   al.,	   2001)	   and	  
protection	   against	   exacerbation	   of	   allergic	   asthma	   following	   pertussis	  




IL-­‐13	  expression	  does	  not	  always	  translate	  into	  higher	  IgE	  responses	  (Ota	  et	  al.,	  
2002).	  	  
	  
The	  low	  level	  responsiveness	  to	  TT	  observed	  at	  14	  weeks	  compared	  to	  BCG	  and	  
SEB	   may	   be	   due	   to	   the	   time	   intervals	   between	   immunization	   and	   blood	  
sampling,	  or	  even	  the	  low	  sample	  size	  for	  this	  antigen	  and	  not	  due	  to	   intrinsic	  
characteristics	  of	  the	  neonatal	  immune	  system.	  The	  low	  TT-­‐stimulated	  samples	  
sizes	   at	   week	   14	   make	   it	   difficult	   to	   assess	   how	   BCG	   timing	   affects	   T	   cell	  
responses	   to	   TT.	   However,	   recent	   data	   shows	   that	   T	   cell	   responses	   to	   TT	  
increase	  after	  14	  weeks	  and	  are	  sustained	  for	  a	  long	  period	  (Soares	  et	  al.,	  2013).	  
	  
	  Thus,	  even	  though	  the	  findings	  in	  this	  dissertation	  suggest	  that	  BCG	  does	  affect	  
immune	   responses	   to	   other	   vaccines	   and	   antigens,	   it	   is	   not	   clear	   what	   these	  
non-­‐specific	   effects	   are	   and	   how	   they	   affect	   pathogen	   susceptibility.	   The	  
remarkable	  changes	  induced	  by	  delayed	  BCG	  vaccination	  seen	  by	  Ota	  et	  al	  (Ota	  
et	   al.,	   2002)	   were	   certainly	   not	   recapitulated	   here,	   however	   the	   assays	   and	  
readouts	  used	  were	  different.	  It	  is	  possible	  that	  ex	  vivo	  stimulation	  followed	  by	  
a	   six	   day-­‐whole	   blood	   culture.	   In	   fact	   many	   activated	   cells	   may	   undergo	  
apoptosis	  when	  restimulated	  and	  not	  be	  reported	  in	  the	  final	  read	  out.	  It	  is	  also	  
possible	  that	  different	  cytokine	  profiles	  could	  have	  been	  obtained	  if	  blood	  was	  
stimulated	  and	  cultured	  for	  a	  shorter	  period.	  In	  order	  to	  better	  interpret	  these	  
results,	   it	   would	   be	   necessary	   to	   assess	   how	   blood	   culture	   length	   affects	  
cytokine	  profiles	  in	  future	  studies.	  Nonetheless	  it	  is	  important	  to	  note	  that	  the	  
cytokine	  profiles	  obtained	  in	  response	  to	  BCG	  in	  this	  study	  were	  very	  similar	  to	  
Kagina	  et	  al	  who	  had	  a	  12	  h	  culture	  time(Kagina	  et	  al.,	  2009).	  
As	   stated	   in	   section	   2.3,	   viral	   load	   was	   not	   routinely	   available	   for	   all	   the	  
mothers.	  Thus,	  it	  was	  not	  possible	  to	  compare	  the	  levels	  of	  HIV	  exposure	  among	  
infants	  and	  assess	  how	  viral	  load	  can	  affect	  immune	  responses	  to	  the	  different	  




of	  exposure	  between	  the	  two	  groups	  of	   infants	   to	  be	  similar.	   In	  addition,	  CD4	  
counts	  are	  good	  indicators	  of	  the	  maternal	  health	  status	  and	  how	  they	  respond	  
to	  ARV	   therapy.	   In	   this	   study,	   infants	   in	   the	   groups	   had	   similar	  maternal	   CD4	  
counts	  and	  maternal	  CD4	  count	  had	  almost	  no	  effect	  on	  T	  cell	  proliferative	  and	  
cytokine	  responses.	  However,	  for	  future	  analyses,	  in	  order	  to	  gain	  more	  insight	  
on	  the	  effects	  of	  HIV	  exposure	  on	  immune	  responses,	  it	  would	  be	  important	  to	  
assess	  how	  viral	  load	  affects	  immune	  responses	  to	  different	  vaccines.	  	  
The	  effects	  incurred	  by	  BCG	  vaccination	  of	  adults	  and	  mice	  in	  Kleinnijenhuis	  et	  
al’s	  experiments	  were	  also	  not	  evident	  here.	  In	  their	  study,	  BCG	  vaccination	  of	  
mice	   protected	   them	   against	   subsequent	   candidal	   and	   bacterial	   challenges	  
(Kleinnijenhuis	   et	   al.,	   2012).	   It	   is	   possible	   that	   more	   effects	   of	   delayed	   BCG	  
vaccination	   on	   cellular	   immune	   responses	   in	   HIV-­‐exposed	   infants	  would	   have	  
been	  evident	  if	  we	  had	  lengthened	  the	  follow-­‐up	  period,	  but	  also	  possible	  that	  
the	  effects	  of	  BCG	  on	  infants	  and	  adults	  or	  mice	  differ.	  	  
Assessing	  how	  BCG	  timing	  affects	  T	  cell	  responses	  to	  BCG	  and	  other	  vaccines	  in	  
in	  HIV-­‐exposed	  infants	  may	  contribute	  to	  developing	  more	  effective	  vaccination	  
strategies	   for	   such	  a	   vulnerable	   group.	   In	   addition,	   determining	   the	  effects	  of	  
BCG	  on	  other	  immune	  cells	  such	  as	  dendritic	  cells,	  monocytes,	  or	  Tregs	  in	  these	  
infants	  would	  help	  understand	  how	  BCG	  and	  HIV-­‐exposure	  affect	  the	  neonatal	  
immune	  system	  maturation.	  Although	  neonatal	  and	  adult	  immune	  systems	  are	  
different,	   HIV-­‐exposed,	   uninfected	   infants	   represent	   a	   formidable	   controlled	  
model	  to	  study	  the	  immune	  system	  of	  other	  highly	  exposed	  individuals	  who	  are	  
at	  high	  risk	  of	  acquiring	  HIV	  such	  as	  commercial	  sex	  workers	  and	  injection	  drug	  
users.	  This	  is	  particularly	  important	  in	  the	  development	  of	  a	  future	  HIV	  vaccine.	  
The	  knowledge	  gained	   in	   this	   study	  will	   assist	   in	  designing	   future	   studies	   that	  
address	  how	  BCG	  timing	  affects	  the	  vaccine	  efficacy	  in	  HIV-­‐exposed	  infants	  and	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